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Cellular reprogramming by Epstein-Barr virus nuclear antigens 
Thesis Abstract 
 
Epstein-Barr virus (EBV) is a widespread human B cell virus that is linked to many malignancies. 
EBV modulates the transcriptome of B lymphocytes to drive immortalisation and viral 
persistence. This is primarily coordinated by the EBV nuclear antigens (EBNA) 2 and the EBNA 3 
family (3A, 3B and 3C), which regulate overlapping sets of cellular genes. Using Chromatin 
immunoprecipitation (ChIP) coupled to next generation sequencing we found >21000 EBNA 2 
and >7000 EBNA 3 binding sites in the human genome, providing the first evidence of EBNA 3 
association with the human genome in vivo. Binding sites were predominantly distal to 
transcription start sites (TSS) indicating a key role in long-range gene control. This was 
especially pronounced for EBNA 3 proteins (84% of sites over 4kb from any TSS). 56% of genes 
previously reported to be regulated by these EBNA proteins in micro array experiments were 
bound by an EBNA. Using ChIP-QPCR we confirmed EBNA 3C bound to and promoted 
epigenetic silencing of a subset of integrin receptor signalling genes (ITGA4, ITGB1, ADAM28, 
ADAMDEC1). Indirect silencing of CXCL10 and CXCL11 chemokines by EBNA 3C was also 
demonstrated. 75% of sites bound by EBNA 3 were also bound by EBNA 2 implicating extensive 
interplay between EBNA proteins in gene regulation. By examining novel (WEE1, CTBP2) and 
known (BCL2L11, ITGAL) targets of EBNA 3 proteins bound at promoter-proximal or distal 
binding sites, we found both cell-type and locus-specific binding and transcriptional regulation. 
Importantly, genes differentially regulated by a subset EBNA 3 proteins were bound by the 
same subset, providing a mechanism for selective regulation of host genes by EBNA 3 proteins. 
In summary, this research demonstrates that EBNA proteins primarily act through long-range 
enhancer elements and regulate gene expression in a locus and gene-specific manner through 
differential binding. 
 
 
 
 
 
 
 
  
  
 
Table of Contents 
1.Introduction…………………………………………………………………………………………………………. 1 
1.1 Regulation of transcription…………………………………………………………………………1 
 1.1.1 RNA polymerase II recruitment and regulation……..……………………..1 
 1.1.2 Chromatin…………………………………………………………………………………….2 
  1.1.2.1 Epigenetics and the regulation of chromatin structure....3 
  1.1.2.2 Histone tail modification……………………………………………….4 
   1.1.2.2.1 Acetylation………………………………………….………….5 
   1.1.2.2.2 Methylation……………………… ………………………….…7 
 1.1.3 Transcription factors……….…………………………………………………………..9 
  1.1.3.1 Transcriptional regulation of B-cell development………....9 
  1.1.3.2 PU.1……….…………………………………………………………………...17 
  1.1.3.3 EBF1……….…………………………………………………………………...17 
  1.1.3.4 NOTCH/RBPJĸ………..…………………………………………………….19 
 1.1.4 Role of DNA elements……………………………………………………………..…20 
  1.1.4.1 Transcriptional regulation via promoter elements……….20 
  1.1.4.2 Long-range regulatory elements………………………………….23 
1.2 Epstein-Barr virus……………..………………………………………………………………………27 
 1.2.1 Discovery…………..……………………………………………………………………….27 
 1.2.2 Initial infection……….………………………………………………………………….28 
 1.2.3 EBV latent gene transcription…………………………………………………….31 
 1.2.4 Course of a latent infection in a healthy host….……………………….…32 
 1.2.5 The host immune response to EBV…………………………………………....36 
 1.2.6 EBV and disease……………………………………………………………………......38 
1.3 Epstein-Barr virus nuclear antigens……………………………………………………….....40 
 1.3.1 EBNA 1…………..…………………………………………………………………………..40 
 1.3.2 EBNA-LP………..……………………………………………………………………………40 
 1.3.3 EBNA 2………..……………………………………………………………………………..41 
 1.3.4 EBNA 3 family…………………………………………………………………………….42 
1.4 Summary…………………………………………………………………………………………………..45 
1.5 Aims of my project…………………………………………………………………………………...46 
  
2. Materials and Methods……………………………………………………………………………………… 47
 2.1 Tissue culture……………….……………….……………….……………….……………………….47 
  2.1.1 Tissue culture media and supplements……………………………..……….47 
  2.1.2 Maintenance of cell lines……………………………………………………………48 
   2.1.2.1 Mutu I and III……….……………….……………….………………….…48 
   2.1.2.2 BL31, BL31 wtBAC, BL31 3CKO, BL31 3CREV and BL31 
E2KO………………………………………………………………………………………………………………………….48 
   2.1.2.3 BJAB PZ1, PZ3, E3C3, E3C7, E3A1 and E3B2………………….48 
   2.1.2.4 PER253 B95.8, PER142 B95.8, PER253 3BKO and PER142 
3BKO LCLs…………………………………………………………………………………………………………………..49 
   2.1.2.5 EREB 2.5 LCL……………………………………………………………..…49 
   2.1.2.6 D2 and D3 wild type (wt) and EBNA 3° (mtB) LCLs……….49 
  2.1.3 Freezing cells…………………………………………………………………………..…49 
  2.1.4 Thawing cells……………………………………………………………………………..50 
  2.1.5 Cell counting………………………………………………………………………………50 
 2.2 Biochemical reagent and methods……………………………………………………………50 
  2.2.1 Preparation of whole cell lysates………………………………………………..52 
  2.2.2 SDS-PAGE…………………………………………………………………………………..52 
  2.2.3 Immunoblotting…………………………………………………………………………52 
  2.2.4 Chromatin Immunoprecipitation (ChIP)……………………………………..52 
   2.2.4.1 Bead preparation…………………………………………………………53 
    2.2.4.1.1 Protein A sepharose bead preparation………….53 
    2.2.4.1.2 Protein A agarose bead preparation……………..53 
   2.2.4.2 Chromatin preparation………………………………………………..53 
   2.2.4.3 ChIP on cross-linked chromatin……………………………………53 
   2.2.4.4 ChIP from non-cross linked chromatin…………………………54 
   2.2.4.5 ChIP Sequencing DNA isolation and library preparation.54 
   2.2.4.6 ChIP-reChIP………………………………………………………………….55 
  2.2.5 RNA isolation……………………………………………………………………………..56 
  2.2.6 Determining RNA concentration…………………………………………….….56 
  2.2.7 cDNA synthesis…………………………………………………………………………..56 
  2.2.8 Q-PCR…………………………………………………………………………………………56 
  
  2.2.9 Determination of DNA fragment size after sonication………………..57 
 2.3 Bioinformatics analysis…………………………………………………………………………..…57 
  2.3.1 Comparison of ChIP sequencing and gene expression microarray 
data……………………………………………………………………………………………………………………………57 
  2.3.2 ChIP sequencing data analysis……………………………………………………58 
  2.3.3 Motif searching………………………………………………………………………….58 
  2.3.4 David gene ontology and Kegg pathway analysis………………………..58 
3. Mapping EBNA 2 and EBNA 3C binding in the human genome…………………………….59 
 3.1 Validation of EBNA 3C antibody for ChIP…………………………………………………..59 
 3.2 Optimisation of ChIP sequencing protocol……………………………………..…………61 
 3.3 ChIP sequencing library preparation…………………………………………………………63 
 3.4 EBNA 3C sheep polyclonal antibody co-precipitates EBNA 3A and EBNA 
3B………………………………………………………………………………………………………………………………66 
 3.5 Distribution of EBNA 2 and EBNA 3 binding sites………………………………………66 
 3.6 Colocalisation of EBNA 2 and EBNA 3 binding sites with histone 
modifications………………………………………………………………………………………………………….….72 
 3.7 Colocalisation of EBNA 2 and EBNA 3 biding sites with cellular transcription 
factors………………………………………………………………………………………………………………………..76 
 3.8 Alignment of genes bound by EBNA 2 and EBNA 3 with genes regulated in 
published micro arrays……………………………………………………………………………………….………81 
 3.9 Discussion………………………………………………………………………………………….……..87 
4. EBNA 3C represses integrin receptor signalling genes via promoter proximal and 
distal elements……………………………………………………………………………………………………… 93 
 4.1 EBNA 3C represses chemokine and integrin receptor signalling genes……..93 
 4.2 EBNA 3C binds to and represses ITGB1 via promoter-proximal and distal 
elements…………………………………………………………………………………………………………….………98 
 4.3 EBNA 3C binds to and represses ITGA4 via a promoter-proximal site……..102 
 4.4 Binding of EBNA 3C to an intragenic peak at the ADAM locus causes 
epigenetic repression of ADAM28 and ADAMDEC1……………………………………………….…102 
 4.5 Epigenetic repression of CXCL10 and CXCL11 in cells expressing EBNA 
3C…………………………………………………………………………………………………………………………….106 
 4.6 Discussion………….…………………………………………………………………………………..110 
  
5. Investigating EBNA 3A, 3B and 3C binding to key target genes and the role of 
shared EBNA 2 and 3 binding sites in gene regulation…………………………………………..116 
 5.1 Validation of antibodies specific to EBNA 3A, EBNA 3B and EBNA 3C and 
differential EBNA 3 binding at ADAM and Bim………………………………............................116
 5.2 identifying key target genes for analysis…………………………………………………120 
 5.3 Coincident binding of EBNA 2, 3A, 3B and 3C at an intragenic peak at the 
CTBP2 gene…………………………………………………………………………………………………..………….125 
 5.4 Regulation of WEE1 by downstream distal EBNA 2 and EBNA 3C coincident 
binding sites…………………………………………………………………………………………………..………..131 
 5.5 ITGAL is differentially bound by EBNA 2 and 3 family proteins and binding is 
cell type specific……………………………………………………………………………………………………….134 
 5.6 EBNA 2 and 3 proteins compete for binding at coincident sites………………140 
 5.7 Discussion……………………………………………………………………………………………….142 
  5.7.1 CTBP2……………………………………………………………………………………….142 
  5.7.2 WEE1……………………………………………………………………………………….150 
  5.7.3 ITGAL………………………………………………………………………………………..154 
6. Discussion…………………………………………………………………………………..…………………… 156 
 6.1 EBNA 2 and EBNA 3 binding sites in the human genome………………….…….156 
 6.2 Histone modifications and EBNA 3C DNA binding……………………………………159 
 6.3 The influence of shared sites and DNA looping…………………………………….…161 
7. Bibliography……………………………………………………………………………………………………. 167 
8. Appendices……………………………………………………………………………………………………… 197 
 Appendix A……………………………………………………………………………………………………197 
 Appendix B……………………………………………………………………………………………………198 
 Appendix C……………………………………………………………………………………………………199 
 Appendix D………………………………………………………………………………………………..…203 
 
 
 
 
 
 
  
Common Abbreviations 
ADAM A disintegrin and metalloprotease  
AID activation-induced cytidine deaminase  
BAC bacterial artificial chromosome  
BCR B-cell receptor 
BL Burkitts lymphoma  
BRD4 dual bromodomain protein 
CBP CREB-binding protein  
ChIP Chromatin Immunoprecipitation 
CLP common lymphoid progenitor 
Cp C promoter 
CTBP1 C-terminal binding protein 1 
CTBP2 C-terminal binding protein 2 
CTD Carboxy-terminal domain  
EBNA EBV nuclear antigen 
EBV Epstein-Barr virus  
ENCODE Encyclopaedia of DNA elements  
EZH2 enhancer of zeste 2 
GC Germinal centre 
GSB Gel sample buffer 
H3 Histone 3 
H3ac acetylated histone H3 
H3K27ac acetylation of lysine 27 on histone H3 
H3K27me3 tri-methylation of lysine 27 on histone H3  
H3K4me1 mono-methylation of lysine 4 on histone H3 
H4 Histone 4 
H4ac acetylated histone H4 
HAT histone acetyl transferase 
HDAC Histone deacetylases  
HL Hodgkins lymphoma  
HMT histone methlytransferases  
HRS Hodgkin/Reed-Sternberg  
HSC Hematopoietic stem cells 
IM infectious mononucleosis 
IP immuno-precipitation 
LCL lymphoblastoid cell line  
LMP latent membrane protein 
NK natural killer 
NPC nasopharyngeal carcinoma  
OriP origin of replication 
PcG polycomb group proteins 
PIC pre-initiation complex 
PRC1 polycomb repressive complex 1 
PRC2 polycomb repressive complex 2 
  
pTEFb positive transcription elongation factor b  
PTLD Post-transplant lymphoprolierative disease 
Qp Q promoter 
RNAPII RNA polymerase II 
TAD transactivation domain  
TF transcription factor 
TFBS transcription factor binding sites 
TSS Transcription start site 
WB western blot 
Wp W promoter 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1.Introduction 
Epstein-Barr virus (EBV) is an almost ubiquitous gamma herpes virus that is capable of 
asymptomatically infecting the vast majority of the worldwide adult population in vivo. It is 
also associated with numerous human malignancies and was discovered through its 
association with Burkitts lymphoma (BL), the most common childhood lymphoma in sub 
Saharan Africa. EBV can immortalise resting B-cells forming permanently proliferating 
lymphoblastoid cell lines (LCLs). During LCL outgrowth EBV virus expresses only 9 proteins, of 
which 6 are nuclear. The Epstein-Barr virus nuclear antigen (EBNA) 2, EBNA 3A, EBNA 3B and 
EBNA 3C play a key role in reprogramming host cells to enable the virus to persist and survive. 
At the start of this PhD project, we had little understanding of how these proteins target and 
deregulate host cell genes. 
1.1 Regulation of transcription 
1.1.1 RNA polymerase II recruitment and regulation 
Eukaryotes have three RNA polymerases, RNAPI, RNAPII and RNAPIII. RNAPII is primarily 
responsible for creating mRNA which can be translated into protein. RNAPII usually initiates 
transcription with the additional binding of general transcription factors at a TATA box, 
typically located 25bp upstream of the transcription start site; which when bound causes a 
distortion in DNA structure which may act as a physical landmark for the location of an active 
promoter (Kim et al. 1993). The subsequent recruitment of further general transcription 
factors and RNAPII then forms the complete transcription pre-initiation complex (PIC). This 
includes a DNA helicase TFIIH, which unwinds DNA and allows RNAPII access to the template 
strand. RNAPII initiation and elongation involves phosphorylation of the RNAPII largest subunit 
(Rpb1) Carboxy-terminal domain (CTD) by members of the transcription initiation complex. 
The CTD has an essential role in regulating efficient transcription, facilitating events in 
initiation, elongation and RNA processing through modifications by regulatory proteins. In 
humans it consists of 52 heptapeptide repeats (Y1S2P3T4S5P6S7). The CTD ‘code’ describes 
RNAPII regulation by transient modifications of the CTD, including serine 5 phosphorylation at 
initiation and serine 2 phosphorylation during elongation (Egloff and Murphy 2008). As well as 
phosphorylation the CTD can also be methylated, glycosylated, ubiquitinated and undergo 
changes in proline isomerisation, all of which have been ascribed particular biological functions 
in relation to RNAPII transcription (reviewed in (Eick and Geyer 2013)). For example, serine 2 
phosphorylation by positive transcription elongation factor b (pTEFb) is required for productive 
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elongation (Marshall and Price 1995). pTEFb also phosphorylates DRB sensitivity-inducing 
factor (DSIF) and negative elongation factor (NELF) relieving promoter proximal pausing of 
RNAPII (Wada et al. 1998; Fujinaga et al. 2004). Interestingly, it appears that promoter 
proximal pausing is required for efficient transcription of many genes by occluding nucleosome 
assembly around the promoter (Gilchrist et al. 2008). RNAPII and general transcription factors 
must also access DNA tightly associated with histones to bind promoter sequences, and post 
translational modifications of histone tails allow direction of RNAPII to target genes. A great 
deal of cross talk exists between RNAPII interacting proteins and histone modifying enzymes. 
For example the dual bromodomain protein, BRD4, associates with acetylated histone tails of 
histones H3 and H4 which are often found at sites of active transcription. BRD4 can then 
recruit p-TEFb and induce RNAPII CTD phosphorylation facilitating high level gene specific 
transcription elongation (Jang et al. 2005; Yang et al. 2005). 
1.1.2 Chromatin   
DNA in the cell is contorted and compacted into chromatin, the basic unit of which is the 
nucleosome. A single nucleosome contains an octamer of histone proteins H3, H4, H2A, H2B 
and has ~147bp of DNA completing nearly two full turns around the nucleosome. Each 
nucleosome is separated by 10-60bp linker piece of DNA which is commonly bound by histone 
H1 (reviewed in (Peterson and Laniel 2004). The first evidence for the manner of DNA 
packaging came from electron microscope images (Oudet et al. 1975) which showed the 
genome existed in uniformly sized particles. Each of these repeating bead like structures was 
called a nucleosome and formed the classic ‘beads on a string’ packaging of DNA. Chromatin is 
further condensed by internucleosomal attraction forming a zig-zag pattern of DNA and 
nucleosomes which further folds in to a ~30nm thick fibre (reviewed in (Woodcock and 
Dimitrov 2001). This fibre is further condensed within the nucleus, partly by interaction with 
the condensing complex (Swedlow and Hirano 2003). Whilst the core histones packed into 
chromatin form highly structured fibres, the individual histones have long unstructured 
histone tails, that protrude from the core fibre. These comprise about 30% of the mass of each 
individual histone and can be post translationally modified at specific residues. Observed 
modifications include acetylation, methylation, ubiquitination and ADP ribosylation (Luger and 
Richmond 1998; Wolffe and Hayes 1999). 
Oudet et al also observed that DNA from actively transcribing cells had the same sized 
nucleosomes but the spaces between them were less uniform and generally larger when 
compared to those of cells undergoing little transcription; this therefore provided the first 
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evidence that nucleosomes are part of the transcriptional regulatory network (Oudet et al. 
1975). Experiments on the structure of ectopic nucleosomes with DNA bound from 
preparations made in Escherichia coli (E.coli) and Chicken erythrocytes gave clues about how 
this may happen. Both sets of nucleosomes had very similar core structure, but histones 
prepared in E.coli had no post-translational modifications on the histone tails (Luger et al. 1997; 
Harp et al. 2000). This suggests that post translational modification of the histone tail does not 
exert biological function by significantly reshaping the nucleosome but by recruitment of 
specific proteins. Purely considering electrostatic interactions at least acetylation and 
phosphorylation are predicted to aid transcription by chromatin decondensation via 
neutralisation of a positive charge and addition of a negative charge respectively (Roth and 
Allis 1992). This process appears to be dynamic as phosphorylation of H1 and H3 has been 
implicated in chromatin condensation during mitosis (Koshland and Strunnikov 1996) but 
specific phosphorylation of serine 10 on histone 3 is directly related to the active transcription 
of MYC, JUN and FOS (Mahadevan et al. 1991; Thomson et al. 1999).  
1.1.2.1 Epigenetics and the regulation of chromatin structure 
Chromatin can be altered in several interconnected ways: through covalent modification of 
histones, exchange of core histones with histone variants, disruption of the nucleosome and 
DNA modification. An essential component in gene silencing by DNA modification and 
chromosome compaction is the polycomb group proteins (PcG), which are conserved in all 
higher eukaryotes. The tri-methylation of lysine 27 on histone H3 (H3K27me3) is thought to be 
the operative chromatin mark that accompanies PcG mediated gene silencing (reviewed in 
(Simon and Kingston 2009)). PcG proteins were originally discovered in Drosophila as 
regulators of development by repression of hox genes. PcG proteins primarily exert their 
function as part of a complex, either Polycomb repressive complex 1 or 2 (PRC1 or PRC2), 
although in mammals multiple forms of PRC1 and PRC2 exist with different subunits. It has 
therefore proved difficult to determine the biological function of individual subunits and 
specific complexes. A known core function of PRC2 is the deposition of H3K27me3 (Cao et al. 
2002), whereas PRC1 is known to ubiquitylate histone H2A and cause nucleosome compaction 
(Francis et al. 2004; Cao et al. 2005). In cancer PcG gain of function mutants appear to be key 
in altering cancer cell expression profiles perhaps by hyper-silencing of tumour suppressor 
genes, especially in aggressive tumours (Yu et al. 2007; Ben-Porath et al. 2008). Interestingly 
whilst this remains true in B-cell lymphomas, PcG mutations found in T cell and myeloid 
leukemia are generally loss of function (Ernst et al. 2010; Ntziachristos et al. 2012). 
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In Drosophila, PcG proteins can be targeted to DNA by polycomb response elements (PREs) 
which bind sequence specific DNA binding proteins in PRC1 and PRC2 (Ringrose and Paro 2007; 
Schuettengruber and Cavalli 2009). PREs are depleted of nucleosomes and can be many 
kilobases from the genes under their control. One important transcription factor involved in 
this process in Drosophila is PHO, the principal polycomb recruitment protein, the human 
homologue of which is YY1, a human polycomb associated transcription factor (Oktaba et al. 
2008). In the case of PHO and YY1 this process appears to be mediated by the 
coactivator/corepressor C-terminal binding protein (CTBP)(Basu and Atchison 2010). Whilst 
PREs appear not to be as important in mammals, functional YY1 dependant PREs have been 
shown to repress human hox genes (Woo et al. 2010). Human PcG recruitment is primarily 
dependent on the presence of CpG islands in a relatively sequence independent manner. This 
was demonstrated by the findings that PRC2 components were recruited to CpG rich bacterial 
artificial chromosome (BAC) derived DNA and CpG rich bacterial DNA when integrated into a 
mouse genome (Mendenhall et al. 2010). Methylation of CpG islands usually results in gene 
silencing by directly preventing transcription factor binding and recruiting methyl-binding 
domain proteins and Histone deacetylases (HDACs) (Taby and Issa 2010). CpG islands incapable 
of binding PcG proteins generally contain binding sites for transcriptional activators or are 
methylated. Methylation dependant binding of PRC2 to DNA is supported by data showing that 
full PRC2 recruitment requires tet methylcytosine dioxygenase 1 (TET1) which can convert 5-
methyl cytosine to 5-hydroxy methyl cytosine, which can be further processed to unmodified 
cytosine (Wu et al. 2011; Tan and Shi 2012). This is a dynamic interaction as PcG proteins 
appear to also recruit TET1 to H3K27me3 sites to maintain hypomethylation of DNA, perhaps 
to maintain bivalent chromatin at a subset of sites (Neri et al. 2013). Interestingly a PRC1 
variant complex containing lysine (K)-specific demethylase 2B (KDM2B) can also be recruited to 
unmethylated CpG islands (Wu et al. 2013) and PRC1 can be recruited to DNA via cellular 
transcription factors such as RUNX1 (Yu et al. 2012). 
1.1.2.2 Histone tail modification 
Epigenetics describes stable changes in gene expression that do not change the genetic code 
itself, allowing multiple cell types to diverge despite a common genetic code. Whilst this term 
first applied to the truly heritable modification of DNA methylation at CpG islands it is now 
used in the context of histone modifications, and as discussed, these processes are related. 
Early findings in the role of histone tail modifications lead to the proposal of a histone code: 
‘multiple histone modifications, acting in a combinatorial or sequential fashion on one or 
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multiple histone tails, specify unique downstream functions’ (Strahl and Allis 2000). Since then 
the true complexity of the histone code has been subject to intense study. In recent years 
many ChIP sequencing experiments mapping the genomic locations of different marks have 
been performed in a variety of cell lines. This data is publicly accessible via the Encyclopaedia 
of DNA elements (ENCODE) project allowing users to align their own sequencing data against 
this resource (http://genome.ucsc.edu/ENCODE/). Some histone modifications studied are 
described in Table 1-1 along with their proposed function by the ENCODE project. Whilst 
discussion of all histone modifications is beyond the scope of this work I shall discuss a few 
pertinent modifications in more detail. 
1.1.2.2.1 Acetylation 
As discussed previously, acetylation of histones is involved in reducing DNA histone contacts 
but also play a role in transcriptional activation, DNA replication, histone deposition and DNA 
repair via recruitment of proteins with acetyl binding domains. In the case of acetyl-lysines this 
is the bromodomain (Kurdistani and Grunstein 2003). Acetyl groups are deposited on histones 
by histone acetyl transferases (HATs) and removed by histone de-acetylases (HDACs), a 
process that requires careful regulation and balance (Marmorstein 2001). The linker histone 
H1 has been shown bind with a lower affinity to core histones with hyperacetylated tails 
contributing to chromatin decondensing (Misteli et al. 2000). Acetylation of histones in general 
may then contribute to the unfolding of nucleosomes at transcriptionally active promoters 
(Boeger et al. 2003). However the chronology of these events is less well understood. A great 
deal of cross talk exists between histone modifications; for example, phosphorylation of serine 
10 in the histone H3 tail causes a conformational change creating additional interaction sites 
with HATs enhancing H3K14 acetylation and transcription (Clements et al. 2003). Apart from 
facilitating open chromatin permissive to transcription (euchromatin), acetylation also plays a 
role in the recruitment of basic transcription machinery. The largest subunit of TFIID binds to 
the di-acetylated H4 tail with 40 fold higher affinity than the mono-acetylated tail (Jacobson et 
al. 2000). 
The deposition of post-translational modifications is site-specific in many cases. For example, 
on histone H3 most acetylation of lysines occurs on K9, K14, K18 and K23, which are 
differentially acetylated during different biological processes (Kuo et al. 1996). Studies on the 
yeast GCN5 HAT revealed it may be directed to H3K14 by surrounding residues, in this case a 
glycine and a proline, suggesting that substrate specificity is in part due to short preferred 
consensus sites (Rojas et al. 1999; Cieniewicz et al. 2014). Post-translational modifications of 
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Histone modification or variant Signal characteristics Putative functions
H2A.Z Peak Histone protein variant (H2A.Z) associated with 
regulatory elements with dynamic chromatin
H3K4me1 Peak/region Mark of regulatory elements associated with 
enhancers and other distal elements, but also 
enriched downstream of transcription starts
H3K4me2 Peak Mark of regulatory elements associated with 
promoters and enhancers
H3K4me3 Peak Mark of regulatory elements primarily associated 
with promoters/transcription starts
H3K9ac Peak Mark of active regulatory elements with 
preference for promoters
H3K9me1 Region Preference for the 5′ end of genes
H3K9me3 Peak/region Repressive mark associated with constitutive 
heterochromatin and repetitive elements
H3K27ac Peak Mark of active regulatory elements; may 
distinguish active enhancers and promoters from 
their inactive counterparts
H3K27me3 Region Repressive mark established by polycomb 
complex activity associated with repressive 
domains and silent developmental genes
H3K36me3 Region Elongation mark associated with transcribed 
portions of genes, with preference for 3′ regions 
after intron 1
H3K79me2 Region Transcription-associated mark, with preference 
for 5′ end of genes
H4K20me1 Region Preference for 5′ end of genes
Table 1-1 Histone modifications and putative function. (adapted from ‘an integrated encyclopaedia 
of DNA elements in the human genome’ (2012)) Many labs have conducted ChIP sequencing 
experiments for Histone modifications. Here are listed the known histone modifications for which 
there is publicly available ChIP sequencing data, the characteristics of the mark and the proposed 
putative function. 
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histone tails also inhibit protein-protein interactions which modulate transcription. TUP1, a 
protein involved in transcriptional silencing in yeast was shown to bind with greater affinity to 
unacetylated or monoacetylated histone H3 and H4 than hyperacetylated forms (Edmondson 
et al. 1996). 
The acetylation of histone H3 on lysine 27 (H3K27ac) is of particular interest as it is widely 
regarded as a marker for active enhancer sites (Creyghton et al. 2010). One mechanism of the 
removal of H3K27ac is via ZEB1 interaction with CTBP proteins which subsequently recruit 
HDAC activity to ZEB1 binding sites, repressing genes such as CDH1 (Postigo and Dean 1999; 
Aghdassi et al. 2012). In some lung cancers ZEB1 is repressed leading to a local and global 
decrease in H3K27ac (Roche et al. 2013). The bulk of H3K27ac is deposited by CREB-binding 
protein (CBP) and in drosophila has been shown to block the PRC2 mark H3K27me3 (Tie et al. 
2009; Pasini et al. 2010). CBP also physically associates with UTX (KDM6A) and BRM (a H3K27 
specific demethylase and a chromatin-remodelling ATPase Brahma respectively) and directs 
them to CBP sites including many polycomb response elements, removing H3K27me3 and 
simultaneously adding H3K27ac. RNAi knock down of UTX and BRM reduces H3K27ac at target 
sites (Tie et al. 2012). H3K27ac exhibits a great deal of crosstalk with other histone 
modifications.  
One intriguing situation concerns a switch from poised chromatin to active chromatin. H3K4 
methylation is indicative of accessible chromatin and is deposited by lysine specific 
methyltransferases such as KMT2 (Allis et al. 2007; Zentner and Henikoff 2013). H3K27me3 is 
associated with repressed chromatin and is deposited by the PRC2 protein EZH2 (enhancer of 
zeste); together they signify poised chromatin, the defining feature of which is rapid 
transitions between transcriptional activation and repression, and is important in development 
(reviewed in (Simon and Kingston 2013; Voigt et al. 2013)). ASH2L-KMT2 complexes have been 
shown to bind to methylated H3K4 with a preference for di and tri methylated forms, this has 
the net effect of removing H3K27me3 and spreading H3K4 methylation (Wang et al. 2010). 
Recently the transcriptional regulator MYC was shown to interact with this complex and also 
promote H3K27ac at these sites, thus facilitating a switch from bivalent to fully active 
chromatin state (Ullius et al. 2014). 
1.1.2.2.2 Methylation  
H3K27me3 is deposited by the core PRC2 protein EZH2, which can perform each of the three 
sequential methylation events but only in complex with two of the other three core PRC2 
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subunits, SUZ12 and EED (Cao and Zhang 2004; Ketel et al. 2005). This activity can be 
modulated by mutation (McCabe et al. 2012), phosphorylation of EZH2 (Chen et al. 2012) or 
other PRC2 components, differential binding of EED isoforms and alternate PRC2 compositions  
(reviewed in (O'Meara and Simon 2012)). PRC2 can also methylate itself and other proteins 
including histone H1 (Kuzmichev et al. 2004; He et al. 2012); furthermore there is evidence 
that EZH2 outside of the PRC2 complex can activate transcription in a methylation dependent 
manner (Xu et al. 2012). PRC2 interacts with many other proteins which modulate its activity, 
for example, Polycomb like proteins (PLCs) aid PRC2 to complete the final methylation of 
H3K27 and facilitate recruitment of PRC2 to CpG islands (Sarma et al. 2008; Hunkapiller et al. 
2012). JARID2, a member of the jumonji family of histone demethylases associates with PRC2 
although the loss of this protein has been reported to only moderately change H3K27me3 in 
both a positive and negative fashion; thus, the biological importance of JARID2 binding 
remains controversial. It may fine tune PRC2 signalling and also PRC2 targeting (reviewed in 
(Herz and Shilatifard 2010)).  
PRC2 positively regulates its own activity as the presence of H3K27me3 has been shown to 
stimulate PRC2 activity. This function may serve to spread H3K27me3 across regulatory 
domains, and indeed, H3K27me3 presents as a broad mark rather than a distinct peak 
(Margueron et al. 2009; Xu et al. 2010). Furthermore, PRC2 preferentially methylates densely 
packed nucleosomes via interactions with histone tails from neighbouring histones; potentially 
serving as a mechanism for linking multiple forms of epigenetic repression (Yuan et al. 2012). 
The presence of various positive regulatory marks and elements can inhibit PRC2 activity. 
H3K4me3 and H3K36me2 or me3 can prevent PRC2 activity although this appears to be via 
allosteric effects rather than a substrate affinity affect (Yuan et al. 2011). PRC2 dependent 
H3K27me3 is mutually exclusive with H3K27ac, with H3K27ac enzymatically occluding PRC2 
activity. H3S28 phosphorylation also prevents PRC2 activity as this residue is adjacent to H3K27 
and allosterically inhibits methylation (reviewed in (O'Meara and Simon 2012)). 
Due to the complex cross-talk between histone modifications, it is extremely difficult to 
determine the output of H3K27me3. In fact, there is still debate as to whether this mark has a 
direct repressive effect or if it is just a by-product of gene repression; an argument supported 
by data showing that gene repression precedes H3K27me3 deposition (Henikoff and Shilatifard 
2011; Yuan et al. 2012). However, loss of PRC2 in drosophila results in 25% (~3500) of genes 
being derepressed with coincident H3K27me3 reduction and increased PolII recruitment. Of 
these the 2100 genes that lacked PolII in wild type lines cells gained 5’ paused PolII in the PRC2 
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mutant, the rest showed increased levels of PolII at the promoter (Chopra et al. 2011). It has 
been reported that in some cases demethylases such as JMJD3 are required to release paused 
PolII into productive elongation (Chen et al. 2012). These promoter specific effects are unlikely 
to be the only output as H3K27me3 exists in broad peaks. The repressive output of H3K27me3 
(if any) appears to be through the recruitment of PRC1. PRC1 CBX subunits have a high affinity 
for H3K27me3, PRC1 then causes histone ubiquitination, nucleosome compaction and directly 
interacts with transcriptional machinery, finally facilitating DNA methylation. It further appears 
likely that PRC2 mediated H3K27me3 deposition may inhibit transcription in other ways 
including: recruitment of non PRC1 proteins, impeding binding of activators or 
initiation/elongation factors, impacting nucleosome packaging, preventing interactions with 
chromatin remodellers and excluding H3K27ac (reviewed in (Simon and Kingston 2009, 2013). 
Remarkably, PcG mediated silencing can be retained post mitosis in daughter cells, although 
the molecular mechanisms of this remains largely unknown. It may be that whilst H3K27me3 is 
reduced post mitosis, enough exists to allow PRC2 to ‘fill in’ the mark and perpetuate 
repression (Hansen et al. 2008). 
1.1.3 Transcription factors 
The character of a cell is determined by its specific transcriptional program, which is primarily 
defined by what subset of transcription factors (TFs) it expresses. TFs bind to DNA to activate 
or repress a set of genes under its control. Transcription factors are often directed to the genes 
under their control via DNA binding motifs, although a good deal of deviation is observed with 
many of these consensus motifs and it is likely that other chromatin or protein-protein 
interactions aids transcription factor recruitment (reviewed in (Li et al. 2000; Georges et al. 
2010; Sive and Gottgens 2014)). The B cell-development pathway has long been used as a 
model for transcription factor interplay and is of vital importance to understanding 
mechanisms of EBV induced immortalisation. Here I will describe the importance of 
transcription factors in B-cell development and focus on a subset of these pertinent to this 
work. 
1.1.3.1 Transcriptional regulation of B-cell development 
B-cell development is one of the best studied in terms of temporal transcriptional control due 
to the ease of identifying subsets of cells and their natural proliferative abilities (Hardy et al. 
2007)(Fig 1-1). How a given cell develops into a B cell rather than a T cell, natural killer cell, 
macrophage or erythrocyte depends on a series of developmental branching points, resolved  
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by the balance of transcription factors, their dosage, chromatin modifications (enhancer or 
promoter priming) and stochastic events. Figure 1-1 shows this process along with when 
relevant transcription factors are expressed. At the DNA level all of classes of cell are identical, 
their fate and function is decided by the repertoire of transcription factors it expresses, and 
transcription factor binding profile, which is dependent on chromatin structure and histone 
modification. The generation of mature B cells is a progressive process, each step 
characterised by a specific transcription program. There is clearly temporal regulation; factors 
such as PU.1, E2A and Ikaros are expressed very early, before the developmental branch for 
lymphoid or myeloid fates. Others such as EBF1 are expressed only during/after commitment 
to the lymphoid branch in common lymphoid progenitors (CLPs). This suggests a 
transcriptional hierarchy (reviewed in (Choukrallah and Matthias 2014)). 
The first progenitor from hematopoietic stem cells (HSCs) are multipotent progenitors (MPPs), 
these have lost the capacity for self-renewal but still have multilineage differentiation 
potential (Adolfsson et al. 2001). The loss of myeloid potential en route to lymphoid cell fate is 
gradual and is associated with increased expression of the flt3 receptor (Adolfsson et al. 2005). 
The developmental branch point of B-lymphocyte or macrophage (CMPs) is primarily resolved 
by the dosage of PU.1 (DeKoter and Singh 2000). The inactivation of PU.1 in sorted CLP cells 
allows B-cell differentiation, primarily towards a lymphoid cell fate, suggesting that PU.1 exerts 
its role in B-cell development early and is not required for later stages (Iwasaki et al. 2005). 
The basic helix-loop-helix proteins E12 and E47 heterodimerise to create E2A which is 
expressed in MPPs and is required for CLP formation. E2A knock out cells do not create any B 
cell progenitors due to the absence of EBF1 (Borghesi et al. 2005). E2A upregulates EBF1 which 
is expressed in CLPs and these proteins cooperatively regulate most B-cell specific genes 
facilitating their conversion into B cells (Kee and Murre 1998). Mice lacking EBF1 fail to express 
important B-cell genes such as CD79a, CD79b, IGLL1 and do not undergo any Immunoglobulin 
recombination (Lin and Grosschedl 1995). Furthermore, ectopic expression of EBF1 in HSCs 
skews differentiation towards B-cell lineage and the expression of EBF1 in E2A deficient mice 
rescues B-cell differentiation although these cells are unable to proliferate following IL-7 
induction (Bain et al. 1997; Zhang et al. 2003; Seet et al. 2004).  
PAX5 is a multifunctional transcriptional regulator which is induced by EBF1 in pro-B cells. It is 
expressed at a relatively stable level throughout the B-cell lineage until differentiation into 
plasma cells where its expression is reduced (Fuxa and Busslinger 2007). Loss of PAX5 arrests 
cells at the pro-B stage and its expression is regarded as being required for initiating and 
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maintaining B-cell commitment (Nutt et al. 1999; Rolink et al. 1999). PAX5 not only activates 
many B-cell specific genes but represses essential receptors for other differentiation pathways 
(Delogu et al. 2006). The later stages of B-cell development occur away from the bone marrow 
and immature B cells can be found in peripheral lymphoid organs. Mature, naïve B cells 
account for ~65% of all B cells in the peripheral blood (Perez-Andres et al. 2010). Naive B cells 
(that is B cells that have not encountered an antigen) created in this way circulate the blood 
stream until an antigen is encountered.  
The process of maturation of an antigen stimulated mature naïve B-cell to a memory B-cell (or 
another fate) is also tightly controlled at a transcriptional level. Upon antigen stimulation naïve 
B-cells are driven to specific microenvironments in the lymphoid organs where they form 
germinal centres (GCs); here they proliferate and form a large clone of cells and undergo 
somatic hypermutations in their Igg genes such that the exact specificity of each cell for the 
activating antigen is slightly different (Jackson et al. 2013). Progression from this stage is 
thought to proceed through centroblasts (CD77+), centrocytes (CD77-), then on to memory B-
cells or plasma cells. Klein et al (Klein et al. 2003) sorted these four cell fractions and 
performed micro-array experiments to characterise transcriptional alterations in these cell 
subtypes. Comparing naïve B-cells to centroblasts they found that 457 genes were 
differentially regulated. Cell proliferation, chromatin remodelling, checkpoint transition and 
pro apoptotic genes were generally all up regulated whereas negative cell cycle regulators, 
anti-apoptotic, cytokine and chemokine receptor and adhesion genes were strongly repressed 
in this transition. Interestingly, centroblasts and centrocytes were found to have little 
significant differences in gene expression although this may be due to the heterogeneity of the 
centrocyte subpopulation as these cells give rise to both memory and plasma cells. Importantly 
they found that memory B-cells generally represent a reversion to a naïve B-cell pattern of 
gene expression. Centrocyte to memory B-cell transition was shown to involve 267 genes, 
whereas comparing differentially expressed genes between the naïve and memory 
subpopulations involved only 62 genes. Of note, it was found that memory B-cells expressed 
significantly higher levels of CD27, which upon encountering its T-cell cell surface ligand CD70, 
promotes differentiation into antibody secreting plasma cells (Jang et al. 2013; Klein et al. 
2003). 
The purpose of B-cell development is to create an effective immune system, capable of 
defending the host from foreign pathogens and to develop a memory to cope with future 
insults whilst not targeting any host tissue (Fig 1-2). To achieve this, throughout this process B-  
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cells are subject to multiple checkpoints to assess their antigen specificity, signalling strength 
and autoreactivity, the result of which is the apoptosis or developmental regression of a large 
proportion of developing B-cells (reviewed in Rowland et al. 2013; Scholz and Cancro. 2012). It 
has been estimated that approximately 50% of B-cell Receptors (BCRs) of Immature B-cells in 
the BM are autoreactive (Wardemann et al. 2003). These are eliminated from the naïve 
repertoire by the process of tolerance and only non autoreactive B-cells are permitted to enter 
the periphery. Essentially BCR signalling alone (tonic signalling) is required for cells at this stage 
of development, and those that are ‘antigen’ stimulated revert to a more pro or pre B-cell 
state and undergo further V(D)J recombination to alter their BCR (Nossal 1983; Osmond 1991; 
Schram et al. 2008; Verkoczy et al. 2007). The reason for this is likely that antigen stimulated 
cells in the BM are almost certainly recognising a self-antigen. In the periphery naïve to mature 
antigen unstimulated B-cells are further selected for based on cytokines such as BAFF, which 
control the fate and quantity of pre-immune cells in the periphery as well as selecting for cells 
that have functional cytokine receptors (Stadanlick et al 2008).  
In the GC, the induction of proliferation is counterbalanced by the induction of pro-apoptotic 
genes (Klein et al. 2003) such that only cells receiving adequate survival signals are permitted 
to progress, this process selects for B-cells which have higher antigen affinity than their near 
clonal neighbours by a process of competition for limited amounts of antigen and T-follicular 
helper cell interaction (Goodnow et al. 2010; MacLennan 1994). Follicular helper T-cells 
produce the IL-21 cytokine which can activate STAT3 and STAT5 in B-cells which in turn 
activates both BCL6 and BLIMP which promote and inhibit a memory B-cell fate respectively 
(Schmidlin et al. 2009). It is unknown whether B-cells encountering IL-21 signalling are 
predisposed to the memory or Plasma cell fate or if kinetic or stochastic mechanisms resolve 
this developmental branch point, however the BCL6 and BLIMP expression appear to be 
mutually exclusive (Cattoretti et al. 2005). Interestingly both PU.1 and PAX5 were shown to 
repress BLIMP1 suggesting that these TFs promote a memory B-cell fate in the GC (Shaffer et al. 
2002; Su et al. 1997). 
There are many more consensus binding sites for TFs than sites that are actually bound. This 
suggests that co-factors and chromatin marks are also crucial to the direction of TFs to target 
genes. However TFs have also been shown to induce changes in the chromatin landscape. We 
are starting to develop an understanding about the chronology of these events and much of 
this work has used the B-cell differentiation pathway as a model due to the hierarchical nature 
of TF expression. One model suggests that regulatory elements are in a pre-active state in early 
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progenitor cells before transcriptional initiation occurs. This ‘gene priming’ has been proposed 
to be conducted by ‘pioneer TFs’ (Zaret and Carroll 2011). The requirements for a ‘pioneer TF’ 
are that it must bind to a regulatory element prior to other factors, it must be able to target 
repressed sites such as those with compacted chromatin and it must induce chromatin 
remodelling to a more permissive state (reviewed in (Zaret and Carroll 2011)). Such sites would 
often present as poised enhancers or promoters prior to further TF binding and gene 
activation and such sites are abundant throughout the hematopoietic system (Ghisletti et al. 
2010; Mercer et al. 2011). An example candidate for a ‘pioneer TF’ is PU.1 which can bind its 
cognate site in condensed chromatin, can recruit histone methyl transferases and chromatin 
remodelling complexes resulting in sites that have the mark of a poised site; H3K4me1 but no 
H3 or H4 acetylation. Subsequent collaborative binding of EBF1, E2A and HATs could then lead 
to enhancer activation and gene transcription (Fig 1-3) (Zaret and Carroll 2011).  
In a study in which E2A expression was conditional, Mercer et al examined histone 
modifications before and after E2A expression and subsequent differentiation (Mercer et al. 
2011). Many enhancers important to B cell differentiation were shown to be pre marked with 
H3K4me1 in MPPs, preceding commitment to myeloid/lymphoid lineage. These sites were 
enriched for PU.1 motifs in pre-E2A expressing cells whereas H3K4me1 sites after E2A 
expression were enriched for E2A, EBF1 and PU.1 motifs. These data suggests that TFs can be 
recruited by chromatin modifications and can create them. PU.1 binding can directly induce 
H3K4me1 at certain loci, yet many bound sites lack this mark, suggesting a requirement for 
additional factors in a locus specific manner (Heinz et al. 2010). Interestingly, at sites where 
PU.1 binds to existing H3K4me1 sites PU.1 was shown to induce chromatin remodelling (Heinz 
et al. 2010). At the PAX5 locus it appears that PU.1 and IRF4 binding precedes gene activation 
and can induce active chromatin marks, priming the gene for subsequent activation by EBF1 
(Decker et al. 2009). However EBF1 can also cause positive epigenetic changes in B-cell 
progenitors (such as at the CD79a promoter where EBF1 can bind despite non permissive 
chromatin) and PAX5 can induce both activation or repression of genes via the recruitment of 
histone modifications (Maier et al. 2004; Cho et al. 2007; Gao et al. 2009; McManus et al. 
2011). It is therefore likely that the term ‘pioneer TF’ is not useful unless used in a specific 
context. Perhaps all TFs can display the previously mentioned qualities given the right context 
and those that do display these qualities may not possess them at other loci. For example at 
some loci PU.1 cannot bind without factors such as E2A and EBF1. What determines which loci 
are permissible to an individual TF acting as a ‘pioneer’ likely depends on protein-protein  
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Figure 1-3 Model of pioneer transcription factor activity. (Choukrallah and Matthias 2014) Gene 
priming by a ‘pioneer TF. (A) In this model an inactive gene with an enhancer site in compacted 
chromatin is bound by PU.1 before any other factors. (B) PU.1 then recruits histone 
methlytransferases (HMT) and chromatin remodelling complexes (CRCs) to create a more 
permissive chromatin environment and deposition of markers of enhancers (H3K4me1). (C) 
subsequent association with other transcription factors such as IRF4, EBF1 or E2A causes further 
activating histone modifications by the recruitment of Histone acetyl transferases (HATs), resulting 
in H3K9ac, H3K27ac  and gene activation. 
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interactions, chromatin modifications, DNA modifications and even long non coding RNAs 
(reviewed in Choukrallah and Matthias 2014). 
1.1.3.2 PU.1 
PU.1 belongs to the ETS family of TFs and is essential for the development of lymphoid cells, 
macrophages and neutrophils (McKercher et al. 1996). PU.1 is expressed in HSCs, lymphoid 
and myeloid progenitors and in mature B-cells (Klemsz et al. 1990; Akashi et al. 2000; Iwasaki 
et al. 2005). PU.1 is not required for later differentiation steps in B-cells despite the fact that it 
is still expressed, suggesting that it has important functions other than specifying B cell fate 
although there is limited evidence of what these roles might be. ChIP sequencing of PU.1 
showed that it primarily associates with intra and inter-genic sites suggesting a role in 
transcriptional regulation via enhancer elements. Furthermore, PU.1 binding sites at 
promoters were highly conserved throughout various HSC derived cells whereas enhancer 
binding sites were highly cell type specific (Heinz et al. 2010). Analysis of enriched motifs at 
PU.1 binding sites revealed that in B-cell progenitors E2A (TCF3), EBF1, OCT and NFKB motifs 
were enriched whereas in macrophages, C/EBP and AP1 were enriched. This suggests that cell-
type specific binding is at least partly dependent on collaborative binding or interaction with 
other TFs. Importantly the dosage of PU.1 was found to be critical to lineage specification at 
developmental branches. High PU.1 expression was shown to correlate with macrophage and 
neutrophil cell types, intermediate with B-cells and low with erythroid and T-cell types (Fig 1-4) 
(DeKoter and Singh 2000; Back et al. 2004). The mechanism of dose dependence of PU.1 
remains poorly understood.  
1.1.3.3 EBF1 
EBF1 was first identified as a DNA binding protein which could activate CD79a, an essential 
component of the B-cell receptor (BCR) and its signalling functions (Hombach et al. 1990; Gold 
et al. 1991; Hagman et al. 1991). It can form stable homodimers in the absence of DNA and has 
an unusual DNA binding motif (its closest relative is NFKB with 14% sequence identity), which 
associates with a long palindromic consensus motif with a 2bp spacer (Hagman et al. 1995; 
Siponen et al. 2010). EBF1 can activate B-cell specific genes including Pax5 which causes B-cell 
lineage commitment (O'Riordan and Grosschedl 1999). Further lineage commitment is also 
provided directly by EBF1 as it downregulates expression of genes driving alternate lineages 
(Thal et al. 2009). At target loci EBF1 can initiate epigenetic changes but often requires existing 
chromatin modifications directed by upstream TFs such as PU.1. For example at CD79a, EBF1  
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binding occurs after PU.1 and RUNX1 associate with an intragenic enhancer and subsequently 
causes increased chromatin accessibility and decreased DNA methylation, facilitating CD79a 
expression (Gao et al. 2009). EBF1 is transcriptionally upregulated by PU.1, E2A and FOXO1 and 
the loss of EBF1 results in complete developmental arrest at the CLP stage of development 
(reviewed in (Hagman et al. 2012)). Furthermore, ectopic expression of EBF1 in non-lymphoid 
cells that lack upstream factors involved in B-cell development causes activation of at least 
part of the B-cell developmental program (Romanow et al. 2000; Medina et al. 2004). Similarly 
to PU.1 the dosage of EBF1 is important for its function. CLP cells expressing low EBF1 can 
differentiate into NK, B or T cells, those with intermediate EBF1 expression differentiate into B 
or T cells whereas those with a high dosage of EBF1 are committed to a B-cell fate only (Fig 1-4) 
(Mansson et al. 2010). This developmental branch point may be decided by stochastic 
mechanisms as EBF1 upregulates its own expression, as well as repressing suppressors of E2A 
and upregulating PAX5, both of which would result in increased EBF1 expression (Smith et al. 
2002; Pongubala et al. 2008; Thal et al. 2009). 
Less is known about the role of EBF1 after progenitor B cells leave the bone marrow as 
immature or mature B cells. However, there is emerging evidence that it has a role as a tumour 
suppressor as EBF1 mutations are commonly found in acute lymphoblastic leukaemia (ALL) 
cases and 25% of relapsed ALL cases show mutations at this locus (Mullighan et al. 2007; Yang 
et al. 2008). Furthermore EBF1 mutations have been shown to be implicated in solid tumours 
including breast and adenocarcinoma cells (Neve et al. 2006; Jones et al. 2008). This may be 
due to its role in maintenance of cell fate and cell differentiation. ChIP-sequencing of EBF1 has 
confirmed its role as one of the primary regulators of B-cell genes and its ability to recruit, and 
be recruited by histone modifications (Lin et al. 2010; Treiber et al. 2010).  
1.1.3.4 NOTCH/RBPJκ 
NOTCH signalling is highly conserved and is involved in a vast array of biological processes, 
including development, differentiation, lymphogenesis and regulation of B-cell activity 
(reviewed in (Radtke et al. 2010; Greenwald 2012)). NOTCH is a membrane protein which upon 
ligand interaction undergoes cleavage by A disintegrin and metalloprotease (ADAM) proteins. 
Cleaved intracellular NOTCH is then transported to the nucleus where it interacts with 
recombination signal binding protein – Jκ (RBPJκ or CBF-1) and recruits coactivators such as 
mastermind proteins (MAML) at RBPJκ consensus DNA binding sites. This nucleates a 
transcriptional activation complex (Gordon et al. 2008; Kopan and Ilagan 2009). Some known 
targets of NOTCH signalling include MYC, HEY1, HES1 and chemokine receptors (Weng et al. 
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2006). Humans have 4 NOTCH proteins (NOTCH1-4) which use Delta like 1, 3, 4 and Jagged 1, 2 
as ligands (Bray 2006). These are non-redundant and whilst there is overlap in function 
between different NOTCH-ligand interactions they fulfil distinct biochemical processes. For 
example, NOTCH1 signalling has been implicated in T-cell development. Hematopoietic stem 
cells (HSC) are not generated in cells lacking NOTCH1 or RBPJκ. However, NOTCH/RBPJκ 
signalling is not required for HSC maintenance and NOTCH signalling must be controlled to 
prevent ectopic differentiation (Kumano et al. 2003; Maeda et al. 2007). Like PU.1 and EBF1, 
the dose of NOTCH signalling is important, with HSCs undergoing more NOTCH signalling more 
likely to become T cells rather than B cells (Fig 1-4) (Dallas et al. 2005). Inducible inactivation of 
NOTCH1, RBPJκ or MAML1 results in a block in T cell development and ectopic B cell 
development, whereas overexpression of intracellular NOTCH results in ectopic T-cells at the 
expense of the B-cell population (Pui et al. 1999; Radtke et al. 1999; Han et al. 2002). NOTCH1 
is also upregulated in mature T-cells after T-cell receptor activation and is responsible for 
promoting proliferation and IFN-γ production (Palaga et al. 2003). NOTCH2 on the other hand 
is preferentially expressed in B-lymphocytes and is essential for the development of marginal 
zone B cells (MZB) along with ADAM proteins and RBPJκ (Saito et al. 2003; Gibb et al. 2010). 
NOTCH signalling in mature B-lymphocytes can cause differentiation into antibody secreting 
cells and enhanced BCR activation (Santos et al. 2007; Thomas et al. 2007). Importantly, 
NOTCH signalling in GC B cells after exposure to antigen protects them from apoptosis by 
interacting with ligands expressed on dendritic cells (Yoon et al. 2009).  
1.1.4 Role of DNA elements 
1.1.4.1 Transcriptional regulation via promoter elements 
Much of the regulation of transcription is initially coordinated by DNA elements, including the 
core promoter, promoter-proximal elements and distal sites such as enhancers, silencers, 
insulators and locus control regions. These DNA elements are usually modular, allowing sets of 
cellular factors to bind in a coordinated fashion to create a vast number of unique expression 
patterns. Combinatorial control of gene expression by factors bound at multiple DNA elements 
also allows cells to rapidly respond to environmental or developmental stimuli. It is 
noteworthy that of the ~25,000 human protein coding genes only ~1850 are DNA binding 
transcription factors (Venter et al. 2001).  
The core promoter is the site at which RNAPII and general transcription factors bind, and 
defines the transcription start site (TSS) and direction of transcription (Smale and Kadonaga 
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2003). The core initiation complex is sufficient to transcribe a gene but generally only produces 
low levels of mRNA. The core promoter is recognised through DNA sequences that aid in 
recruiting members of the RNAPII initiation complex (Table 1-2). However, statistical analysis 
of ~10,000 known promoters revealed that only one in eight contain a TATA box, and one 
quarter possess none of the proposed core promoter DNA elements (Gershenzon and 
Ioshikhes 2005). This suggests that there may be other core promoter elements which have yet 
to be described or the known sequences can be much more degenerate than originally 
thought. Another hypothesis is that the exact sequence is secondary to the DNA secondary 
structure at the core promoter ((Florquin et al. 2005). There is also evidence that the 
composition of core promoter elements contributes the regulatory specificity of distal 
regulatory inputs (Morris et al. 2004).  
For 60% of human genes the promoter is near a CpG island, an area with a high G and C 
content typically 500bp-2kb in length, which can be methylated to modulate binding of 
activators (Venter et al. 2001). Methylated DNA is indicative of gene repression as many 
activators are not able to bind to methylated forms of their DNA recognition sequences. 
Furthermore proteins such as MeCP2 can specifically bind methylated CpG nucleotides and 
recruit histone modifying complexes to establish a repressive chromatin structure (Jones et al. 
1998).  
Basal transcription can be stimulated by the action of activators which are broadly defined as 
sequence-specific DNA binding proteins. Activators generally bind to promoter-proximal 
elements within a few hundred base pairs of the core promoter (Ptashne and Gann 1997) and 
can categorised as belonging to one of the following families: zinc finger, homeobox, helix-
loop-helix, basic leucine zipper, fork head, ETS and POU DNA binding domain proteins (Pabo 
and Sauer 1992). The DNA binding site for transcription factors is sequence specific but many 
are degenerate. Transcription factor consensus binding motifs are therefore created by 
examining all known binding sites and determining the most represented nucleotides 
(Claessens and Gewirth 2004). The degeneracy of transcription factor binding sites may in fact 
have biological significance as the precise sequence can modulate activator binding strength 
and affinity (Yang et al. 2014), dimerization partners (Claessens and Gewirth 2004) and even 
activator structure (Lefstin and Yamamoto 1998). Importantly, it has also been shown that 
PU.1 and Ets-1 (ETS family proteins with little amino acid identity in their ETS domain binding 
site) both bind to the same ETS consensus site but via different mechanisms (Wang et al. 2014). 
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Table 1-2 promoter proximal elements (adapted from(Maston et al. 2006)). Current known 
core promoter elements, their common abbreviation and consensus motif are shown. 
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Transcription factors (activators) can stimulate transcription in numerous ways. In some cases 
TFs increase PIC formation via direct interactions with components of the transcriptional 
machinery (Orphanides et al. 1996). Further roles in aiding PIC assembly, initiation, elongation 
and reinitiation have also been described (Lee and Young 2000). Furthermore transcription 
factors can play a role in modulating local chromatin structure to facilitate transcription by 
recruiting chromatin structure modifiers (de la Serna et al. 2005). Indeed, recent work suggests 
that the binding of a particular transcription factor to a piece of DNA allows for accurate 
prediction of histone modifications present at that site (Benveniste et al. 2014). The effects of 
activators on transcription can be synergistic; that is, a gene targeted by more than one 
activator can have an effect on its transcription greater than the sum of each by itself. This is 
likely due to activators aiding recruitment of different parts of the PIC or altering different 
aspects chromatin structure and histone modification (Green 2005). Activators and 
transcription factors can have their activity further controlled by the action of co-activators. 
These do not exhibit intrinsic sequence specific DNA binding activity but instead use protein-
protein interactions with DNA bound activators. Co-activators function in many of the same 
ways as activators, modifying chromatin landscape and altering the composition of the core 
transcriptional machinery. Co-activators/repressors can positively or negatively affect 
transcription dependant on the gene in question and the proteins it is associated with (Lonard 
and O'Malley 2005). 
1.1.4.2 Long-range transcriptional regulatory elements 
The first vertebrate distal DNA element was described at the immunoglobulin heavy chain 
locus where it was shown to dramatically increase the expression of a number of nearby genes. 
It was able to do this regardless of the orientation of the element and acted over distances of 
several hundred to several thousand base pairs (Banerji et al. 1983). These are the features of 
an enhancer element, these element characteristically function independently of orientation 
and distance from the promoter. A single promoter can be acted upon by distinct enhancers at 
different times or in different tissues, allowing more unique expression patterns than could be 
gained from promoter-proximal elements alone (Atchison 1988). Enhancers typically contain a 
cluster of transcription factor binding sites (TFBS), the spatial organisation and orientation of 
which is important to its function. Strikingly, it has been shown that even inserting 6bp of 
random DNA between two TFBS in an enhancer reduces its activating ability by ~17 fold 
(Thanos and Maniatis 1995). Enhancers are functionally similar to promoter proximal elements; 
in fact their only defining feature may be the distance over which they act. It appears protein-
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bound enhancers use many of the same mechanisms to stimulate transcription as promoter 
proximal elements and can physically contact the promoter in question via DNA looping (Fig 1-
5) (Vilar and Saiz 2005). Interestingly, contacts have also been detected between enhancers 
and promoters on different chromosomes. In fact one enhancer was shown to interact with 
multiple promoters on different chromosomes, and it is likely that some promoters are 
contacted by multiple enhancers from different chromosomes (Spilianakis et al. 2005; 
Lomvardas et al. 2006). How enhancers specifically target promoters is not well understood. 
Silencers share many of the same attributes as enhancers and promoter-proximal elements 
only their effect on transcription is primarily negative. Silencers typically act independent of 
orientation or distance and are binding sites for negative transcription factors or repressors 
and co repressors. Indeed some activators can become repressors by interactions with 
particular co-factors (Murayama et al. 2004). The mechanism of transcriptional repression can 
be as straightforward as allosteric inhibition of activator binding to a nearby site, or by direct 
competition for a binding site. Some can establish repressive chromatin structures by 
recruiting histone modifying or chromatin stabilising factors, thereby inhibiting general 
transcription factor binding (Srinivasan and Atchison 2004). Unlike enhancers, there is little 
evidence for silencers repressing transcription via looping 
Another important DNA element involved in the regulation of transcription the insulator 
element. Generally, these elements block genes from being affected by the transcriptional 
activity of neighbouring genes through association with proteins or via chromatin structure. 
Insulators have been reported to prevent enhancer-promoter communication and to prevent 
the spread of chromatin modifications, delineating chromatin domains such as 
heterochromatin or euchromatin. These two mechanisms appear to be separable activities, ie 
not all insulators prevent both (Recillas-Targa et al. 2002). The transcription factor CTCF 
appears to be one protein that can mediate insulator activity, reviewed in (Holwerda and de 
Laat 2013). The mechanism of insulator function is not well understood. One model proposes 
that by interacting with transcriptional activators and histone modifiers, insulators create 
areas of chromatin permissive to transcription thereby blocking the spread of heterochromatin 
whilst preventing bound activators from interacting with target promoters (Defossez et al. 
2005). A second model is that insulators physically separate areas of DNA by interacting with 
each other or nuclear attachment proteins thereby forming large scale chromatin secondary 
structures. This model is supported by recent genome wide chromosome conformation  
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B 
C 
Figure 1-5 Model for gene activation via enhancer looping. (A) A repressed promoter with a 
downstream unoccupied enhancer element indicated in red. In this situation DNA would likely 
be associated with repressive histone modifications and condensed chromatin. A ‘pioneer TF’ 
indicated in grey can associate with this enhancer element. (B) Association of the ‘pioneer TF’ 
with the enhancer facilitates the recruitment of other TFs, co factors and histone modifying 
enzymes. (C) The enhancer complex physically associates with TFs at the promoter facilitating 
the recruitment of the PIC and transcriptional initiation. 
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capture (HiC) studies which observe large-scale domain separation, a process possibly 
mediated by CTCF induced DNA looping (Lieberman-Aiden et al. 2009). 
CTCF is a transcription factor which can act as a repressor (Lobanenkov et al. 1990) or activator 
(Klenova et al. 1993) of transcription. It acts at insulator elements to prevent enhancer, 
promoter communication and insulates chromatin modifications (Bell et al. 1999; Recillas-
Targa et al. 2002). CTCF can also promote promoter enhancer looping (Handoko et al. 2011). 
At the β-globin locus CTCF insulates the activity of a local locus control region (LCR) and 
prevents heterochromatin spreading into the region using a mechanism that involves looping 
between two CTCF sites either side of the locus in a cell type specific manner (Farrell et al. 
2002; Bulger et al. 2003; Palstra et al. 2003; Splinter et al. 2006). CTCF is a DNA binding protein 
with a large and degenerate consensus motif. This has been shown to be functionally relevant 
to CTCF function with changes in which sites (degree of difference from consensus) are bound 
during the course of mouse embryonic stem cell development (Plasschaert et al. 2014). The 
methylation of CTCF binding sites prevents CTCF binding which in turn allows allele specific 
gene expression via the removal of a CTCF bound insulator element and subsequent promoter 
enhancer looping (Bell and Felsenfeld 2000; Hark et al. 2000). CTCF itself can influence DNA 
methylation via interactions with PARP1 mediated DNMT1 inactivation resulting in methyl free 
DNA at CTCF binding sites (Zampieri et al. 2012), but has also been shown to increase the 
repressive H3K27me3 mark as knock down of CTCF results in less H3K27me3 in repressed 
domains (Van Bortle et al. 2012). This process is perhaps mediated via concentrating polycomb 
group proteins via the insulator activity of CTCF. ChIP sequencing experiments reveal that CTCF 
associates with tens of thousands of sites in the human genome, only ~30% of which are 
conserved across cell types (Kim et al. 2007; Wang et al. 2012). At MYC and other genes, CTCF 
has been shown to bind to promoter proximal elements, and the removal of a CTCF site from 
the MYC promoter induced gene repression via DNA methylation (Barski et al. 2007; Gombert 
and Krumm 2009). CTCF mediated looping appears in part to be dependent on its association 
with cohesin (Rubio et al. 2008) and at the MHCII locus CTCF, cohesin and CIITA can induce 
promoter enhancer loops increasing gene expression (Majumder and Boss 2011). It can also 
recruit the basal transcription factor TAF3 to intergenic sites in embryonic stem cells allowing 
TAF3 dependant enhancer looping and gene activation (Liu et al. 2011). CTCF is even 
implicated in RNAPII stalling potentially aiding the incorporation of weak exons or RNAPII 
processivity (Shukla et al. 2011). CTCF activity is likely decided by which other transcription 
factors it associates with at a given binding site in a tissue and genomic context specific 
manner, reviewed in (Holwerda and de Laat 2013).  
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LCRs are regions of the genome with clusters of enhancers, silencers and insulators bound by 
transcription factors, coactivators, repressors, co repressors and chromatin modifiers can be 
found and they typically regulate entire gene clusters or loci (Li et al. 2002). One of the best 
described LCRs is involved in the regulation of the β-globin locus. Here five globin genes that 
are differentially expressed during development are arranged in order of developmental 
expression. The distal LCR confers a high level of activity to all genes in this cluster, a function 
which was shown to be orientation dependant as inversion of the LCR ablated transcriptional 
activation (Tanimoto et al. 1999). If LCRs are functionally distinct from their individual 
components remains to be determined.  
The in silico prediction of DNA elements such as transcription factor binding sites, promoter-
proximal elements, enhancers, silencers and others is challenging. Even high throughput 
experiments such as ChIP-sequencing are difficult to analyse as function cannot readily be 
dissected from binding data. Programmes such as MEME-ChIP 
(http://meme.nbcr.net/meme/doc/meme-chip.html) are able to use consensus binding motifs 
to predict potential transcription factor binding sites, and this coupled with ChIP sequencing 
data is improving the in silico process. But how transcription factors bind to sites with no 
consensus motif, or why they don’t bind to perfect consensus motifs is a paradox that so far 
only gene by gene analysis can answer. It may eventually be possible to incorporate all histone 
modification, transcription factor and gene expression (RNA sequencing data) to provide 
accurate predictions for novel enhancers, silencers, insulators and LCRs. This is likely to be cell 
type and environment specific, and is the ultimate goal of the ENCODE project. 
1.2 Epstein-Barr virus 
1.2.1 Discovery 
Epstein-Barr virus (EBV) is a gamma herpesvirus first discovered in 1964 by Anthony Epstein, 
Yvonne Barr and Bert Achong (Epstein et al. 1964). Unlike most viruses which are identified 
due to an acute illness in the patient, EBV was discovered due to its association with Burkitt’s 
lymphoma (BL), a B-cell lymphoma first described in the 1950s by the Irish surgeon Dennis 
Burkitt (Burkitt 1958). BL manifests as a malignant tumour of the jaw, eye or abdomen with 
high occurrence in young children in Africa. In a subsequent ‘tumour safari’ Burkitt noticed 
that the cancer had a particular geographical distribution: firstly, BL was found to be endemic 
only in the malaria belt of equatorial Africa, where it is the most common childhood cancer; 
secondly, within central Africa a higher incidence of BL was observed in the lowlands with 
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tropical climate compared to higher-level areas with less rainfall (Burkitt 1962). This led Burkitt 
to believe that the tumour had infectious agent involvement, possibly transmitted by the 
mosquito as malaria is.  
EBV was confirmed as the first human tumour virus in the 1970s when culture media in which 
BL cells had been growing was found to be able to immortalise B cells (reviewed in (Andersson 
2000; Bornkamm 2009)). More recently it has been discovered that nasopharyngeal carcinoma 
(NPC), a cancer found most commonly in southeast Asia and southern China is also significantly 
linked with EBV infection (Chang et al. 2009). The association between EBV and these endemic 
cancers is strong, almost 100% of endemic BL cells are infected with EBV. (Kutok and Wang 
2006). Early studies into EBV prevalence in BL patients and control groups discovered that 
approximately 95% of the adult population worldwide is infected with EBV and in the vast 
majority of cases such an infection is asymptomatic (Henle et al. 1969). Epstein-Barr virus has 
become one of the best studied herpes viruses and is a model for viral latent infection. Its 
study may aid the treatment of numerous EBV-associated malignancies and progress our 
general understanding of tumourigenesis, viral infection and B-cell biochemistry. 
1.2.2 Initial infection 
In common with other members of the gammaherpesvirinae family, EBV most commonly 
infects B cells, although in the case of EBV it has also been shown to productively infect 
epithelial and T cells. The virus exists as a 172kb double stranded linear DNA molecule encased 
in a protein envelope. EBV gains entry to B cells by the interaction between the cellular 
compliment receptor 2 (CR2 or CD21) protein and a viral membrane fusion complex containing 
gp350/220 (Tanner et al. 1988). EBV proteins gH/gL and gp42 then bind human leukocyte 
antigen (HLA) class II which triggers viral entry into the B cell (Li et al. 1997). gH, gL, gB and 
gp42 are indispensable for EBV infection of B cells whilst only gH, gL and gB are indispensable 
for epithelial cell infection (Li et al. 1995; Li et al. 1997; Haan et al. 2001). How EBV enters 
epithelial and T-cells is less well understood. It is likely that EBV can infect B cells at multiple 
stages of B-cell development but only immature and mature infected B-cells are found in the 
peripheral blood in vivo and lymph nodes. 
Upon internalisation the terminal repeats at either end of the viral genome fuse forming a 
circular episome which can then be transcribed by cellular transcription machinery to enable 
expression of the range of EBV proteins required to establish viral persistence (Fig 1-6). The 
circularisation of the EBV genome is detectable 20 hours post infection and is required for  
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Figure 1-6 Epstein Barr Virus genome. (Murray and Young 2001) Diagram showing the location of 
latency genes within the viral genome.  Origin of replication (OriP) is shown in orange and the 
primary message produced from Wp or Cp is shown in red. This is then alternatively spliced to 
produce the latent genes shown with purple arrows. The transcript from Qp encoding EBNA 1 is 
shown in blue. Terminal repeats where circularisation takes place is shown in pink. The location and 
details of the LMP promoters and locations of the EBV encoded RNAs are also displayed. 
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immortalisation. B-cell activation is indicated by a coincident increase in CD23 expression, a 
marker of activated B cells (Hurley and Thorley-Lawson 1988). B cells infected by EBV in vitro in 
the absence of an immune response are transformed into indefinitely proliferating 
lymphoblastoid cell lines (LCLs).  
The initial infection of epithelial cells in the nasopharynx is followed by further lytic activation 
creating infected cell plaques of up to 105 cells and amplifying viral output before plaque 
growth is halted by the immune system. During this time virus is continually shed into the 
saliva such that mouth washing every two minutes fails to reduce the quantity of EBV viral 
progeny in the saliva (Hadinoto et al. 2009). Viral infection of epithelial cells occurs in a non 
CR2 (CD21) dependant manner and likely occurs through alternative viral glycoproteins gH and 
gL with an unknown epithelial cell receptor (gHgLR). Viral progeny created in epithelial cells are 
better able to infect B cells due to higher levels of viral glycoprotein gp42 and viral progeny 
created in B cells are better at infecting epithelial cells. This suggests that an epithelial 
amplifying infection is likely to occur prior to initial infection and on virion release (reviewed in 
(Hutt-Fletcher 2007)). This process is vigorously controlled by the immune response at all 
stages resulting in persistent infection, continual production of viral progeny and host-virus 
balance.  
Upon infection EBV expresses a ‘pre latent’ gene profile including some genes normally 
associated with lytic cycle, the effects of which are controversial. One of these genes is BZLF1 
which encodes Zta (ZEBRA or Z), the master regulator of the switch from latency to lytic cycle, 
which is expressed alongside a set of latency genes described as the latency III pattern of gene 
expression. Other lytic associated genes such as BRLF1, another ‘immediate early’ lytic gene 
which encodes Rta (which is directly transactivated by Zta) are also expressed. Late lytic genes 
are not expressed in the pre-latent stage and no viral progeny are released (Kalla et al. 2010). 
However Halder et al have showed in a similar system that a more extensive set of lytic genes 
are expressed in the pre-latent stage of infection including late lytic genes such as the major 
capsid protein Bclf1, which is detectable as early as 6 hours post infection, and that such an 
infection does produce infectious viral progeny (Halder et al. 2009). They postulate that this 
strategy allows the expansion of the number of infected B cells on initial infection and that 
either some cells survive lytic replication and return to a latent form or that some cells become 
lytic upon initial infection and die whereas others express a latent pattern of gene expression. 
It was subsequently proven that Zta has a much higher affinity for some binding sites with 
methylated CpG dinucleotides and that the incoming viral DNA is unmethylated and does not 
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produce viral progeny (Kalla et al. 2012). This may occur because PCNA, which is required to 
tether cellular DNA methyltransferase to newly replicating DNA, does not participate in herpes 
viral DNA amplification (Muylaert and Elias 2010). Discrepancies between the two studies may 
be due to the preparation of EBV virions. Halder et al transfected 293t cells with EBV GFP BAC 
to produce viral progeny whereas Kalla et al used HEK293 cell transfected with maxi-EBV 
plasmid p2098 (Halder et al. 2009; Kalla et al. 2010). This could result in differences between 
methylation states of either viral progeny.  
The expression of lytic genes early in infection may facilitate immune evasion strategies. BCRF1 
has also been shown to be expressed in the pre-latent stage and encodes vIL-10 (viral IL-10 
homolog) which has been shown to protect EBV-infected cells from NK cell mediated 
elimination and is secreted to prevent release of antiviral cytokines abrogating the CD4+ T cell 
response (Jochum et al. 2012a). BNLF2a is also expressed early in infection and impairs 
recognition of virally infected cells by EBV specific CD8+ T lymphocytes (Jochum et al. 2012a). 
The expression of this restricted lytic subset of genes has also been shown to support the 
proliferation of resting B cells (Halder et al. 2009) and protect against apoptosis (Altmann and 
Hammerschmidt 2005). Intriguingly it has recently been reported that viral mRNA for BZLF1, 
BNLF2a, BCRF1, LMP1, LMP2A/B and EBNA 2 has been found to be present within the virion 
and is transduced and translated immediately upon infection which may contribute to the 
immune evasion and rapid proliferation provided by the pre latent stage of expression 
(Jochum et al. 2012b). The pre-latent phase is transient and appears to completely cease 1-2 
weeks post infection as a result of extensive CpG methylation of the viral genome and is 
followed by a strictly latent gene profile (Kalla et al. 2010). 
1.2.3 EBV latent gene transcription 
On initial infection of B cells by EBV in vitro and most likely in vivo, a latency III pattern of gene 
expression is adopted resulting in the expression of nine viral proteins, including the Epstein-
Barr nuclear antigen (EBNAs), latent membrane proteins (LMPs) and non-coding viral RNAs 
such as the Epstein-Barr virus-encoded small RNAs (D'Souza et al. 2006) and BART miRNAs. 
Initially the virus uses the BamHI W promoter (Wp) which drives expression of EBNA 2 and 
EBNA leader protein (EBNA-LP). The latent W promoters consist of tandemly arrayed W 
repeats and is dependent on cellular factors such as CREB/ATF (Kirby et al. 2000). The 
production of EBNA 2 drives a switch to the C promoter (Cp) from which a long primary 
transcript encoding EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C is transcribed. Wp is then largely 
silenced by epigenetic changes (Hutchings et al. 2006) such as DNA methylation of CpG islands 
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(Tierney et al. 2000). EBNA 2 binding to Cp results in a significant local increase in H4 and H3 
acetylation by EBNA 2 mediated p300 recruitment. This recruits bromodomain protein 4 (BRD4) 
which in turn allows recruitment of positive transcription elongation factor b (pTEFb). At Cp 
there is significant promoter proximal stalled RNAPII, negative elongation factor (NELF) and 
DRB sensitivity inducing factor (DSIF)(Palermo et al. 2011). Promoter proximal stalling is 
required at Cp for keeping the promoter free of nucleosomes and to necessitate the 
recruitment of pTEFb thereby maintaining serine 2 CTD phosphorylation (Palermo et al. 2011). 
The single transcript produced from Cp in a latency III pattern of gene expression is 
alternatively spliced to produce EBNA 1, EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C. LMP1 and 
and LMP2B are expressed from their own bidirectional promoter. The LMP2A promoter is in 
the opposite orientation to that of LMP1 and the two genes transcripts overlap (Kerr et al. 
1992) (Fig 1-6). In all forms of latency the noncoding Epstein Barr encoded RNA (EBER) 1 and 2 
and the Bam H1 A rightward transcripts (BARTs) are expressed (Kim do et al. 2011). Latency III 
gene products promote EBV-induced cell growth, B cell transformation, immune evasion and 
resistance to apoptosis and also induces a vigorous cytotoxic T cell response (Middeldorp and 
Pegtel 2008). This is normally sufficient to eliminate rapidly proliferating cells in vivo, however 
in cases of immunodeficient individuals this can result in life threatening neoplasias. In vitro, 
and in the case of post-transplant lymphoproliferative disease (PTLD), the absence of an 
immune response results in infected B cells persisting as EBV immortalised lymphoblastoid cell 
lines (LCLs) continuously expressing the latency III pattern of gene expression. In vivo it is likely 
that latency III is only adopted during primary infection and perhaps sporadically during 
persistent infection but such cells are destroyed by the host immune system.  
1.2.4 Course of a latent infection in a healthy host 
The latency III gene products drive resting naïve B cells to proliferate as active b-blasts, it is 
these cells that then migrate to the GC. It is generally agreed that EBV gene expression is 
gradually shut down, going through latency II in the GC, and latency I patterns of gene 
expression in the final memory B cell (Fig 1-7)(reviewed in (Roughan and Thorley-Lawson 2009; 
Roughan et al. 2010)). Infection of resting B-cells ex vivo, without a GC or immune response 
instead gives rise to permanently proliferating lymphoblastoid cell lines (LCLs) continuously 
producing latency III gene products (Young et al. 2000). There is general agreement that the 
process of LCL outgrowth resembles the process of initial infection of naïve B-cells prior to 
differentiation and long term persistence in vivo. Therefore the initiation and sustaining of 
proliferation at this early stage in the host is a required step in the EBV life cycle. Latency III  
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gene products induce this hyperproliferative state, and maintain it despite intrinsic barriers to 
aberrant replication and a strong immune response. Nikitin et al showed that EBV infection 
caused a transient period of hyperproliferation 3-4 days post infection which correlated with 
an increased DNA damage response pathway activation. Analysis of transcript levels in resting, 
hyperproliferating and outgrown LCLs revealed that a number of genes involved in pathways 
including cell proliferation and DNA damage response were upregulated from resting to 
proliferating cells and subsequently attenuated in LCLs (Nikitin et al. 2010). This 
hyperproliferative phase may be similar to that induced by in vivo infection and, intriguingly, 
proliferation rates observed were similar to those of B cells in the GC (MacLennan 1994). The 
roles of individual latency III gene products in this process will be discussed later in this 
introduction. 
The initial burst of viral induced proliferation in infected naive B cells is rapidly curbed by the 
developing EBV specific CD8+ T cell response (reviewed in (Odumade et al. 2011)). However 
during the period of initial latent gene expression EBV infected activated B cells migrate to the 
GC (Laudencia-Chingcuanco et al. 2011) where a latency II pattern of gene expression is 
observed. In latency II EBV expresses EBNA1 and LMP1, 2A and 2B using the viral Q promoter 
and LMP specific and bidirectional promoters (see Fig 1-6). In the GC activated B cells first 
rapidly proliferate in the ‘dark zone’ accumulating somatic hypermutations (SHM) in their 
immunoglobulin genes which results in increased affinity of the B cell receptor for its antigen 
in some of the proliferating cells. Further differentiation causes migration to the ‘light zone’ 
where B cells with the highest affinity antigen outcompete others for the survival signal 
produced by T helper cells and undergo class switching by DNA recombination (CSR) to alter 
the function of their immunoglobulins. EBNA 2, which is not expressed in latency II, inhibits GC 
reactions, partly by inhibiting activation-induced cytidine deaminase (AID), which is essential 
for both CSR and SHM (Tobollik et al. 2006). It also downregulates BCL6 and TCL1, both 
germinal centre associated genes, of which BCL6 is absolutely indispensable for the GC 
reaction and SHM (Boccellato et al. 2007). The few B cells that survive the GC reaction 
differentiate to become either plasma cells or memory B cells. Cells that do not receive 
adequate survival signals rapidly undergo apoptosis (reviewed in (Spender and Inman 2011)).  
EBV infected cells surviving the GC reaction display all the hallmarks of a normally selected 
memory B cell. Such cells have accumulated SHM, have undergone CSR and the resulting 
immunoglobulins appear to have experienced normal antigen selection pressure as proper 
protein fold and increased antigen binding affinity are displayed (Souza et al. 2005). Also, 
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infected as well as uninfected B cells express GC transcription factor BCL6 and upon receiving 
survival signals uptake the BCL2 survival protein, suggesting normal B cell maturation 
(Roughan et al. 2010). It is also observed that infected B cells surviving the process express the 
expected chemokine profile and are therefore phenotypically indistinguishable from normally 
produced GC memory B cells (Roughan and Thorley-Lawson 2009). EBV therefore is likely to 
play a role in improving the survival chances of its host B cell in the GC rather than altering the 
process dramatically. LMP1 and 2 possess CD40 and BCR signalling functions providing pro 
survival signalling. Levels of LMP2A have been discovered to correlate with those of integrin-
alpha-6 (ITGα6), which is involved in cell migration and improved cell-cell contact, perhaps 
further contributing to survival signalling (Pegtel et al. 2005). LMP1 has been implicated in 
both increased cell proliferation and immune system evasion by regulating various chemokines 
(eg. CCL17), cytokines (eg. IL6) and adhesion molecules (eg. CD18)(Middeldorp and Pegtel 
2008). The fate of B cells leaving the GC appears to be dependent on the cytokine environment 
and relative strength and duration of interaction with antigen and T helper cells (Bernasconi et 
al. 2002). Prolonged T helper cell exposure may be more likely to lead to a memory B cell fate 
which is the desired destination for EBV infected cells as it allows persistent infection in the 
peripheral blood. It is therefore likely that EBV exploits the normal GC reaction rather than 
overriding it to produce latently infected memory B cells which can persist in the peripheral 
blood. 
Upon entering the peripheral blood as a memory B cell EBV assumes a latency I pattern of 
gene expression in which only EBNA 1, BARTs and the EBERs are expressed. EBNA 1 appears to 
induce no dramatic immune response in vivo due to purine bias in the glycine alanine repeat 
region forming G-quadruplexes. This results in reduced EBNA 1 translation and antigen 
presentation (Murat et al. 2014). However, whilst EBNA 1 is protected from presentation to 
cytotoxic T cells via the MHC class I pathway it does appear that it is presented to CD8+ and 
CD4+ helper T cells in vivo, perhaps via exogenous uptake of antigen via dentritic cells and 
subsequent ‘cross priming’ in both primary and memory stages of infection (Blake et al. 2000; 
Leen et al. 2001). Infected memory cells are phenotypically indistinguishable from uninfected 
cells and the viral episome mimics the host DNA; it is packaged in cellular histones, co-
replicates with cellular DNA once during S phase and is split into two daughter cells during 
mitosis. Latency 0 is also observed in vivo as EBV infected cells expressing no viral protein and 
only EBERs. This however may be due to EBNA 1 expression correlating with sporadic memory 
cell division requiring EBV to preserve its own genome (Hochberg et al. 2004). The switching 
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between the various forms of latency and lytic cycles of EBV is largely controlled by particular 
promoters within its genome being activated at specific times.  
In latency I circulating memory B-cells the Qp promoter is active, producing only the EBNA 1 
nuclear antigen, which along with oriP is sufficient for the virus to maintain its own genome 
(Leight and Sugden 2000; Fejer et al. 2008). Six EBNA 1 binding sites within the oriP region 
have also been shown to increase the activity of EBNA 2 induced transcriptional activation 
from Cp (Zetterberg et al. 2004). In order for EBV to infect new hosts, infected circulating 
memory B cells return to the GC in the tonsils and undergo periodic reactivation to produce 
infectious virus. As circulating memory B cells express an extremely limited set of genes the 
signal to do this likely comes from host factors during memory cell differentiation. The process 
of memory cell differentiation upon antigen stimulation usually results in plasma cells which 
are essentially biochemical factories for antibody production. In infected cells the terminal 
differentiation into a plasma cell and the associated changes in cellular gene expression and 
epigenetic environment results in the expression of Zta resulting in lytic phase activation 
(Laichalk and Thorley-Lawson 2005; Murata et al. 2012). In the lytic phase the virus arrests the 
cell cycle in G0/G1 thereby inhibiting growth whilst it amplifies its own genome 100-1000 fold; 
producing the components of its viral progeny before lysing the cell and releasing viral progeny 
(Tsurumi et al. 2005). Viruses released from B-cells then infects epithelial cells as virions in the 
saliva appear to originate from a non B cell (Jiang et al. 2006). 
1.2.5 The host immune response to EBV 
EBV infection is tightly controlled by the host immune system. Perturbing the balance of EBV 
infection with the host immune response is a common cause of EBV related diseases. If initial 
infection occurs in adolescence 25% of individuals develop infectious mononucleosis (IM), 
which is an acute but self-limiting disease with symptoms including fever, sore throat, 
lymphadenopathy and is characterised by a large quantity of atypical lymphoblasts of CD8+ T 
cell origin in the blood (Crawford et al. 2006). IM is not entirely caused by late exposure to EBV 
as it sometimes occurs in childhood infection and may in fact be underdiagnosed (Chan et al. 
2003). In acute IM up to 10% of all B-cells in the blood are EBV positive. Natural killer (NK) cells 
are key components of the early innate immune response to microbial infection. NK cells have 
been shown to inhibit EBV induced B-cell transformation if added within a few days post 
infection, an effect that is at least in part due to the release of IFN-ϒ (Lotz et al. 1985). 
However, this is unlikely to be the dominant pathway for controlling EBV infection as 
individuals undergoing T cell transplantation are prone to EBV driven lymphoproliferative 
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disease despite the fact that NK cell levels are restored rapidly post transplantation (O'Reilly et 
al. 1997). 
The primary host response to EBV comes from CD8+ and CD4+ T-cells. In response to acute IM 
there is a dramatic proliferation of EBV epitope specific CD8+ T-cells responses, accounting for 
40% of total T-cells for lytic epitopes. There is also a CD8+ T-cell latent epitope response that 
accounts for up to 5% of the total CD8+ T-cell response. This is primarily directed against the 
EBV EBNA 3 family (reviewed in (Hislop et al. 2007)). Lytic specific CD8+ T-cells in IM blood 
rapidly undergo apoptosis without antigen stimulation due to low levels of expression of anti-
apoptotic BCL2 and BclX proteins and high expression of the pro-apoptotic Bax (Tamaru et al. 
1993; Callan et al. 2000). This helps to explain the rapid shut down of the CD8+ T cell response 
to IM as the infection is brought under control. In contrast the CD8+ T-cells with specificity to 
latent epitopes are less down regulated and as a result undergo a relative increase in the 
percentage of total circulating CD8+ T-cells (Hislop et al. 2005). After initial infection only 1-50 
per million B cells are infected with EBV. These sporadically undergo lytic reactivation when an 
antigen is encountered. Still epitope specific CD8+ T-cells account for up to 2% of the total pool 
for lytic epitopes and up to 1% for latent epitopes (Benninger-Doring et al. 1999). This stays 
relatively stable throughout the host’s life; however individuals over 60 tend to show 
increased levels of EBV epitope specific CD8+ T cells, reaching 14% of circulating T-cells in 
some cases (Ouyang et al. 2003). 
Less is known about the CD4+ host response, and whilst it is crucial for control of EBV infection, 
CD4+ cells do not rapidly expand in IM; however CD4+ epitope specific responses are 
detectable in IM blood for viral epitopes (Maini et al. 2000; Precopio et al. 2003). There is also 
detectable immune responses from memory CD4+ cells against EBV epitopes including EBNA 1, 
LMP proteins and BZLF1 resulting in IFNϒ production (Dukers et al. 2000; Bickham et al. 2001; 
Adhikary et al. 2006). Different EBV encoded proteins have different immunogenic properties. 
The CD8+ response is primarily composed of cells specific to BZLF1 and BRLF1 for lytic cycle 
proteins and the EBNA 3 family for latent proteins. The CD4+ response generally targets 
epitopes from BZLF1 for lytic cycle proteins and primarily EBNA 1 for latent proteins although 
EBNA 2 and EBNA 3C are also targeted (reviewed in (Hislop et al. 2007). This is not consistent 
across all infected hosts, for example in some cases CD8+ T-cells can be primarily composed of 
cells targeting epitopes from EBNA 2, EBNA-LP or LMP2 (Lee et al. 1997; Chapman et al. 2001). 
EBNA 1 has long been considered invisible to the CD8+ T-cell response due to the presence of a 
glycine-alanine repeat preventing its processing by the proteasome; however in some donors a 
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CD8+ IFNϒ type response is mounted against EBNA 1 epitopes suggesting the glycine-alanine 
repeat region offers protection rather than immunity (Lee et al. 2004). To counteract the host 
immune response EBV has evolved a plethora of immune evasion strategies in both lytic and 
latent stages of infection. The role of EBNA 2 and EBNA 3 family proteins in immune evasion 
will be discussed later in this introduction. 
1.2.6 EBV and disease 
Whilst it does not appear that EBV benefits from killing or compromising its host it is 
associated with approximately 1% of all tumours worldwide (Delecluse et al. 2007). If primary 
infection is delayed to adolescence EBV can cause infectious mononucleosis (IM) resulting in 
rapid proliferation of infected B cells and high viral titres. This is normally controlled by the 
cytotoxic T cell response but fatal forms of IM do occur where proliferation continues 
uncontrolled (Williams and Crawford 2006).  
EBV was initially discovered through its association with BL, which is extremely aggressive with 
one of the fastest doubling times of any human cancer (Burkitt 1958, 1962; de Leval and 
Hasserjian 2009). There are in fact three subtypes of BL, endemic (eBL), sporadic (sBL) and HIV 
associated. Whilst nearly 100% of eBL are EBV positive only 5-15% of sBL and 40% of HIV 
associated BL are EBV positive (Wright 1999; van den Bosch 2004; Young and Rickinson 2004). 
The unifying feature of BL is a translocation of the oncogene MYC to an immunoglobulin locus; 
this translocation is dependent on activation-induced cytidine deaminase (AID) which is highly 
expressed in GC B cells (Filipovich et al. 1992; Dorsett et al. 2007; Pasqualucci et al. 2008; 
Allday 2009). Furthermore BL predominantly express a latency I pattern of gene expression. 
Whilst the EBERs have been shown to have anti-apoptotic potential, EBNA1 has been shown to 
have limited oncogenic capabilities, raising the question of how EBV is involved in BL (Kitagawa 
et al. 2000). Hyper activation of MYC signalling as a result of its translocation to the 
immunoglobulin locus normally results in apoptosis. MYC induced apoptosis is mediated by 
p53 and Bim and the repression of either of these genes can allow a cell to survive a MYC 
translocation (Allday 2009). Importantly, Bim is one of the best characterised targets for EBV 
induced repression. EBNA 3A and EBNA 3C have been shown to promote H3K27me3 at this 
site resulting in eventual CpG methylation and persistent gene silencing (Paschos et al. 2012). 
Hodgkins lymphoma (HL) is characterised by disrupted lymph node architecture and the 
presence of Hodgkin/Reed-Sternberg (HRS) cells surrounded by T and B-lymphocytes. 
Hodgkins lymphomas account for 30% of all lymphoid malignancies and, depending on the 
39 
 
subtype of the disease, is up to 95% associated with EBV (Harris et al. 1999). A common 
feature of HL is that cells have lost a functional BCR during the GC reaction and should undergo 
apoptosis due to lack of survival signals. HRS cells express a latency II pattern of gene 
expression, including LMP1 and LMP2A which mimic CD40 and BCR signalling respectively 
(reviewed in (Kapatai and Murray 2007)). Interestingly, HRS cells have been reported to lack 
critical B-cell transcription factors such as PU.1 (Torlakovic et al. 2001). Furthermore the 
inhibitor of DNA binding family protein ID2, has been shown to be over expressed in HRS cells 
(Renne et al. 2006). ID2 specifies an erythroid fate for MLL cells and does so by negatively 
regulating E2A (Mathas et al. 2006; Ji et al. 2008); in turn E2A activates EBF1 which represses 
ID2, a process that is essential for B-cell development (Thal et al. 2009). It has been suggested 
that the repression of B-cell lineage transcription factors and subsequent T-cell like phenotype 
of HRS cells is important for escaping apoptosis induced by lack of a BCR.  
Nasopharyngeal carcinoma (NPC) is an epithelial cell tumour most commonly found in 
southern china in 20-50 per 100,000 individuals.  NPC is up to 100% associated with EBV 
depending on subtype and location and in southern china was discovered to be in early, 
preinvasive lesions indicating the virus in the initiation of tumours (Wolf et al. 1975; Raab-
Traub et al. 1987; Pathmanathan et al. 1995). NPCs also express a latency II pattern of gene 
expression and EBNA 1, LMPs and EBV encoded RNAs have been shown to play a role in its 
carcinogenesis (Niedobitek 2000; Zheng et al. 2007; Marquitz and Raab-Traub 2012). EBV 
associated tumours expressing a latency II pattern of gene expression have also been found in 
T/NK cell lymphomas. These are prevalent in Asia and China and are characterised by an 
absence of T cell antigens and the expression of the NK cell maker CD56 (Jaffe et al. 1996; 
Wensing and Farrell 2000).  
In immunocompromised individuals EBV can cause numerous diseases. EBV is present in ~60% 
of HIV related lymphomas, with prevalence varying in subtype. These include: BL, diffuse large 
B cell lymphoma, extranodal marginal zone lymphoma, peripheral T-cell lymphoma, HL, 
primary effusion lymphoma, plasmablastic lymphoma of the oral cavity and post-transplant 
lymphoproliferative disease (PTLD) like lymphoma (Patte et al. 2001). Individuals who have 
undergone transplantation almost always require the artificial knock down of the immune 
system to prevent graft vs host disease. A major risk factor in this procedure is the 
development of PTLD which is nearly 100% associated with EBV. These cells express a latency 
III pattern of gene expression, the products of which are generally considered to be the 
primary effector in tumour development (Brink et al. 1997). 
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1.3 Epstein-Barr virus nuclear antigens  
EBV expresses nine proteins during the latency III pattern of gene expression, LMP1, LMP2A, 
LMP2B and the Epstein-Barr virus nuclear antigens (EBNA) EBNA 1, EBNA 2, EBNA LP, EBNA 3A, 
EBNA 3B and EBNA 3C. Of these EBNA 2, EBNA 3A, EBNA 3C and LMP1 are essential for in vitro 
infection and immortalisation. 
1.3.1 EBNA 1 
EBNA 1 is a homo-dimeric DNA binding protein that binds specific sequences in the host and 
viral genome. EBNA 1 binding sites within the EBV OriP mediate EBV genome synthesis and 
non-random partitioning of EBV episomes into daughter cells by tethering the episome to the 
host genome (reviewed in (Westhoff Smith and Sugden 2013). EBNA 1 can also operate as a 
transcriptional activator of Cp and LMP1, and as a transcriptional repressor at Qp, negatively 
regulating its own expression via CTCF mediated looping interactions from OriP (Sample et al. 
1992; Gahn and Sugden 1995; Altmann et al. 2006; Tempera et al. 2011). EBNA 1 ChIP 
sequencing studies have revealed extensive interaction with the host genome, one reported 
247 significant binding sites at human gene promoter proximal elements and another reported 
4785 binding sites throughout the human genome. Interestingly the DNA binding consensus 
for EBNA 1 is much more variable in the human genome than in the viral genome (Dresang et 
al. 2009; Lu et al. 2010). Some bound genes such as STAT1 and PBX2 have previously been 
reported to be regulated by EBNA 1, however, the mechanism of EBNA 1 transcriptional 
regulation remains largely undefined and there is generally a poor correlation between 
regulated and bound genes suggesting EBNA 1 is not the primary transcriptional regulator of 
host genes (Wood et al. 2007; Lu et al. 2010). Lu et al performed ChIP sequencing analysis of 
EBNA1 binding sites in the viral and human genome. Surprisingly they found 4785 candidate 
sites which were enriched for promoter regions of cellular genes. Potential targets of EBNA1 
include MAP3K7IP2, CDC7 and HDAC3 as well as smaller peaks close to MYC and IgH, IgD 
regions. The result of this binding is as yet unconfirmed (Lu et al. 2010). 
1.3.2 EBNA-LP 
EBNA LP is coordinately expressed with EBNA 2 within hours of infection of resting B-cells from 
Wp and is important to EBV mediated transformation (Mannick et al. 1991). EBNA LP 
commonly co-regulates genes with EBNA 2 and can stimulate EBNA 2 transactivation domain 
mediated transcriptional activation (Harada and Kieff 1997). EBNA LP can also activate 
transcription by interactions with Hsp72 to repress histone modifying proteins such as HDACs 
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and can decrease RBPJĸ binding to its repressive partner NCOR (Peng et al. 2007; Portal et al. 
2011). 
The primary modulators of cellular transcription are EBNA 2 and the EBNA 3 family of proteins 
which are all incapable of binding DNA themselves and must associate with cellular 
transcription factors to direct them to DNA. 
1.3.3 EBNA 2 
EBNA 2 is essential for persistent infection, immortalisation and continued proliferation of EBV 
infected B cells (Cohen et al. 1989; Tomkinson et al. 1993; Kempkes et al. 1995). EBNA 2 is the 
master controller of latent viral gene transcription and drives transcription from Cp, producing 
the long alternatively spliced transcript from which all EBNA proteins are translated 
(Woisetschlaeger et al. 1991). Furthermore, expression of LMP1, LMP2A and LMP2B depend 
on EBNA 2 mediated transcriptional activation via association with promoter proximal 
elements (Wang et al. 1990b; Zimber-Strobl et al. 1993; Laux et al. 1994). These interactions 
depend on EBNA 2 association with RBPJĸ at LMP2A and LMP2B, and PU.1 at LMP1, both of  
which directs EBNA 2 to target promoters (Ling et al. 1993; Grossman et al. 1994; Henkel et al. 
1994; Waltzer et al. 1994; Robertson et al. 1996). Strikingly, EBNA 2 can mimic the effects of 
intracellular (active) NOTCH in its association with RBPJĸ and can functionally replace the 
intracellular region of NOTCH (Sakai et al. 1998). Furthermore, activated NOTCH1 can 
transactivate some EBNA 2 regulated promoters (Hofelmayr et al. 1999; Strobl et al. 2000). 
EBNA 2 transcriptional activation of LMP1 is further mediated by its interaction with PU.1 and 
ATF; removal of the PU.1 binding site at the LMP1 promoter completely eliminates EBNA 2 
responsiveness (Johannsen et al. 1995; Sjoblom et al. 1995; Sjoblom et al. 1998) whereas EBNA 
2 activation of Cp requires the cellular transcription factor AUF1 (Fuentes-Panana et al. 2000). 
LCLs appear to ubiquitously express PU.1 which targets many genes essential to B-cell function 
(Siemer et al. 2008). More recently both EBF and RUNX proteins have been implicated in 
targeting EBNA 2 to DNA (Zhao et al. 2011). 
Once associated with DNA through a cellular binding partner EBNA 2 can activate transcription 
through numerous mechanisms. EBNA 2 contains an acidic transactivation domain (TAD) which 
has shown to be essential for transformation and transactivation (Cohen et al. 1991). EBNA 2 
transactivation domain fused to GAL4 was shown to upregulate expression from plasmids 
containing GAL4 binding sites 125 fold compared to GAL4 only (Cohen and Kieff 1991). 
Multiple general transcription factors including TFIIB, TAF40, TFIIH and TFIIE have been shown 
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to interact with EBNA 2 implicating it with the recruitment and activation of RNAPII to target 
promoters (Tong et al. 1995a; Tong et al. 1995b; Tong et al. 1995c). Further transactivation 
potential derives from EBNA 2 TAD association with HATs including p300, CREB binding protein 
(CBP) and lysine acetyltransferase 2B (KAT2B or PCAF) (Wang et al. 2000). EBNA 2 also induces 
permissive chromatin formation at target genes by recruiting chromatin remodelling via RBPJĸ, 
including LMP2A. This association could be prevented by deletion of the TATA box at the 
promoter suggesting that EBNA 2 requires other cellular factors to  recruit chromatin 
remodelling activity (Wu et al. 2000). EBNA 2 also activates repressed subsets of RBPJĸ 
targeted genes by binding to and masking the RBPJĸ repressive domain whilst recruiting 
transcriptional activators to the same sites (Hsieh and Hayward 1995). 
Numerous direct cellular targets of EBNA 2 transcriptional activation have been reported 
including MYC, FGR, RUNX3, CD23 and CR2 (CD21, the cellular surface antigen through which 
viral entry is facilitated). The upregulation of MYC causes a dramatic increase in cellular 
activation and proliferation; furthermore RUNX3 represses RUNX1, preventing RUNX1 
mediated growth inhibition (Cordier et al. 1990; Knutson 1990; Kaiser et al. 1999; Spender et al. 
2002). Genes involved in survival are also affected by EBNA2, such as the p55α subunit of PI3K, 
which is involved in signal transduction from chemokines, growth factors and cytokines. The 
PI3K subunit is up-regulated by EBNA2 and subsequent down-regulation by RNAi causes LCLs 
to undergo apoptosis (Spender et al. 2006). EBNA 2 also activates cyclin D2 expression in 
resting B cells causing G0 to G1 cell cycle transition (Sinclair et al. 1994). 
To date, five gene expression microarrays using cells that conditionally express EBNA 2 have 
been published. In total they have identified 654 unique cellular genes regulated at the RNA 
level by EBNA 2 (Spender et al. 2002; Maier et al. 2006; Spender et al. 2006; Zhao et al. 2006b; 
Lucchesi et al. 2008). All arrays used a chimeric form of EBNA 2 fused to an estrogen receptor 
in different cell background. These data confirmed many known targets of EBNA 2 regulation 
including MYC, CR2 and RUNX3. However, this technique has identified many novel targets of 
EBNA 2. Whilst the mechanism of regulation for most cellular genes is unknown and could 
include downstream targets of EBNA 2, it is clear that EBNA 2 has an important and extensive 
role in regulating the host transcriptome. 
1.3.4 EBNA 3 family 
The EBNA 3 family (EBNA 3A, EBNA 3B and EBNA 3C) are expressed following EBNA 2 
activation of Cp. They likely arose from gene duplication events as they are arrayed in tandem 
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in the EBV genome and share a similar gene structure with a short 5’ exon and a long 3’ exon; 
however they share little amino acid identity and perform overlapping and distinct functions in 
EBV biology (Young et al. 2000; Touitou et al. 2005). EBNA 3A and 3C are essential for in vitro 
EBV induced transformation and immortalisation whilst EBNA 3B was shown to be entirely 
dispensable for this process (Tomkinson and Kieff 1992; Tomkinson et al. 1993; Young and 
Murray 2003). EBNA 3A deficient virus is capable of immortalising resting B-cells and creating 
LCLs but with greatly reduced efficiency (Hertle et al. 2009). Like EBNA 2, EBNA 3A, 3B and 3C 
are incapable of binding to DNA directly but can bind via RBPJκ. Competition for the same 
cellular TF as EBNA 2 results in EBNA 3 repression of EBNA 2 activities at certain targets. Co-
transfection of all EBNA 3 proteins with EBNA 2 inhibited EBNA 2 activation of a 
chloramphenicol acetyltransferase (CAT) reporter gene plasmid attached to the LMP1 
promoter (Le Roux et al. 1994). EBNA 3A and EBNA 3C were also shown to induce similar 
inhibitory effects on EBNA 2 activation on the cellular thymidine kinase promoter attached to 
CAT and four upstream RBPJĸ binding sites (Waltzer et al. 1996). However, promoter-reporter 
constructs were not sensitive to the activity of EBNA 3 proteins in these assays. It was 
suggested from this and other data that EBNA 3 proteins were not recruited to DNA via RBPJκ 
but instead inhibited EBNA 2 activation by binding to, and destabilising RBPJκ. 
EBNA 3C has also been shown to also interact with PU.1, and co activates LMP1 though PU.1 
binding sites at the promoter (Zhao and Sample 2000). EBNA 3 proteins are both activators 
and repressors of transcription and the domains responsible within EBNA 3A and 3C have been 
mapped by GAL4 fusion constructs (Marshall and Sample 1995; Bain et al. 1996; Bourillot et al. 
1998; Cludts and Farrell 1998; White et al. 2010). The repression and activation of target genes 
by EBNA 3 proteins is at least in part mediated by protein-protein interactions allowing EBNA 3 
mediated recruitment of co-repressors and co-activators to EBNA 3 sites. All EBNA 3 proteins 
can interact with CTBP proteins, which are potent oncogenes and transcriptional co-repressors 
and co-activators (Touitou et al. 2001; Hickabottom et al. 2002; Chinnadurai 2009). EBNA 3A 
and 3C have also been shown to recruit histone deacetylases and PcG proteins for part of their 
repressive function (Radkov et al. 1999; Knight et al. 2003; Paschos et al. 2012). The 
mechanism of transcriptional activation by EBNA 3 proteins is less well known but at least 
EBNA 3C can interact with the histone acetyltransferase p300, mediating gene activation by 
histone acetylation (Subramanian et al. 2002).  
Much of the current understanding of the cellular targets of EBNA 3 protein regulation comes 
from gene expression microarray analysis. mRNA levels have been documented in the 
44 
 
presence or absence of EBNA 3A in LCLs and in BL31 and similar data exists for EBNA 3B (Hertle 
et al. 2009; White et al. 2010). One gene expression micro array dataset exist for cells that are 
entirely lacking EBNA 3B and have decreased expression of EBNA 3C (Chen et al. 2006). Most 
studies have examined mRNA levels in various cell lines in the presence or absence of EBNA 3C 
(Zhao et al. 2006a; White et al. 2010; McClellan et al. 2012; Skalska et al. 2013). Finally data 
exists for cells infected with a BAC derived virus lacking all three EBNA 3 proteins (White et al. 
2010).  
It has been established that EBNA 3A and 3C cooperatively repress the key tumour suppressor 
p16INK4A through recruitment of PcG proteins, a process that is dependent on CTBP proteins 
(Skalska et al. 2010). This has been proposed to be the primary barrier to proliferation as cells 
without functional EBNA 3C undergo growth arrest following p16 derepression whereas cells 
also lacking p16 do not (Skalska et al. 2013). Bim (BCL2L11) is another key target for EBNA 3 
proteins. Bim is a potent initiator of apoptosis due to its ability to inhibit pro-survival proteins 
such as BCL2 and its activation of the pro-apoptoic protein BAX which causes cytochrome c 
release from mitochondria (Enders et al. 2003; Fischer et al. 2007). In the germinal centre Bim 
is a major regulator of life and death signals involved in B-lymphogenesis and mice lacking Bim 
accumulate excess lymphoid cells (Egle et al. 2004). Bim is directly activated by MYC which is 
activated by EBNA 2 and translocated to the immunoglobulin locus in all BL cells (Dang et al. 
2005). EBNA 3A and EBNA 3C cooperate to repress Bim in a PcG dependent manner suggesting 
that they are able to counteract the apoptotic effects of a hyperactive MYC (reviewed in 
(Allday 2013)).  
White et al performed a gene expression micro array experiment in which BL cells were 
infected with wild type, or 3A, 3B or 3C knock out or revertant BAC derived virus. 36 genes 
were shown to be regulated by all 3 EBNA 3 proteins. Gene ontology analysis of EBNA 3C 
regulated genes revealed that genes involved in cell cycle and mitosis were most significantly 
enriched as well as genes involved in chromosome organisation. Cells infected with a virus 
lacking all 3 EBNA 3 proteins had altered transcript levels of 1008 genes which were enriched 
for gene ontology clusters including cell migration, lymphocyte activation, differentiation and 
apoptosis. They further discovered that 17 TF associated with B-cell development were altered 
at the transcript level by EBNA 3 proteins including NOTCH2, EBF1, PU.1 and PAX5 (White et al. 
2010). These genes were repressed by different subsets of EBNA 3 proteins. Investigation of 
the promoters of NOTCH2 (repressed by 3A and 3C) RASGRP1 (repressed by 3B and 3C) and 
TOX (repressed by all) revealed that H3K27me3 was decreased in knock out lines relative to 
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wild type, correlating with gene derepression. H3K4me3 however was unchanged creating a 
poised chromatin state at these genes in the absence of one or more EBNA 3 proteins. H3K9Ac 
increases correlated with increased TOX and RASGRP1 expression but was unchanged at 
NOTCH2 suggesting that the mechanism of regulation by EBNA 3 proteins is context specific. 
Importantly genes regulated by EBNA 3B in an LCL background revealed only modest overlap 
with genes regulated by EBNA 3B in a BL background. Only 14/89 EBNA 3B upregulated genes 
in LCLs were also upregulated in BLs, and only 32/108 EBNA 3B repressed genes were 
commonly repressed in both cell lines (White et al. 2010). This suggests that cell context is 
crucial for directing EBNA 3 proteins to different targets and modulating transcription. This 
may be due to different chromatin contexts or abundance of different TFs and cofactors. 
Importantly, work from this paper implicates EBNA 3B as an essential EBV gene in vivo as many 
genes regulated by it are essential in the GC reaction which is not reproduced in in vitro 
immortalisation. 
Together the EBNA 3 proteins are a highly transforming family of proteins and are some of the 
main drivers of EBV induced transcriptional regulation, transformation and apoptosis 
resistance. This is emphasised by Wp restricted BL cell lines. Wp restricted BL cell lines appear 
to have arose from in vivo cells as cells expressing this pattern of genes have been found in 
original tumour biopsies. Such cells always involve an EBNA 2 deletion but retain the classical 
MYC translocation associated with BL suggesting that EBNA 2 activity is not compatible with 
MYC translocation. The lack of EBNA 2 results in sole usage of the W promoter and prevents 
normal promoter switching to Cp (Woisetschlaeger et al. 1991). Unlike classical BL these cells 
express EBNA 3A, 3B and 3C and are highly resistant to apoptosis even compared to classically 
transformed BL cell lines, making such cells highly prone to tumour development (Kelly et al. 
2005).  
1.4 Summary 
The transcriptome defines the fate and function of a cell. The cellular transciptome is 
modulated by chromatin accessibility, proximal or distal DNA elements and the binding of 
transcription factors and cofactors. EBV can alter the fate and function of resting B-cells with a 
restricted set of viral proteins. The viral proteins EBNA 2, 3A, 3B, 3C are known to alter the 
transcript levels of thousands of cellular genes, via association with cellular transcription 
factors; however, remarkably little is known about the mechanism of EBV transcriptional 
regulation by these factors. 
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1.5 Aims of my project 
To elucidate the mechanism of transcriptional regulation by EBNA 2 and EBNA 3 proteins, we 
determined to perform chromatin immunoprecipitation coupled with next generation 
sequencing to generate a library of all DNA elements bound by these factors. Using this data 
we would examine known regulated genes and examine if EBNA 2 and EBNA 3 binding 
targeted these genes, as well as elucidate new cellular target genes. As EBNA 2 and EBNA 3 
proteins share cellular TFs as binding partners we also resolved to study the interactions 
between these proteins at potential shared sites and how this impacted gene regulation. 
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2. Materials and Methods 
All reagents were purchased from Fisher Scientific unless otherwise stated 
2.1 Tissue Culture 
2.1.1 Tissue culture media and supplements 
100x Penicillin-Streptomycin-Glutamine (PSG) (Life Technologies) 
Contains 100 units/ml penicillin G, 100 µg/ml streptomycin sulphate and 29.2 mg/ml L-
glutamine with 0.85% saline and 10 mM citrate buffer. Stored in 5 ml aliquots -20°C. Used at 
1x in all media 
β-estradiol (Sigma) 
Dissolved in DMSO and stored as 100mM aliquots at 4°C. 
Dimethyl Sulphoxide (DMSO) (Sigma) 
Dulbecco’s Phosphate Buffered Saline without CaCl2 and MgCl2 (PBS) (Life Technologies) 
Fetal Bovine serum (FBS) (Life Technologies)  
Pre-screened for endotoxins (≤5 EU/ml), haemoglobin (≤10 mg/dl) levels and heat inactivated 
at 56°C for 30 mins. Stored in 50ml aliquots at -20°C. 
Freezing mix 
80% RPMI media (supplemented with 10% FBS and PSG), 10% FBS and 10% DMSO. 
G418 (life technologies) 
Dissolved in 100mM HEPES and stored as 200mg/ml aliquots at 4°C. 
Hygromycin B (Life Technologies)  
Stored as 50mg/ml stock at 4°C. 
Sodium Pyruvate (Sigma) 
Dissolved in PBS and stored as 100mM aliquots at 4°C. 
RPMI 1460 media without L-glutamine (Life Technologies) 
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RMPI 1460 media phenol red free (Life Technologies) 
Thioglycerol (Sigma) 
Diluted in PBS and stored as 100mM aliquots at 4°C. 
2.1.2 Maintenance of cell lines 
All cells were incubated at 37°C with 5% CO2. 
2.1.2.1 Mutu I and III 
Mutu I (clone 179) is an EBV latency I BL cell line derived from a 7-year old African black male 
with Burkitt’s Lymphoma (Gregory et al. 1990). Mutu III (clone 48) is a clonal cell-line that 
arose as a result of drifting of Mutu I in culture to a latency III pattern of gene expression  
(Gregory et al. 1990). Both cell lines were kindly provided by Prof. Martin Rowe (University of 
Birmingham) and were passaged 2-3 times weekly in RPMI media supplemented with 10% FBS 
and PSG. 
2.1.2.2 BL31, BL31 wtBAC, BL31 3CKO, BL31 3CREV and BL31 E2KO 
BL31 is an EBV negative BL cell line. BL31 wtBAC, BL31 3CKO, BL31 3CREV and BL31 E2KO are 
BL31 cell lines infected with wild-type (BL31 wtBAC 2, BL31 wtBAC 3), EBNA 3C knock out (BL31 
3CKO 2, BL31 3CKO 4), EBNA 3C revertant (BL31 3CREV 3, BL31 3CREV 6) or EBNA 2 knock out 
(BL31 E2KO) recombinant EBV BACs. EBNA 2 or Individual EBNA3 genes were deleted from the 
EBV genome by RecA-based homologous recombination between the B95.8 EBV BAC. The 
deleted gene was then restored in each case to generate revertant BACs (White et al. 2003; 
Kelly et al. 2005; Anderton et al. 2008). Cell lines were kindly provided by Dr. Rob White and 
Prof. Martin Allday (Imperial College London) and were passaged 2-3 times weekly in RPMI 
media supplemented with 10% FBS,PSG, 1mM Na Pyruvate, 50µM thioglycerol and in the case 
of all cell lines other than BL31, 100µg/ml hygromycin B for BAC selection. 
2.1.2.3 BJAB PZ1, PZ3, E3C3, E3C7, E3A1 and E3B2 
BJAB is an EBV negative B cell Lymphoma which lacks translocated MYC. PZ1 and PZ3 are BJAB 
clones transfected with the empty pZipNEOSV(X) expression vector containing neomycin 
phosphotransferase providing resistance to the neomycin analogue G418. E3C3, E3C7 are BJAB 
clones transfected with pZipNEOSV(X) expression vector also containing the open reading 
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frame for EBNA 3C (Wang et al. 1990a). E3A1 and E3B2 are transfected with plasmids 
expressing EBNA 3A and EBNA 3B respectively. Cell lines were kindly provided by Prof. Alan 
Rickinson (University of Birmingham) and were passaged 2-3 times weekly in RPMI media 
supplemented with 10% FBS, PSG and 2mg/ml G418. 
2.1.2.4 PER253 B95.8, PER142 B95.8, PER253 3BKO and PER142 3BKO LCLs 
PER253 and PER142 LCLs are generated by infection of primary B-cells from donor PER253 and 
PER142 with the B95.8 strain of EBV. PER253 3BKO and PER142 3BKO LCL are B-cell lines from 
the same donors transformed with B95-8 EBNA 3B-knock-out recombinant virus (Chen et al. 
2005). These cell lines were kindly provided by Dr. Heather Long (University of Birmingham)  
and were passaged 2-3 times weekly using RPMI media supplemented with 10% FCS and PSG.  
2.1.2.5 EREB 2.5 LCL 
EREB 2.5 is an LCL transformed by co-transfection of EBV viral strain P3HR1 which lacks EBNA2 
and a viral mini plasmid containing an estrogen receptor tagged EBNA2 fusion protein (ER-
EBNA 2). ER-EBNA 2 is conditionally active as it is sequestered in the nucleus and released on 
hormone binding. β-estradiol causes ER-EBNA 2 translocation to the nucleus and EBNA 2 
activity (Kempkes et al. 1995). EREB 2.5 cells were kindly provided by Prof. Paul Farrell 
(Imperial College London) and passaged 2-3 times weekly in phenol red free RMPI media 
supplemented with 10% FCS, PSG and 1µM β-estradiol. For β-estradiol withdrawal and add-
back experiments ER/EB 2.5 cells were incubated in the absence of β-estradiol for 4 days and 
1mM β-estradiol was re-added for 6 or 17 hrs prior to cell harvest. 
2.1.2.6 D2 and D3 wild type (wt) and EBNA 3A (mtB) LCLs 
D2wt1, D2wt2, D2wt3, D2mtB1, D2mtB2, D2mtB3 and D3wt1, D3wt2, D3wt3, D3mtB1, 
D3mtB2, D3mtB3 are B cells from two donors (D2 and D3) infected with the wild type EBV 
strain B95-8 (wt1, wt2, wt3) or B95.8 EBNA 3B-knock-out recombinant virus (mtB1, mtB2, 
mtB3) (Hertle et al. 2009). Cells were kindly provided by Prof. Bettina Kempkes (Department of 
Gene Vectors, Munich) and were passaged 2-3 times weekly in RMPI media supplemented 
with 10% FCS and PSG. 
2.1.3 Freezing cells 
200 mls of cells were pelleted by centrifugation at 1300rpm for 10 minutes at 4°C in a sorvall 
legend centrifuge and resuspended in 5 mls of freezing mix. Cells were divided between 5 
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cryogenic vials in 1ml aliquots, and frozen at -80°C in a freezing container (Nalgene) with 
isopropanol. Vials were transferred to liquid nitrogen storage after at least 24 hrs at -80°C. 
2.1.4 Thawing cells 
Cells were transferred from liquid nitrogen storage to a 37°C water bath. Once thawed, the 
1ml of cells were added to 10mls pre-warmed RPMI media in a 25ml flask and incubated 
overnight at 37°C with 5% CO2. 
2.1.5 Cell counting 
15 µl of cell suspension in DPBS was diluted 1:1 in trypan blue (HyClone) which stains dead 
cells, and added to a Neubauer haemocytometer by capillary uptake under a coverslip. Live 
cells in the 4 corner squares were counted. The average cell counts of the four squares were 
used to calculate the cell culture concentration using the formula: 
Average cell count= Count x 1x104 cells/ml 
This was doubled to take account of the addition of trypan blue. 
2.2 Biochemical reagents and methods 
BSA (Sigma) 
Dissolved in PBS and stored as 100mg/ml aliquots at -20°C. 
Cell lysis buffer 
85 mM KCl, 0.5% NP-40, 5 mM PIPES pH 8.0. Before use buffer was chilled on ice and made to 
1 mM PMSF (Sigma). 1 EDTA-free protease inhibitor cocktail tablet (Roche)/10mls was added. 
ECL solution I 
125 µM Luminol (250 mM stock in DMSO), 20 µM coumaric acid (Sigma)(90 mM stock in DMSO) 
and 5 mM Tris pH 8.5 in 1 ml Milli-Q water 
ECL solution II  
0.0075% Hydrogen Peroxide (H2O2) and 5 mM Tris pH 8.5 in 1 ml Milli-Q water. 
Elution Buffer 
10 mM Tris pH 8.0, 5 mM EDTA, 1% SDS 
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Gel sample buffer 
50 mM Tris, 4% SDS (w/v), 5% 2-Mercaptoethanol (Sigma), 10% Glycerol, 1 mM EDTA and 0.01% 
Bromophenol blue. 
High salt buffer 
0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 500 mM NaCl. Chilled on ice 
before use. 
Immunoprecipitation dilution buffer (IP) 
0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0,167 mM NaCl. Chilled on ice 
before use and made to 1 mM PMSF. 1 EDTA-free protease inhibitor cocktail tablet /10 mls 
was added. 
Lithium Chloride buffer (LiCL) 
250 mM LiCl, 1% NP40, 1% Na deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.0. Chilled on ice 
before use. 
Low salt buffer 
0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 150 mM NaCl. Chilled on ice 
before use. 
PBS-Tween 
100 PBS tablets (Oxoid) and 10mls Tween-20 made up in 10L dH20. 
Proteinase K (Sigma) 
Dissolved in water and stored as 20mg/ml aliquots at -20°C  
SDS lysis buffer 
1% SDS, 10 mM EDTA, 50 mM Tris pH 8.0. Chilled on ice before use and made to 1 mM PMSF. 1 
EDTA-free protease inhibitor cocktail tablet /10 mls was added. 
TE buffer 
10 mM Tris pH 8.0, 1 mM EDTA. Chilled on ice before use. 
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Western blot Transfer buffer 
15g Tris, 72g Glycine, 4L dH20 and 1L Methanol 
2.2.1 Preparation of whole cell lysates 
Cells were washed in PBS, counted and resuspended in 100 µl GSB/1x106 cells. Cells were 
sonicated on ice using the Vibra-Cell VC 750 sonicator (Sonics) for 7 pulses at 25% amplitude 
for 10 seconds with 10 second gaps. Samples were boiled at 95°C for 10 mins, vortexed, briefly 
centrifuged for 30 seconds and stored at -20°C or loaded directly onto SDS-PAGE gels. 
2.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
10µl samples were loaded into pre-poured 4-12% Bis-Tris gel (Life Technologies) using a gel 
loading tip. Lysates were resolved using 1x MOPS running buffer (Life Technologies). 15 µl of 
SeeBlue Plus2 pre-stained standard marker (Life Technologies) was also loaded and 
electrophoresis carried out for 50 mins at 200 V. 
2.2.3 Immunoblotting 
After separation by SDS-PAGE, proteins were transferred onto Protran nitrocellulose 
membranes (Whatman) in transfer buffer at 85 V for 90 mins using a blotting cell (Bio-Rad). 
Membranes were incubated with Ponceau stain (Sigma) for one minute to examine loading 
and verify a successful transfer. Membranes were cut as required to probe for multiple 
proteins on one blot. Membranes were washed three times for 5 minutes in PBS-Tween on a 
shaker and blocked for 1hr using 2% (w/v) milk powder (Marvel) in PBS-Tween. Primary 
antibodies (Appendix B) were added to membranes in a 2% (w/v) milk PBS-Tween solution and 
incubated overnight at 4°C with rocking. After further washing with PBS-Tween (3x10 mins), 
secondary antibodies conjugated to a horse-radish peroxidase (HRP) enzyme (Appendix A) 
made up in 2% (w/v) milk PBS-Tween solution were added to membranes and incubated with 
rocking at room temperature for 1 hr. Final washing (3x10 mins) in PBS-Tween was performed 
and equal volumes (1ml each) of ECL solutions I & II were added to membranes and mixed. 
Membranes were imaged on a LiCor Odyssey imaging system or Membranes were exposed to 
Fuji medical X-ray film (Fisher) for varying time periods and developed using the Konica SRX-
101A film processor.  
2.2.4 Chromatin Immunoprecipitation (ChIP) 
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2.2.4.1 Bead preparation 
2.2.4.1.1 Protein A sepharose bead preparation 
 Protein A sepharose beads (Sigma) in aqueous ethanol solution were washed 3 times in PBS. 
500µl Protein A sepharose beads were blocked using 350 µg of single-stranded sonicated 
salmon testes DNA (Sigma) and were rotated for 1hr at 4°C. Beads were then washed 3 times 
in PBS and stored as a 1:1 slurry with IP dilution buffer at 4°C prior to use.  
2.2.2.4.2 Protein A agarose bead preparation 
Protein A agarose beads (Merck Millipore) in aqueous ethanol solution were washed 3 times in 
PBS. 400 µl Protein A agarose beads were blocked using 5mg of BSA diluted in PBS and rotated 
for 1hr at 4°C. Beads were then washed 3 times in PBS and stored as a 1:1 slurry with IP 
dilution buffer at 4°C prior to use. 
2.2.4.2 Chromatin preparation  
Cells were resuspended to 5x105 cells/ml 24 hrs prior to chromatin preparation. Cells were 
then diluted to 1x107cells/ml in RPMI 1640 media and crosslinked using 1% formaldehyde 
(Sigma) for 15 mins on a rocker at RT. Cross-linking was halted by incubation with 125 mM 
glycine for 10 mins at room temperature on a rocker. Cells were pelleted by centrifugation at 
1300 rpm for 10 mins at 4°C in a Sorvall legend centrifuge and washed in PBS. Cell pellets were 
lysed on ice for 10 mins in 300µl cell lysis buffer per 107cells. Nuclei were pelleted at 8000 rpm 
for 5 mins at 4°C in accuspin benchtop centrifuge and resuspended in 200µl SDS lysis buffer 
per 1x107cells mixing well. Chromatin was then sonicated using the Vibra-Cell VC 750 sonicator 
(Sonics) for 10 pulses at 30% amplitude for 10 seconds with 10 second gaps. and stored as 
aliquots at -80°C. 
2.2.4.3 ChIP from cross-linked chromatin 
100 µl (5x106 cells) of chromatin was diluted ten-fold in IP dilution buffer and pre-cleared by 
adding 45 µl of blocked protein A Sepharose or protein A agarose beads and rotating at 4°C for 
an hour. After removal of beads by pelleting at 4000rpm 4°C in an accuspin benchtop 
centrifuge for 1 minute, an input control (40 µl) was removed from the pre-cleared chromatin 
and stored at -20°C. The remaining chromatin was incubated with or without (no antibody 
control) primary antibodies (see Appendix A) overnight at 4°C with rotation. Secondary 
antibodies were added where required (Appendix A) and samples rotated for a further 2 hrs 
4°C. Immune complexes were collected by rotating for 3 hrs at 4°C with 45 µl of 1:1 pre-
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blocked protein A sepharose bead or protein A agarose bead slurry. Samples were then 
washed for 10 mins with rotation at 4°C in 1ml of each of the following wash buffers; 1x low 
salt, 1x high salt, 1x LiCl and 2x TE. Immune complexes were eluted in 150 µl elution buffer at 
65°C for 20 mins, resuspending beads every 5 minutes by agitation. Beads were removed by 
pelleting at 4000rpm at 4°C in an accuspin benchtop centrifuge for 1 minute and DNA-protein 
immuno complexes were incubated at 65°C overnight to reverse crosslinking. Input controls 
were also incubated overnight in 150 µl elution buffer to reverse crosslinks. Proteinase K (50 
µg) and TE buffer (150 µl) were added to samples and protein digested for 2 hrs at 50°C. DNA 
was purified using a QIAquick® Gel extraction kit (Qiagen) according to the manufacturer’s 
instructions (QG and propan-2-ol were substituted for PB in most cases) and DNA then eluted 
in 110 µl sterile millipore water. 
2.2.4.4 ChIP from non-cross linked chromatin 
ChIP protocol was performed on chromatin that had been prepared without formaldehyde. 
After washing Immune complexes were eluted in 35 µl GSB and boiling. Beads were pelleted 
and supernatant loaded directly onto SDS-PAGE gels. 
2.2.4.5 ChIP Sequencing DNA isolation and library preparation 
600 µl (30x106 cells) of Mutu III chromatin was diluted ten-fold in IP dilution buffer and pre-
cleared by adding 270 µl of BSA blocked protein A Sepharose beads and rotating at 4°C for an 
hour. After removal of beads by pelleting an input control (40 µl) was removed from the pre-
cleared chromatin and stored at -20°C. The remaining chromatin was incubated with primary 
antibodies (see Appendix A) overnight at 4°C with rotation. Secondary antibodies were added 
where required (Appendix A) and samples rotated for a further 2 hrs 4°C. Immune complexes 
were collected by rotating for 3 hrs at 4°C with 270 µl of 1:1 pre-blocked protein A sepharose 
bead or protein A agarose bead slurry. Samples were then washed for 10 mins with rotation at 
4°C in 6  ml of each of the following wash buffers; 1x low salt, 1x high salt, 1x LiCl and 2x TE. 
Immune complexes were eluted in 900 µl elution buffer at 65°C for 20 mins, resuspending 
beads every 5 minutes by agitation. Beads were removed by pelleting and DNA-protein 
immuno complexes were incubated at 65°C overnight to reverse crosslinking. Input controls 
were also incubated overnight in 150 µl elution buffer to reverse crosslinks. Samples were 
incubated with RNAse A (Sigma) at 37°C  for 1 hour (30ng for input and 0.18 µg for IP samples). 
Proteinase K (50 µg for input and 300 µg for IP samples) and TE buffer (150 µl for input and 
900 µl IP samples) were added to samples and protein digested for 2 hrs at 50°C.  
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Input DNA was purified using a QIAquick® Gel extraction kit (Qiagen) according to the 
manufacturer’s instructions (replacing QG and propan-2-ol with 750 µl PB (Qiagen)) and eluted 
in 55 µl sterile millipore water. 4.5 mls of PB was added to IP samples and samples mixed by 
pipetting. 750 µl samples were added to three QIAGEN columns from the QIAquick® Gel 
extraction kit (Qiagen) and subjected to centrifugation at 13000rpm at 4°C in an accuspin 
benchtop centrifuge for 1 minute. Flow through was discarded and the process repeated until 
all of the IP samples were added to the three columns. Columns were washed according to the 
manufacturer’s instructions. DNA was eluted by the addition of 55 µl sterile millipore water to 
one column, incubating at room temperature for 1 minute and subjected to subjected to 
centrifugation at 13000rpm at 4°C in an accuspin benchtop centrifuge for 1 minute. Flow 
through was then re-added to the same column and process repeated. After removing the first 
column, flow through was then added to the second column and process repeated such that 
each of the 3 columns undergoes 2 DNA elutions. Used columns each had 110 µl water to 
them and residual DNA eluted as above. 
ChIP and input DNA (10 ng) were used to generate sequencing libraries with a ChIP-Seq sample 
preparation kit (Illumina). DNA fragments were end repaired and phosphorylated, 3′-dA 
overhangs were added, and adapters were ligated according to the manufacturer's 
instructions. PCR-amplified samples (16 cycles) were separated on a 2% agarose gel in Tris-
acetate–EDTA (TAE) buffer and visualized using SYBR-safe stain and a Dark Reader 
transilluminator instrument (Clare Chemical Research). The region of the gel containing 150- to 
350-bp DNA fragments was excised, and DNA was purified using a min-elute gel extraction kit 
(Qiagen). The library generated was quantified using an Agilent bioanalzer instrument and 
subjected to 35-bp single-end read sequencing with an Illumina IIx genome analyzer. 
2.2.4.6 ChIP-reChIP 
600 µl (30x106 cells) of Mutu III chromatin was diluted ten-fold in IP dilution buffer and pre-
cleared by adding 270 µl of BSA blocked protein A Sepharose beads and rotating at 4°C for an 
hour. After removal of beads by pelleting an input control (40 µl) was removed from the pre-
cleared chromatin and stored at -20°C. The remaining chromatin was incubated with primary 
antibodies (see Appendix A) overnight at 4°C with rotation. Secondary antibodies were added 
where required (Appendix A) and samples rotated for a further 2 hrs 4°C. Immune complexes 
were collected by rotating for 3 hrs at 4°C with 270 µl of 1:1 pre-blocked protein A sepharose 
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bead or protein A agarose bead slurry. Samples were then washed for 10 mins with rotation at 
4°C in 6  ml of each of the following wash buffers; 1x low salt, 1x high salt, 1x LiCl and 2x TE. 
Immune complexes were eluted in 900 µl elution buffer at 65°C for 20 mins, resuspending 
beads every 5 minutes by agitation. Beads were removed by pelleting and each IP split into 6 
aliquots each of 150 µl. 
With one aliquot the ChIP was continued as described. On the 5 other aliquots a fresh ChIP 
was performed, using the protocol described in 2.3.4 with the exception that instead of 
diluting 100 µl of chromatin in 900 µl IP dilution buffer, 150 µl of eluted sample was diluted in 
850 µl IP dilution buffer. 
2.2.5 RNA isolation 
RNA was extracted from cells using TRI Reagent (Sigma) and purified using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s guidelines. 
2.2.6 Determining RNA concentration 
Samples were diluted 1 in 50 (2µl in 98µl sterile Millipore water) and quantified using the 
eppendorf BioPhotometer using a UV-Cuvette micro (Brand). RNA concentration (µg/ml) was 
calculated using the formula A260 x 40µg/ml x dilution factor (50). The purity was measured by 
the ratio of the two absorbance’s between 260nm and 280nm (1.8 to 2 for pure RNA). 
2.2.7 cDNA synthesis  
cDNA was synthesised from purified RNA using the ImProm-II Reverse Transcription system 
(Promega) based on the manufacturers specifications. 1µg of RNA was incubated at 70°C for 5 
mins with 0.5µg of random primer and Millipore sterile water to a final volume of 5µl. Samples 
were left on ice for 5 mins and spun in the Techico mini microfuge.  
2.2.8 Q-PCR 
Quantitative PCR (QPCR) was performed using an Applied Biosystems step one plus real-time 
PCR machine. For ChIP analysis, 3µl DNA was added to a SYBR green master mix containing 
7.5µl 2xGoTaq QPCR master mix (Promega), 150nM forward and 150nM reverse primers 
(Appendix B) and sterile Millipore water to a final volume of 15µl. Samples were heated to 
95°C for 10 mins, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min and dissociation 
curve analysis. Input controls were serially diluted to generate a standard curve for each 
57 
 
primer set (Appendix B). A percentage input value was obtained by measuring the crossing 
threshold (Ct) value in relation to each standard.  
 
For cDNA analysis, samples were analysed using the absolute quantification method. Standard 
curves were generated from cDNA from either BL31, EREB 2.5 +est 17hrs, D2mtB1 LCL or 
PER142 3BKO LCL. Transcript levels were determined using cDNA-specific primers for CTBP2, 
ITGAL or WEE1 (Appendix B) and values obtained were made relative to the signal from 
GAPDH cDNA specific primers. 
2.2.9 Determination of DNA fragment size after sonication 
Mutu III chromatin was prepared as normal. After resuspension of nuclear pellet in SDS lysis 
buffer 1/3rd of the chromatin was removed and stored at -80°C. Remaining chromatin was then 
sonicated using the Vibra-Cell VC 750 sonicator (Sonics) for 10 pulses at 30% amplitude for 10 
seconds with 10 second gaps at 4°C. This aliquot was split into 2 and one half frozen. 
Remaining half was subjected to an additional 10 pulses of sonication and stored at -80°C. At 
time of use for ChIP a 5 µl aliquot of each was taken and diluted in 92.5 µl Tris pH7.5. 50 µg of 
proteinase K was added and diluted chromatin incubated at 65°C. 20 µl aliquots with 5 µl DNA 
loading dye were loaded into a 1% TBE agarose gel alongside a 1kb DNA ladder and subjected 
to gel electrophoresis at 90V for 1 hr. Gel was imaged on a LiCor Odyssey imaging system.  
2.3 Bioinformatics analysis 
2.3.1 Comparison of ChIP sequencing and gene expression microarray data 
Lists of genes bound in ChIP sequencing and genes regulated in gene expression microarray 
data sets were assembled and analysed in Microsoft EXCEL. Gene expression microarray gene 
nonclamenture were converted to official gene symbols using the Database for Annotation 
Visualization and Integrated Discovery (DAVID) gene ID conversion tool. These were then 
compared to lists of genes either from other gene expression microarray data sets or lists of 
genes bound in ChIP sequencing experiments provided by Dr. Aditi Kanhere (University College 
London). Lists were compared by using a COUNTIF function (=COUNTIF(range,criteria)) where 
any cell in the range (eg all official gene symbols of upregulated genes in a dataset) was 
analysed to see if  matched the criteria (eg an official gene symbol from a gene shown to be 
bound by ChIP sequencing data). 
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2.3.2 ChIP sequencing data analysis (performed by Dr Aditi Kanhere and Dr Richard Jenner, 
University College London) 
ChIP sequencing data from our lab and from the Kieff lab for EBNA 2 and RBPJĸ ChIP 
sequencing experiments in IB4 cells were processed and analysed, Initial processing of 
sequencing images generated by the Illumina IIx genome analyzer was performed using the 
CASAVA pipeline. Polony identification, base calling, and quality control statistics were 
performed using GOAT and Bustard modules. Thirty-six-bp short reads were aligned to the 
hg19 build of the human genome using ELAND software. Only reads with zero to two 
mismatches were aligned, and only uniquely aligned reads passing the quality threshold were 
retained. When multiple reads matched to the same position, only a single read was 
considered for further analysis. Sequence reads were extended to 150 bp. WIG files were 
generated by calculating tag density in 10-bp windows and were normalized to reads per 
million total reads using in-house R scripts. The data for the EBNA 2 and EBNA 3 sequencing 
run were then background corrected using data from input DNA. Significant peaks of EBNA 2 
and EBNA 3 binding were identified with MACS (P < 10−7)  (Zhang et al. 2008). Encyclopedia of 
DNA elements (ENCODE) ChIP-Seq data for transcription factors and histone modifications in 
the EBV-immortalized LCL GM12878 were accessed through the human genome browser at 
http://genome.ucsc.edu/cgi-bin/hgGateway and compared with our data. RBPJĸ data from a 
recently published ChIP sequencing experiment was compared sites of significant EBNA 2 and 
EBNA 3 binding (Zhao et al. 2011).  
2.3.3 Motif searching 
Motif searching was performed by generation of FASTA files from ChIP sequencing MACS 
peaks data and used as an input to MEME http://meme.nbcr.net/meme/cgi-bin/meme-
chip.cgi. Default settings were used (normal mode, zero or one occurrence per sequence). 
2.3.4 DAVID gene ontology analysis 
Official gene symbols were submitted to DAVID as a gene list in the background of homo 
sapiens. Functional annotation clustering selecting only GOTERM-BP (biological process) or 
Kegg pathway analysis was performed with default significance settings 
http://david.abcc.ncifcrf.gov/. 
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3. Mapping EBNA 2 and EBNA 3C binding in the human genome 
At the start of this project most information on the regulation of transcription by EBNA 2 and 3 
proteins came from studies of EBV promoters. EBNA 2 was known to activate the C, LMP1/2B 
and LMP2A promoters through RBP-J sites. PU.1 sites in the LMP1 promoter were also shown 
to be required for full activation by EBNA 2. EBNA 3 proteins were documented as competitive 
binders to RBP-Jĸ, inhibiting EBNA 2 activation in reporter assays, although independent 
repressive effects of EBNA 3C on Cp and coactivation of LMP1 transcription with EBNA 2 via 
the PU.1 site were also reported. Direct interactions between EBNA 2 and EBNA 3C and PU.1 
were also reported.  In contrast, no EBNA 3 binding sites in the human genome were known 
and information on EBNA 2 activation of cellular genes was restricted to a few targets where 
RBP-Jĸ sites could be identified in the target gene promoters and shown to confer 
responsiveness in promoter-reporter assays. However, many known regulated genes were not 
responsive to EBNA 2, EBNA 3A, EBNA 3B or EBNA 3C in these assays. In order to gain 
important insights into the mechanism of cellular gene regulation by these key EBNAs, 
Chromatin immunoprecipitation coupled to next generation sequencing was performed to 
map the genome-wide binding profiles of EBNA 2 and EBNA 3C, the best characterised of the 
EBNA 3 proteins.  
3.1 Validation of EBNA 3C antibody for ChIP 
EBNA 2 binding to Cp, LMP1 and LMP2A had already been confirmed by ChIP using the EBNA 2 
mouse monoclonal antibody PE2 by others in our laboratory (Palermo et al. 2011). The -310 
primer set amplifies DNA containing two RBPJĸ binding sites at -298 to -290 and -223 to -212. 
This site had also previously been reported as an EBNA 3C binding site and was the only site 
known in the viral or human genome where EBNA 3C bound (Jimenez-Ramirez et al. 2006). 
This study used a sheep polyclonal anti-EBNA 3C antibody (exalpha) which was not validated 
for use in ChIP. We had previously used an anti-EBNA 3C sheep polyclonal antibody (abcam) 
for immunoprecipitations and western blotting. To examine if this antibody could successfully 
precipitate DNA in ChIP conditions, and to confirm EBNA 2 binding to LMP1 in other EBV 
immortalised cell lines, ChIP was conducted using PE2 and the anti-EBNA 3C sheep polyclonal 
antibody (abcam) in Mutu III BL cells and PER253 LCL, both expressing all latency III gene 
products. ChIP DNA was analysed using primers at the LMP1 locus including sites previously 
identified as EBNA 2 binding sites in Mutu III cell lines. We were able to confirm EBNA 2 
association with LMP1 in Mutu III (Fig 3-1 C), and showed that EBNA 2 also binds to the -310 
region in the PER253 LCLs (Fig 3-1 A). Importantly, QPCR analysis of DNA precipitated by the  
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Figure 3-1 EBNA 3C sheep polyclonal antibody ChIP precipitated DNA is enriched at LMP1 
regulatory elements. ChIP experiments conducted in PER253 LCL and Mutu II cell lines. Location of 
primer sets used are indicated as distance from the 5’ end of the forward primer to the LMP1 TSS. 
Percentage input signals, after subtraction of signals of controls with no antibody, are expressed 
relative to the highest signal obtained. Results are shown as ± standard deviations of two 
independent experiments. ChIP-QPCR data for EBNA 2 in PER253 (A), EBNA 3C sheep polyclonal 
antibody in PER253 (B), EBNA 2 in Mutu III (C), EBNA 3C sheep polyclonal antibody in Mutu III (D).  
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EBNA 3C sheep polyclonal antibody revealed increased quantities of DNA using the -310 and 
+34 primer sets relative to those within the LMP1 gene in both PER253 (Fig 3-1 B) and Mutu III 
cell lines (Fig 3-1 D). These data confirm that the EBNA 3C antibody used can precipitate DNA 
in ChIP conditions. 
3.2 Optimisation of ChIP sequencing protocol 
ChIP sequencing required high yields of good quality ChIP DNA eluted in a small volume. 
Before conducting this experiment, optimisation and adaptation of the current ChIP protocol 
was required. After cross linking with formaldehyde, cells are lysed and then subjected to 
sonication to randomly break DNA into small fragments. ChIP sequencing involves a size 
selection step where DNA between 150-300 bp is selected before being sequenced. If DNA 
fragments precipitated in a ChIP are too large it will result in a reduced yield after this stage as 
DNA will be removed. To determine if yield could be improved by altering the pulses of 
sonication that chromatin is subjected to, Mutu III chromatin, either un-sonicated or subjected 
to 10 and 20 pulses was resolved using agarose gel electrophoresis. This revealed that DNA 
fragment size is reduced by increasing rounds of sonication (Fig 3-2 A). We also used the same 
chromatin in ChIP assays using antibodies against EBNA 2 and PU.1 and quantified precipitated 
DNA at the LMP1 locus where both are known to bind. These data reveal no significant 
changes in the ratio of bound and unbound sites but a loss of input DNA precipitated was 
observed with 20 pulses of sonication compared to 10 (Fig 3-2 B vs C and Fig 3-2 D vs E). In 
EBNA 2 precipitated DNA samples there was ~15% less DNA amplified by the -310 primer set in 
the 20 pulsed aliquot compared to the 10 pulsed aliquot. From this data it was decided to use 
10 rounds of sonication in future experiments. 
The ChIP protocol for QPCR includes a blocking step where beads are incubated with salmon 
sperm DNA. This step is required for reducing non-specific binding of DNA and proteins in the 
cell lysate to the beads. However, if salmon sperm DNA is eluted from the beads at the elution 
step of ChIP then this DNA may contaminate our sample for sequencing. This would reduce 
sequencing reads as a proportion of the DNA submitted for sequencing would not map to the 
human genome. To test whether salmon sperm DNA would be eluted from the beads at the 
end of the ChIP experiment, we performed ChIP in Mutu III cells for EBNA 2 using beads 
blocked with either salmon sperm DNA or BSA. We designed primers at the salmon insulin 
gene to amplify a site that has no homology to human insulin. QPCR on DNA precipitated from 
beads blocked with salmon sperm DNA or BSA confirmed that salmon insulin DNA was 
enriched in EBNA 2 ChIP DNA blocked with salmon sperm compared to EBNA 2 ChIP DNA  
62 
 
 
 
 
 
Figure 3-2 Optimisation of sonication step of chromatin preparation Mutu III chromatin either 
un-sonicated or sonicated for 10 or 20 pulses was examined. (A) Size of DNA fragments sonicated 
0, 10 or 20 times. Leftmost lane was loaded with a 1kb ladder. ChIP experiments performed on 
chromatin sonicated with 10 or 20 pulses using antibodies for EBNA 2 and PU.1. Location of primer 
sets used are indicated as distance from the 5’ end of the forward primer to the LMP1 TSS. Signal 
for no antibody are displayed. ChIP QPCR for EBNA 2 with 10 pulses (B), EBNA 2 with 20 pulses (C), 
PU.1 with 10 pulses (D) and PU.1 with 20 pulses (E).  
(+)1564 (+)1564 
(+)1564 (+)1564 
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blocked with BSA  (Fig 3-3 A). To test if this enrichment was significant or at background levels, 
we also used primer sets at the LMP1 locus to analyse salmon sperm and BSA blocked EBNA 2 
ChIP DNA. Data was plotted alongside the percentage ChIP input obtained using salmon insulin 
primer sets and the no antibody negative control. These data show that in EBNA 2 ChIP DNA 
salmon DNA is present at a level significantly higher than that of the no antibody and is 
equivalent to EBNA 2 background binding in the LMP1 gene (Fig 3-3 B). No salmon DNA was 
detected in BSA blocked beads, and BSA blocked beads were able to precipitate EBNA 2 as 
shown by enrichment of EBNA 2 precipitated DNA at the -310 and +34 primer set of LMP1 (Fig 
3-3 C).  Due to this finding we subsequently blocked all beads in BSA. 
3.3 ChIP sequencing library preparation 
A large-scale ChIP protocol was designed and performed on Mutu III chromatin using EBNA 2 
specific and anti-EBNA 3C sheep polyclonal antibodies. This used six times more starting 
chromatin per antibody (3x107 cells) and DNA was diluted in half of the standard volume of 
water creating a 12-fold concentrated DNA sample. This was not necessary for the input DNA 
as this is already sufficiently concentrated in a standard ChIP experiment. After elution of DNA 
from DNA purification columns an extra elution step was carried out using the standard 
volume of water in a ChIP experiment. This was performed in order to test if the large scale 
ChIP method did not overload the DNA purification columns and leave large quantities of 
residual DNA. An aliquot of the concentrated ChIP samples was diluted 12 fold and analysed 
alongside residual DNA by QPCR using primers at the LMP1 locus. These data show that the 
large scale ChIP successfully enriched DNA bound by EBNA 2 (Fig 3-4 A) and EBNA 3C sheep 
polyclonal antibody (Fig 3-4 B) as a higher signal was obtained using the -310 and +34 primer 
set than the +574 primer set. It also demonstrates that residual DNA from EBNA 2 (Fig 3-4 A) 
and EBNA 3 (Fig 3-4 B) was detectable from the second elution step. Given that the 
concentrated DNA sample was diluted 12-fold, residual DNA accounts for ~ 8-15% of the total 
DNA precipitated by each antibody (Fig 3-4 A, B). 
ChIP sequencing library preparation was carried out using an Illumina kit but on advice of our 
collaborator, Dr. Richard Jenner (University College London), we altered the protocol to 
conduct PCR enrichment of DNA prior to gel extraction and size selection. After library 
amplification by PCR, DNA samples were size selected by agarose gel electrophoresis and the 
150-350bp fragment was purified. As QG buffer was necessary for gel extraction it was 
necessary to re-purify DNA as guanidium salts in the QG buffer absorb strongly at 230nm.  
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Figure 3-3 Salmon DNA is eluted from salmon sperm blocked beads in ChIP conditions. (A) ChIP 
QPCR from Mutu III chromatin using salmon sperm and BSA blocked beads and EBNA 2 antibody. 
Primers were designed for a region of the salmon insulin gene with no homology to humans. (B) 
ChIP in Mutu III using EBNA 2 antibody and salmon sperm blocked beads (B) and BSA blocked 
beads (C) analysed by QPCR at LMP1. Location of primer sets used are indicated as distance from 
the 5’ end of the forward primer to the LMP1 TSS. Signal for no antibody and signal obtained from 
salmon insulin primers are shown. 
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Figure 3-4 Quality control of ChIP DNA. EBNA 2 (A) and EBNA 3 (B) ChIP QPCR from Mutu III 
chromatin using LMP1 primers. DNA eluted from QIAGEN column was diluted 1:12 and residual 
DNA left on the column was eluted in water. Bioanalyser data for input (C), EBNA 2 (D) and EBNA 3 
(E) ChIP experiments. X axis displays fluorescent units used to measure quantity of DNA and Y axis 
displays the fragment sizes is base pairs. Markers at 35bp and 10380bp are also displayed.  
 
(+) 574 (+) 574 
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Samples were then examined on a bioanalyser. The plots show the size of the purified DNA on 
the x-axis, and the quantity of DNA measured in fluorescent units on the y-axis for input DNA 
(Fig 3-4 C), EBNA 2 precipitated DNA (Fig 3-4 D) and EBNA 3C sheep polyclonal antibody 
precipitated DNA (Fig 3-4 E). These were analysed alongside a DNA ladder of known DNA 
concentration and sized fragments allowing quantification of library prepared DNA. Having 
shown that ChIP DNA had been successfully purified, samples were submitted for illumina next 
generation sequencing at UCL genomics. 
3.4 EBNA 3C sheep polyclonal antibody co-precipitates EBNA 3A and EBNA 3B 
After submitting samples for sequencing we received a personal communication from a 
member of the Allday lab suggesting that the EBNA 3C sheep polyclonal antibody co-
precipitates EBNA 3A and EBNA 3B. To determine the specificity of the EBNA 3C antibody we 
performed immunoprecipitations (IPs) on non-crosslinked chromatin from the BJAB stable 
transfectants E3A1, E3B2 and E3C3; EBV negative B cell lymphomas which express only EBNA 
3A, EBNA 3B and EBNA 3C respectively. IPs were conducted using anti-EBNA 3A, anti-EBNA 3B, 
EBNA 3C sheep polyclonal antibodies and IgG as a negative control. Western blotting analysis 
of whole cell lysates from these cells confirmed that each cell line expresses the correct EBV 
nuclear antigen (Fig 3-5 left column). Probing blots with anti-EBNA 3C antibody showed that 
EBNA 3C was successfully immunoprecipitated by the EBNA 3C sheep polyclonal antibody. 
However, blots probed with either anti-EBNA 3A or anti-EBNA3B antibodies showed that these 
proteins were also precipitated by the EBNA 3C SP antibody (Fig 3-5 right). This effect was 
specific as blots probed for TATA box binding protein (TBP) showed that this was not 
precipitated by the EBNA 3C antibody (Fig 3-5 bottom panel). This blot also shows that the 
EBNA 3A and EBNA 3B antibodies used did not cross react with the other EBNA 3 proteins as 
only the correct antigen was precipitated in each IP (Fig 3-5 lanes 1 and 3 of IPs). From these 
data we concluded that the EBNA 3C antibody was in fact pan specific to all EBNA 3 proteins, 
as it could precipitate EBNA 3A and EBNA 3B, albeit at reduced levels to EBNA 3C when 
compared to the amount of protein in the whole cell lysate. 
3.5 Distribution of EBNA 2 and EBNA 3 binding sites 
This analysis identified 21,605 EBNA 2 and 7,044 EBNA 3 binding sites in the human genome. 
The data for EBNA 2 and EBNA 3 sequencing runs were background corrected using data from 
input DNA and aligned with the human genome. Significant peaks of EBNA 2 and EBNA 3  
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Figure 3-5 EBNA 3C sheep polyclonal antibody co-precipitates EBNA 3A and EBNA 3B under 
ChIP conditions. Immunoprecipitations performed under ChIP conditions. IPs were performed 
with anti-EBNA 3A, anti-EBNA 3B, anti-EBNA 3C sheep polyclonal antibodies and IgG as a 
negative control. IPs were performed in E3A1, E3B2 and E3C3 which express only EBNA 3A, EBNA 
3B and EBNA 3C respectively. Precipitates were subjected to western blotting (WB) using anti-
EBNA 3A, anti-EBNA 3B and anti-EBNA 3C antibodies. Leftmost column shows whole cell lysates. 
Top panel: IPs in E3A1 probed for EBNA 3A, second panel: IPs in E3B2 probed for EBNA 3B, third 
panel: IPs in E3C3 probed for EBNA 3C, bottom panel: IPs in E3C3 probed for TBP. 
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binding were identified with MACS (P-value < 10−7)(Zhang et al. 2008). By analysing the 
distribution of significant EBNA 2 and EBNA 3 binding sites we found that 75% of EBNA 2 (Fig 3-
6 A), and 84% (Fig 3-6 B) of EBNA 3 binding sites were more than 4Kb away from any gene TSS, 
suggesting these proteins primarily target enhancer elements. Further analysis examined the 
distribution of binding sites from any TSS, which revealed that EBNA 2 had a bimodal 
distribution with high frequencies of binding sites both 0.2-0.5 kb and 20-50kb from any TSS 
(Fig 3-6 C). Interestingly EBNA 3 peaks did not share the same pattern of binding sites and 
predominantly targeted regions 20-50kb from any gene TSS (Fig 3-6 C). This analysis was gene 
centric and only the nearest peak to a gene was recorded. For each significant EBNA 2 binding 
site the average number of sequencing reads per million was analysed over a 2 kb window, 
centred on the centre of each binding site (Fig 3-6 D). The same analysis was also performed 
on EBNA 3 binding sites (Fig 3-6 E). This revealed that EBNA 2 and EBNA 3 binding profiles 
around the centre of each peak are similar.  Together this data reveals extensive association of 
EBNA 2 and EBNA 3 proteins via distinct binding sites primarily found at distal regions. The 
abundance of EBNA 2 binding sites at 0.2-0.5 kb from gene TSSs may reflect the known role of 
EBNA 2 recruitment of general TFs to promoter proximal domains, mediated by the EBNA 2 
TAD. This data also explains why known EBNA 2 and EBNA 3 regulated genes were not often 
responsive to promoter reporter assays as EBNA 2 and EBNA 3 binding sites are not commonly 
promoter proximal. We were also able to map our sequencing reads to the EBV genome. 
Reassuringly, this confirmed binding sites at Cp, LMP1 and LMP2A for EBNA 2, and LMP1 for 
EBNA 3 (Fig 3-7 A, B). EBNA 3 association with LMP2A is a novel finding. 
To identify cellular genes targeted by the binding of EBNA 2 and 3 proteins, each binding site 
was analysed and the closest gene was termed as bound by that site. We first analysed genes 
that were bound by promoter proximal peaks (<2kb from a TSS). This revealed that 3554 genes 
were bound at a promoter proximal element by EBNA 2 and 664 were bound by EBNA 3 
proteins. Of the EBNA 3 targeted genes 62% (412/664) were also bound by EBNA 2 (Fig 3-8 A). 
we then expanded this analysis to examine genes bound at any distance from a TSS. 
Remarkably this revealed that 80% (3157/3937) of genes targeted by EBNA 3 proteins were 
also targeted by EBNA 2 (Fig 3-8 B). These data suggests a high degree of cross talk between 
the EBNA 2 and 3 proteins and that they likely co-regulate a subset of cellular genes. EBNA 2 
and EBNA 3 cross talk has already been implicated by gene expression microarray data but 
these data suggest the overlap in gene regulation is even more pronounced than expected 
(Hertle et al. 2009; White et al. 2010). We next analysed whether genes were being targeted  
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Figure 3-6 Distribution of EBNA 2 and EBNA 3 binding site (A) Pie chart showing the distribution 
of all significant binding sites for EBNA 2 relative to any gene TSSs. (B) Distribution of EBNA 3 
family binding sites. (C) The frequency of EBNA 2 or EBNA 3 protein binding sites plotted as 
distance from the TSS of the closest gene. (D) average signal from every EBNA 2 binding site, 
centred on the middle of the binding site. (E) average signal from every EBNA 3 binding site.  
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Figure 3-7 EBNA 2 and EBNA 3 proteins map to known binding sites in the viral genome (A) 
alignment of EBNA 2 and EBNA 3 sequencing reads to the EBV virus genome at Cp. Viral genes 
are annotated along with direction of transcription of each gene. X-axis shows distance from 
OriP. (B) alignment of EBNA 2 and EBNA 3 sequencing reads to the viral genome at LMP1 and 
LMP2A. 
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Figure 3-8 Coincident binding of EBNA 2 and 3 in the human genome. (A) Venn diagram of all 
genes with a promoter proximal EBNA 2 or EBNA 3 peak with the overlap showing genes bound 
by both. (B) Venn diagram of all genes most proximal to any peak for EBNA 2 or 3.(C) Pie chart 
showing the proportion of sites identified for EBNA 2 and EBNA 3 family proteins that are shared 
or unique.  
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by individual EBNA 2 and EBNA 3 sites or if these proteins were binding to shared sites. We 
found that only 8% of all EBNA 2 and 3 binding sites in the human genome were bound by 
EBNA 3 proteins alone and 25% of sites were bound by both EBNA 2 and EBNA 3 proteins (Fig 
3-8 C). This analysis was conducted using a significance ‘not bound’ for potentially shared 
peaks. Crucially, this discovery shows that not only do EBNA 2 and EBNA 3 proteins target 
overlapping sets of cellular genes, but that they do so via the same enhancer elements. 
3.6 Colocalisation of EBNA 2 and EBNA 3 binding sites with histone modifications 
The Encyclopedia of DNA elements (ENCODE) project provides freely-available ChIP sequencing 
data from numerous cell lines and primary cells on a wide range of transcription factors, 
histone modifications and other proteins involved in transcription. Our EBNA 2 and EBNA 3 
ChIP sequencing data tracks were aligned against published ChIP sequencing tracks showing 
the location of various histone modifications from the EBV immortalised LCL GM12878. The 
most significant 1000 EBNA 2 and EBNA 3 peaks (+/-1 1kb from the peak centre) were analysed 
and colocalised peaks of histone modifications from GM12878 ChIP-sequencing data by 
hierarchical clustering and displayed as a heat map. From these data we found that EBNA 2 
bound sites are commonly enriched for histone modifications including H3K27ac, H3K4me and 
H3K9ac in GM12878 LCLs (Fig 3-9). Active enhancer clusters were defined by high levels of 
acetylated lysine 27 on histone H3 (H3K27ac) and mono-methylated lysine 4 on histone H3 
(H3K4me1) whereas the poised clusters are defined by the presence of H3K4me1 but a lack of 
H3K27ac. EBNA 2 binding sites appeared not to co-localise with the repressive mark tri-
methylation on lysine 27 histone H3 (H3K27me3) or the PRC2 protein EZH2 which is 
responsible for depositing this mark (Fig 3-9). Analysis of EBNA 3 binding sites also revealed a 
co-localisation with active enhancer elements; however the most active sites were also 
strongly bound by EBNA 2 (Fig 3-10). The remaining EBNA 3 most significant peaks were 
clustered with poised enhancers as shown by an enrichment of H3K4me1 (Fig 3-10).  
Further analysis was conducted by taking an average signal across a 2kb window centred on 
the middle of the top 1000 binding sites for EBNA 2. This was compared to the average ChIP 
sequencing data for GM12878 histone modifications at these sites (Fig 3-11 A). These data 
confirms peaks of H3K27ac, H3K4me and H3K9ac are abundant in GM12878 at sites where 
EBNA 2 is bound significantly. The same analysis was performed on EBNA 3 binding sites and 
the same marks were enriched (Fig 3-11 B). In both cases it is striking that the top 1000 EBNA 2 
peaks are also commonly bound by EBNA 3 and vice versa. The lack of enrichment at the top 
1000 peaks for histone modifications at the middle of the binding site is a common feature of  
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Figure 3-9 Colocalisation of histone modifications at the top 1000 most significant EBNA 2 
binding sites. Heatmap of EBNA2, EBNA 3 and histone modification ChIP-sequencing signals at the 
top 1000 EBNA 2 binding sites. EBNA 2 and 3 ChIP-sequencing data from Mutu III BL cells was 
aggregated with ENCODE histone modification ChIP-seq data from the GM12878 LCL using 
hierarchical clustering. Each window displays the ChIP-seq signal -/+1 kb around the EBNA 2 
binding site midpoint. Clusters of active enhancers (H3K4me1+, H3K27ac+) and poised enhancers 
(H3K4me1+, H3K27ac-) are indicated. 
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Figure 3-10 Colocalisation of histone modifications at the top 1000 most significant EBNA 3 
binding sites. Heatmap of EBNA2, EBNA 3 and histone modification ChIP-sequencing signals at the 
top 1000 EBNA 3 binding sites. EBNA 2 and 3 ChIP-sequencing data from Mutu III BL cells was 
aggregated with ENCODE histone modification ChIP-seq data from the GM12878 LCL using 
hierarchical clustering. Each window displays the ChIP-seq signal -/+1 kb around the EBNA 2 
binding site midpoint. An active enhancer (H3K4me1+, H3K27ac+) and poised enhancer 
(H3K4me1+, H3K27ac-) clusters are indicated. 
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Figure 3-11 Average ChIP sequencing signal of histone modifications at the top 1000 most 
significant EBNA 2 and EBNA 3 binding sites. (A) Average EBNA2, EBNA 3 and histone modification 
ChIP-sequencing signals from ENCODE histone modification ChIP-seq data for the GM12878 LCL at 
the top 1000 EBNA 2 binding sites. (B) Average signals for the top 1000 EBNA 3 binding sites. 
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histone modifications and can readily be observed on the ENCODE database at known 
enhancer sites. This likely represents a local depletion of histones at sites where proteins bind 
in abundance. Together these data may suggest that EBNA 2 and EBNA 3 proteins are targeted 
to active and poised enhancers by cellular TFs. This may serve as another explanation of why 
promoter reporter assays had failed to be responsive for EBNA 2 and EBNA 3 proteins as these 
are conducted out of chromatin context. In summary it appears that histone modifications 
have a prominent role to play in gene regulation by EBNA 2 and EBNA 3 bound enhancers. 
3.7 Colocalisation of EBNA 2 and EBNA 3 biding sites with cellular transcription factors 
As it is known that EBNA 2 and EBNA 3 proteins cannot bind DNA directly our next approach 
was to analyse which cellular transcription factors co-localised with peaks of binding. This was 
performed to confirm known binding partners of EBNA 2 and 3 proteins (RBPJĸ and PU.1) and 
could potentially identify unknown candidate partners. We analysed GM12878 LCL ChIP 
sequencing data for cellular TFs (ENCODE database) and recently published EBNA 2 and RBPJĸ 
ChIP sequencing data from the EBV immortalised LCL IB4 (Portal et al. 2011), at the top 1000 
EBNA 2 binding sites. We found that EBNA 2 co-localised with a plethora of B cell transcription 
factors, many of which have not previously been described as EBNA associated proteins (Fig 3-
12). EBNA 2 significantly colocalised with its known binding partner RBPJĸ and other B cell 
transcription factors including: BATF, BCL11A, Bcl3, IRF4, PAX5, SP1 and TCF12. EBNA 2 binding 
sites also co-localised with the histone acetyl transferase p300, a co-activator usually 
associated with enhancer elements (Erwin et al. 2014)(Fig 3-12). The most significant 1000 
EBNA 3 binding sites also co-localised with the same set of B cell transcription factors (Fig 3-13). 
We also took the average signal for transcription factor binding signal in GM12878 and IB4 
LCLs at all 1000 EBNA 2 sites (Fig 3-14 A). This analysis confirmed co-localisation of B-cell 
transcription factors at EBNA 2 sites and in this case the signal for PU.1 was included, revealing 
co-localisation. A similar result was obtained from analysis of the average ChIP sequencing 
signal of cellular TFs at the top 1000 EBNA 3 peaks (Fig 3-14 B). It is noteworthy that of all the 
B-cell transcription factors in GM12878 on which there is ChIP-seq data, the highest signal at 
EBNA 2 peaks was EBF1. 
To further examine potential cellular TFs involved in targeting EBNA 2 and EBNA 3 proteins to 
DNA we performed unbiased analysis using MEME ChIP (motif analysis of large DNA datasets) 
to identify any enriched motifs in EBNA 2 and EBNA 3 precipitated DNA. Enriched motifs were 
then compared for matches to known TF consensus binding sites. Using DNA sequences at the 
top 300 most significant EBNA 2 binding sites we found that the most enriched (p-value 5E-161)  
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Figure 3-12 Colocalisation of TFBS at the top 1000 most significant EBNA 2 binding sites. 
Heatmap of EBNA 2, EBNA 3 and transcription factor ChIP-sequencing signals at the top 1000 
EBNA 2 binding sites. EBNA 2 and 3 ChIP-sequencing data from Mutu III BL cells was aggregated 
with ENCODE histone modification ChIP-seq data from the GM12878 and IB4 LCLs. Each window 
displays the ChIP-seq signal -/+1 kb around the EBNA 2 binding site midpoint.  
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Figure 3-13 Colocalisation of TFBS at the top 1000 most significant EBNA 3 binding sites. 
Heatmap of EBNA 2, EBNA 3 and transcription factor ChIP-sequencing signals at the top 1000 
EBNA 3 binding sites. EBNA 2 and 3 ChIP-sequencing data from Mutu III BL cells was aggregated 
with ENCODE transcription factor ChIP-seq data from the GM12878 and IB4 LCLs. Each window 
displays the ChIP-seq signal -/+1 kb around the EBNA 2 binding site midpoint. 
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Figure 3-14 Average ChIP sequencing signal of transcription factors at the top 1000 most 
significant EBNA  2 and EBNA 3 binding sites. (A) Average EBNA 2, EBNA 3 and transcription factor 
ChIP-sequencing signals from ENCODE histone modification ChIP-sequencing data for the 
GM12878 and IB4 LCLs at the top 1000 EBNA 2 binding sites. (B) Average signals for the top 1000 
EBNA 3 binding sites. 
 
80 
 
 
 
 
 
Figure 3-15 Enriched motifs at the top 300 most significant EBNA 2 binding sites. The top three 
most enriched motifs from the DNA sequences of the top 300 EBNA 2 binding sites generated by 
unbiased motif searching. All sequences are displayed 5’ to 3’. Letter height represents frequency 
of a position being that nucleotide within the motif-like sequences. These were compared to 
consensus motifs for cellular TFs from the ENCODE project and JASPAR database. Areas within an 
enriched motif that are similar to a known TF consensus site are indicated. Consensus and reverse 
consensus sites are displayed below the enriched motif and part of consensus or reverse 
consensus found in the enriched motif are underlined. Numbers show the p-value for site 
enrichment. (A) EBF1 like motif, (B) RBPJĸ like motif, (C) EICE (PU.1 and IRF4) like motif. 
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motif by EBNA 2 binding was an almost exact match for EBF1 (Fig 3-15 A).  A motif similar to 
the RBPJĸ consensus was also significantly enriched (Fig 3-15 B). The third most enriched motif 
was found to be similar to a composite PU.1, IRF4 site or EICE (Fig 3-15 C). This enriched motif 
was not highlighted as aligned against any known TF consensus site by MEME as it does not 
examine composite overlapping sites. EICEs are however a well categorised subclass of TF 
binding sites and combine the core PU.1 consensus (GGAA) with that of IRF4. The same 
analysis of the DNA sequence of the top 300 most significant EBNA 3 peaks revealed that the 
most enriched sequence was almost identical to that of the consensus binding site for PU.1 
(Fig 3-16 A). The enriched sequence also bore similarity to the EICE consensus sequence but 
the IRF4 portion of this was not as consistently found at the top 300 EBNA 3 binding sites as 
the core PU.1 consensus was. The next two most significantly enriched consensus motifs (p-
value 9.9E-8 and 3.2E-6) did not align to any known cellular TF consensus motif (Fig 3-16 B, C). 
They may represent complex composite sites or may be an artefact, as the P-value of these 
enriched motifs is lower than other EBNA 2 and EBNA 3 enriched motifs. As we had found that 
a large proportion of our binding sites were bound by both EBNA 2 and EBNA 3 proteins we 
also analysed DNA sequences from all shared EBNA 2 and EBNA 3 binding sites. We did this to 
determine EBNA 2 and EBNA 3 targeting to a shared site was dependent on their joint 
recruitment by a particular cellular TF. We found that DNA sequences bound by both EBNA 2 
and EBNA 3 contained significantly enriched motifs, the top 3 of which were shown to be 
similar to the EICE (Fig 3-17 A), EBF1 (Fig 3-17 B) and PU.1 (Fig 3-17 C) consensus sequences 
respectively.  
3.8 Alignment of genes bound by EBNA 2 and EBNA 3 with genes regulated in published 
micro array data sets 
To determine if EBNA 2 and 3 family binding correlated with gene regulation we assembled a 
list of all the genes most proximal to a binding site (8386 genes for EBNA 2 (Table 3-1) and 
3937 genes EBNA 3 (Table 3-2)). We compared these list with all genes known to be regulated 
by EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C from gene expression microarray data (Spender et 
al. 2002; Chen et al. 2006; Maier et al. 2006; Spender et al. 2006; Zhao et al. 2006a; Zhao et al. 
2006b; Lucchesi et al. 2008; Hertle et al. 2009; White et al. 2010; McClellan et al. 2012; Skalska 
et al. 2013).  
1. 3A KO LCL (Hertle et al. 2009). Compared expression data from wild type infected LCLs 
vs LCLs infected with a virus lacking EBNA 3A. 
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Figure 3-16 Enriched motifs at the top 300 most significant EBNA 3 binding sites. The top three 
most enriched motifs from the DNA sequences of the top 300 EBNA 3 binding sites generated by 
unbiased motif searching. All sequences are displayed 5’ to 3’Letter height represents frequency of 
a position being that nucleotide within the motif-like sequences. These were compared to 
consensus motifs for cellular TFs from the ENCODE project and JASPAR database. Areas within an 
enriched motif that are similar to a known TF consensus site are indicated. Consensus and reverse 
consensus sites are displayed below the enriched motif and part of consensus or reverse 
consensus found in the enriched motif are underlined. Numbers show the p-value for site 
enrichment. (A) PU.1 like motif, (B) unaligned motif, (C) unaligned motif. 
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Figure 3-17 Enriched motifs at all EBNA 2 and EBNA 3 shared binding sites. The top three most 
enriched motifs from the DNA sequences of all EBNA 2 and EBNA 3 binding sites generated by 
unbiased motif searching. Letter height represents frequency of a position being that nucleotide 
within the motif-like sequences. All sequences are displayed 5’ to 3’. These were compared to 
consensus motifs for cellular TFs from the ENCODE project and JASPAR database. Areas within an 
enriched motif that are similar to a known TF consensus site are indicated. Consensus and reverse 
consensus sites are displayed below the enriched motif and part of consensus or reverse 
consensus found in the enriched motif are underlined. Numbers show the p-value for site 
enrichment. (A) EICE (PU.1 and IRF4) like motif, (B) EBF1 like motif, (C) PU.1 like motif. 
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2. 3A KO BL31 (White et al. 2010). Compared expression data from EBV negative BL31 
cells infected with wild type BAC derived virus with BL31 cells infected with BAC 
derived virus lacking EBNA 3A. 
3. 3B KO LCL (White et al. 2010). Compared expression data from wild type infected LCLs 
vs LCLs infected with a virus lacking EBNA 3B. 
4. 3B KO BL31 (White et al. 2010). Compared expression data from EBV negative BL31 
cells infected with wild type BAC derived virus with BL31 cells infected with BAC 
derived virus lacking EBNA 3B. 
5. 3B-/3C low LCL (Chen et al. 2006). Compared expression data from wild type infected 
LCLs vs LCLs infected with a virus lacking EBNA 3B and with low EBNA 3C expression. 
6. BJAB 3C +/- (McClellan et al. 2012). Compared expression data from EBV negative B-
cell lymphoma BJAB lines transfected with a control plasmid, or a plasmid stably 
expressing EBNA 3C. 
7. 3CHT LCL (Zhao et al. 2006a). Data from an EBV immortalised LCLs expressing a 
hydroxy-tamoxifen  (HT) conditional EBNA 3C; compared expression data from LCLs 
growing in HT to LCLs grown for 7 days without HT, corresponding to LCL levels of 
EBNA 3C vs depleted levels of EBNA 3C but prior to growth arrest. Cut off 1.5 fold. 
8. 3C KO BL31 (White et al. 2010). Compared expression data from EBV negative BL31 
cells infected with wild type BAC derived virus with BL31 cells infected with BAC 
derived virus lacking EBNA 3C. 
9. 3CHT LCL (Skalska et al. 2013). Data from an p16INK4A deleted EBV immortalised LCLs 
expressing a hydroxy-tamoxifen (HT) conditional EBNA 3C; compared expression data 
from LCLs growing in HT to cells after HT removal, and those growing without HT to 
those to which HT has been re added. 
10.  3CHT LCL (Skalska et al. 2013). Data from an p16INK4A deleted EBV immortalised LCLs 
expressing a hydroxy-tamoxifen (HT) conditional EBNA 3C; compared expression data 
from LCLs growing in HT to cells after HT removal, and those growing without HT to 
those to which HT has been re added. (1.4 fold) 
11. E3 KO BL31 (White et al. 2010). Compared expression data from EBV negative BL31 
cells infected with wild type BAC derived virus with BL31 cells infected with BAC 
derived virus lacking EBNA 3A, EBNA 3B and EBNA 3C. 
12. ER/EB2 BL41 (Maier et al. 2006). Data from EBV negative BL41 lines transfected with a 
plasmid expressing a β-estradiol conditional EBNA 2. Compared expression data from 
cells with active EBNA 2 to those without. 
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13. ER/EB2 BJAB (Maier et al. 2006). Data from EBV negative B-Cell lymphoma lines 
transfected with a plasmid expressing a β-estradiol conditional EBNA 2. Compared 
expression data from cells with active EBNA 2 to those without. 
14. EB2 LCL (Zhao et al. 2006b). Data from an EBV immortalised LCLs expressing a hydroxy-
tamoxifen  (HT) conditional EBNA 2; compared expression data from LCLs growing in 
HT to LCLs grown for 24 hours without HT, corresponding to EBNA 2 cytoplasmic re-
localisation. Cut off 1.5 fold. 
15. EB2 Ak31 (Lucchesi et al. 2008). Compared expression data from EBV negative Ak31 
cells transfected with a control plasmid, or a plasmid containing type 1 or type 2 EBNA 
2. 
16. EB2 EREB 2.5 (A) (Spender et al. 2006). Data from an EBV immortalised LCLs expressing 
a β-estradiol conditional EBNA 2; compared expression data from LCLs growing 
without β-estradiol for 5 days to LCLs which have had β-estradiol re-added for 6 hours. 
17. EB2 EREB 2.5 (B) (Spender et al. 2002). Data from an EBV immortalised LCLs expressing 
a β-estradiol conditional EBNA 2; compared expression data from LCLs growing 
without β-estradiol for 5 days to LCLs which have had β-estradiol re-added for 6 hours. 
Using the 8386 EBNA 2 bound genes we found that 18.9% have previously been shown to be 
regulated by at least one of EBNA 2, EBNA 3A, EBNA 3B or EBNA 3C. 24.7% of 3937 genes 
bound by EBNA 3 have been shown to be regulated in at least one data set. The percentage of 
bound genes regulated in individual arrays was striking. In one data set 96% of genes shown to 
be regulated by EBNA 2 were bound by EBNA 2 in our ChIP sequencing data set. Furthermore, 
in an EBNA 3C array, 45.3% of EBNA 3C regulated were bound by EBNA 3 proteins. As EBNA 2 is 
regarded as an activator of transcription and EBNA 3 proteins generally as repressors of 
transcription; we next examined if EBNA 2 bound genes more likely to be activated by EBNA 2 
(Fig 3-18) and EBNA 3 bound genes were more likely to be repressed by EBNA 3 proteins (Fig 3-
19). Data was plotted as percentage of total genes. Whilst we could observe limited 
correlations within individual data sets it appears in general that EBNA 2 and EBNA 3 proteins 
activate and repress similar ratios of cellular genes. This data strongly suggests that EBNA 2 
and EBNA 3 binding to the human genome is functionally relevant to their transcriptional 
effects on nearby genes. 
3.9 Discussion 
EBV is capable of immortalising resting B cells through the concerted effect of its latent gene 
products. Latency III proteins have been shown to perturb cell cycle progression, immune  
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response, cell migration and growth control through both protein-protein interactions and 
transcriptional effects. Many cellular genes regulated by EBNA 2, 3A, 3B and 3C have been 
previously identified by gene expression microarray data but very little was known about how 
regulation was mediated. Here we show that EBNA proteins likely exert a large proportion of 
their influence by extensive interactions with the human genome. EBNA 2 and EBNA 3 binding 
sites do not seem to be spread randomly across the genome as genes most proximal to these 
binding sites are also likely known targets of EBNA proteins from expression data (Table 3-1, 
Table 3-2, Fig, 3-18, Fig 3-19). These include extensively studied targets of EBV such as CR2 
(CD21)(Calender et al. 1987) and BCL2L11 (Bim)(Clybouw et al. 2005). Furthermore the EBNA 
binding sites cluster such that only a limited number of genes are most proximal to a site. The 
21605 EBNA 2 and 7044 EBNA 3 sites are most proximal to 8385 and 3936 genes respectively. 
A high proportion of these sites are shared between EBNA 2 and EBNA 3 proteins suggesting 
extensive interplay between them, although both also have unique binding sites (Fig 3-7). We 
also show that EBNA 2 and EBNA 3 binding sites are commonly found distal to any gene TSS 
suggesting that enhancers play a key role in EBNA 2 and EBNA 3 mediated gene regulation (Fig 
3-6). However, the data presented here does not show the complete mechanism of 
transcriptional regulation by EBNA 2 and EBNA 3 proteins, or indeed if a particular EBNA 2 or 
EBNA 3 bound site is directly responsible for the transcriptional regulation of the nearest gene; 
as recent chromatin looping experiments have shown that enhancer-promoter interactions 
can occur between extremely distal genes, and even between chromosomes (Spilianakis et al. 
2005; Lomvardas et al. 2006). 
The data obtained also provided information on the relationship of histone modifications with 
EBNA 2 and EBNA 3 binding. The histone modifications present at the peaks of binding were 
enriched for active and poised chromatin marks (Fig 3-9 to 3-11). EBNA 3C and EBNA 2 can 
transactivate LMP1 but cellular gene activation by EBNA 3C is less well characterised, so this 
result was unexpected. Also, although EBNA 3 proteins have also been implicated in 
H3K27me3 mediated repression, there was a lack of enrichment at EBNA 3C binding sites for 
this repressive mark H3K27me3 or for EZH2 (Fig 3-10). The reason for this may be cell type 
specific differences in histone modifications between Mutu III and GM12878 LCLs (the cell line 
histone modification ChIP sequencing was examined). Another explanation could be that 
H3K27me3 appears to be found in broad peaks across large segments of a chromosome 
between insulating sites, distinguished by CTCF and other insulator protein binding sites 
(Lhoumaud et al. 2014). Lastly this analysis could be complicated by the fact that a high 
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proportion of the top 1000 EBNA 3 binding sites were also bound by EBNA 2 which is generally 
considered to be an activator of transcription.  
Analysis of EBNA 2 binding site DNA sequences revealed enriched motifs which corresponded 
to known cellular interaction partners; RBPJĸ and PU.1 (Fig 3-15). The most enriched motif at 
significantly bound EBNA 2 sites was EBF1, which was also the strongest average signal at the 
top 1000 EBNA 2 binding sites (Fig 3-14). To date, EBF1 has not been shown to target EBNA 2 
to DNA but there is increasing evidence that EBNA 2 and EBF1 at least share a great number of 
binding sites (Zhao et al. 2011). These data add to this finding. EBNA 3 bound DNA sequence 
analysis revealed an enriched motif which was highly similar to the consensus PU.1 binding site, 
suggesting that EBNA 3 proteins are brought to cellular sites by this factor (Fig 3-16). The role 
of EICEs in targeting EBNA 2 and EBNA 3 proteins to the human genome is one that is only just 
being investigated. A ChIP sequencing experiment using antibodies against EBNA 2 also found 
EICE consensus sites to be commonly found in EBNA 2 precipitated DNA (Zhao et al. 2011). 
Furthermore a recent study found that this consensus motif was enriched at genes 
differentially regulated by EBNA 2 type 1 and 2 and is found at the LMP1 promoter where both 
EBNA 3C and EBNA 2 can bind (Tzellos et al. 2014). It is therefore noteworthy that an EICE was 
found in the most enriched motif in DNA bound by both EBNA 2 and EBNA 3. What role EICEs 
have in recruitment of EBNA 2 and EBNA 3 to shared sites remains to be discovered. 
This study was based on the knowledge that EBNA 2 and EBNA 3 proteins are important 
regulators of cellular transcription. Much of this knowledge was gained from gene expression 
microarray data sets. Here we show that a remarkably high proportion of these previously 
reported genes are bound by EBNA 2 and EBNA 3 proteins. This suggests that EBNA 2 and 
EBNA 3 proteins exert their influence on host transcription by extensive binding to the human 
genome.  
In summary we have developed a ChIP method that precipitates sufficient amounts of native, 
endogenous EBNA 2 and EBNA 3 protein and associated DNA to perform ChIP-sequencing 
experiments. This data shows that EBNA 2 and the EBNA 3 proteins associate extensively with 
the human genome and that EBNA binding sites are significantly enriched for histone 
modifications indicative of open or poised chromatin. It also appears that the EBNA proteins 
preferentially target long-range enhancer elements to perturb host transcription. Furthermore 
a large number of B cell transcription factors are enriched at these sites although which of 
these transcription factors are targeting the EBNAs to the host genome has yet to be 
elucidated. We also found a striking overlap between genes that have been previously 
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reported as regulated by EBNA 2 and EBNA 3 proteins and our ChIP sequencing data. 
Importantly, this data suggests that EBNA 2 and EBNA 3 proteins are targeted to enhancers by 
B-cell transcription factors to regulate the transcription of cellular genes. 
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4. EBNA 3C represses integrin receptor signalling genes via promoter 
proximal and distal elements 
The West lab had previously carried out gene expression analysis using Affymetrix microarray 
chips to determine which cellular genes were regulated by EBNA 3C to gain functional insight 
into how EBNA 3C contributes to B-cell immortalisation. EBNA 3C is a potent repressor of 
transcription when tethered to DNA via GAL4 fusion proteins (Bain et al. 1996). It is known to 
also co-activate LMP1 with EBNA 2 via PU.1 sites (Lin et al. 2002). At the time this work was 
conducted this in fact was the only EBNA 3C DNA associated site in the viral or human genome. 
Other gene expression microarray experiments have revealed that EBNA 3C regulates over 
1500 cellular genes (Chen et al. 2006; Zhao et al. 2006a; White et al. 2010; McClellan et al. 
2012; Skalska et al. 2013). Our ChIP sequencing data suggests that much of the regulatory 
effects of EBNA 3C occur via EBNA 3C associations with DNA. We wanted to find out if any of 
the highly repressed genes highlighted by expression data were directly bound by EBNA 3C. 
Furthermore we wished to determine the mechanism of repression via EBNA 3C DNA 
interactions and resolved to investigate changes in histone modifications at repressed genes as 
EBNA 3C dependant changes in histone methylation and acetylation have been observed at 
other loci (White et al. 2010).  
4.1 EBNA 3C represses chemokine integrin receptor signalling genes 
To investigate potential direct targets of EBNA 3C on host cell gene transcription we analysed 
gene expression microarray data from our lab (McClellan et al. 2012). Total RNA was extracted 
from stable transfectants of the EBV-negative B-cell lymphoma BJAB cell lines E3C4 and PZ2 
(described in (Wang et al. 1990a). E3C4 stably expresses EBNA 3C in the absence of other EBV 
proteins whereas PZ2 contains a control plasmid and is both EBV and EBNA 3C negative. Two 
independent RNA preparations were used on Affymetrix GeneChip arrays and normalised data 
was analysed using four different pairwise comparisons of signals from E3C4 and PZ2. Data 
obtained in this way revealed 47 genes were downregulated and 122 genes were upregulated 
by 2 fold or more. We decided to focus on the genes repressed by EBNA 3C as more is known 
about how EBNA 3C may repress transcription. We found that of the top 20 most 
downregulated genes there were a number of chemokine and integrin receptor signalling 
genes (Table 4-1). We then used all 47 repressed genes as an input to DAVID which highlighted 
that several pathways were statistically enriched in this data set including chemokine signalling 
and focal adhesion. 8 out of the 47 genes were annotated as being involved in the chemokine  
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Table 4-1 Top 20 most down regulated and upregulated genes in BJAB EBNA 3C positive and 
control cells. Gene expression microarray data conducted in BJAB EBNA 3C positive cell line E3C3 
and BJAB EBNA 3C negative cell line PZ2 was analysed and the top 20 most upregulated and 
downregulated were examined. Genes are listed by the average log ratio signal from two 
independent RNA extractions analysed using four different pairwise comparisons, only genes 
counted 3 or more times are listed. Log 2 ratio was used to linearise data and ratios of +1 and -1 
would be equivalent to a two fold up regulation or two fold down regulation respectively. 
Microarray experimetns were performed by Sarika Khasnis and table is adapted from supplementary 
table 1 in McClellan et al 2012  (McClellan et al. 2012).  
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signalling pathway and subsets of these 8 genes were also involved in cytokine-cytokine 
receptor interaction and toll-like receptor signalling (Table 4-2). The focal adhesion and 
leukocyte activation pathways were also significantly enriched, each with 4 out of the 47 genes 
annotated as being part of that pathway. These two pathways are highly related as ITGA4, 
ITGB1 and VAV3 are annotated as being in both and will be collectively referred to as integrin 
receptor signalling pathway. The significance value for the enrichment of this pathway is likely 
an underestimate as the top 20 most downregulated genes included the a disintegrin and 
metalloproteases ADAM28 and ADAMDEC1. These were not annotated in DAVID for focal 
adhesion despite the fact that ADAM28 has published roles in adhesion and ADAMDEC1 is a 
related gene and has a role in adhesion (Bridges et al. 2002; Bridges et al. 2005; Lund et al. 
2013). We therefore included ADAM28 and ADAMDEC1 in our future analysis and concluded 
that EBNA 3C, when expressed without other EBV proteins, specifically and significantly 
represses chemokine signalling and integrin receptor signalling genes. 
In the chemokine signalling pathway EBNA 3C appears to target multiple points primarily 
regulating the levels of chemokines and therefore the input signal into the pathway (CXCL10, 
CXCL11, CCL3, CCL4, CCL3L1 and CCL3L3)(Fig 4-1). Secreted chemokines fundamentally 
function as chemoattractants. C-X-C motif ligand (CXCL) 10 and 11 along with CXCL9 are 
involved in leukocyte trafficking, are co-located in the genome and secreted by leukocytes and 
tissue cells (such as epithelial cells). Interestingly they all share the CXCR3 receptor. CXCR3 is 
rapidly induced on naïve T-cells following stimulation and is highly expressed on CD4+, CD8+ T-
cells and NK cells. CXCL9, 10 and 11 have overlapping, antagonistic, distinct and redundant 
roles depending on the cellular and environmental context. In general however they function 
in the generation of T-cells and the interactions and migration behaviour of effector T-cells 
(reviewed in (Groom and Luster 2011; van den Borne et al. 2014). CCL3, CCL4 and the CCL3 like 
proteins CCL3L1/2 are also chemoattractants with overlapping roles to CXCL proteins. CCL3 
and CCL4 produced by NK cells has been shown to inhibit HIV replication and provide 
protection against human cytomegalovirus by recruitment of other effector immune cells 
(Robertson 2002). Chronic lymphocytic leukaemia cells are characterised by high levels or 
production and secretion of CCL3 and CCL4 which appear to provide survival advantages by the 
recruitment of helper T-cells and accessory factors (Stratowa et al. 2001; Davids and Burger 
2012). Whilst the function of chemokine signalling appears to be context specific it is generally 
true that it is an important pathway by which the body communicates with the immune 
system, facilitating recruitment, migration and survival of immune cells.  
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EBNA 3C also downregulates VAV3 and ITK which are downstream targets in this pathway and 
affect the regulation of actin cytoskeleton. VAV3 had also been shown to be important in acute 
lymphoblastic leukaemia with its loss resulting in increased apoptosis (Chang et al. 2012). 
Interestingly VAV proteins are also targeted by LMP2 which blocks the effect of surface 
immunoglobulins through the LYN and SRC family protein kinases thereby repressing lytic 
activation (Miller et al. 1995). Both ITK and VAV3 have been highlighted as key genes 
downregulated during LCL generation with mRNA reduction detectable just 4 weeks after 
exposure to EBV (Dai et al. 2012). Furthermore mutations in ITK have been shown to be 
directly related to EBV associated lymphoproliferation (Huck et al. 2009; Linka et al. 2012).  
The integrin receptor signalling pathway is also regulated at multiple points by EBNA 3C 
including the integrin receptor α4β1 expressed from ITGA4 and ITGB1. There is a large degree 
of cross talk between the chemokine receptor signalling pathway and integrin receptor 
signalling and both signal through proteins such as SRC (Fig 4-2). ADAM28 is a ligand for α4β1 
integrin (expressed from ITGA4 and ITGB1 genes), with binding of soluble ADAM28 mediating 
adhesion and lymphocyte infiltration of tissue through VCAM-1 (Bridges et al. 2002; Bridges et 
al. 2005). VCAM-1 signalling in endothelial cells causes changes in cell morphology and gene 
expression facilitating transendothelial migration. This process is dependent on ezrin, radixin 
and moesin (ERM) signalling which is required for T-cell adhesion and homing to lymphoid 
organs (Chen et al. 2013). Communication between endothelial cells and leukocytes during 
migration results in α4β1 binding to JAM2 which allows penetration through the epithelial cell 
layer (Cunningham et al. 2002). Less is known about ADAMDEC1 although it is expressed in B 
cells, is down regulated during tumourigenesis and is found on the same gene cluster as 
ADAM28 and ADAM7. It also shares 47% sequence identity to ADAM28 and has recently been 
shown to be a secreted, active enzyme capable of cleaving α2-macroglobulin and casein (Lund 
et al. 2013). 
We next investigated whether these genes were bound by EBNA 3 proteins in our ChIP-
sequencing analysis to try to gain functional insights into their mechanism of repression. 
Interestingly many of the most downregulated genes in these pathways were also bound by 
EBNA 3 proteins in our Mutu III ChIP-sequencing data. To investigate the mechanism of 
repression by EBNA 3C and to validate EBNA 3C binding in BJAB background we used ChIP-
QPCR to investigate a subset of these genes in more detail, focussing on ITGA4, ITGB1, 
ADAM28, ADAMDEC1, CXCL10 and CXCL11. 
4.2 EBNA 3C binds to and represses ITGB1 via promoter-proximal and distal elements  
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To confirm binding of EBNA 3C to repressed genes which had been shown to have proximal 
peaks of EBNA 3 binding in our ChIP sequencing data we performed ChIP-QPCR using the EBNA 
3 pan specific antibody in BJAB control cell lines PZ1, PZ3 and the EBNA 3C-only-expressing 
BJAB cell lines E3C3 and E3C7. As PZ2 and E3C4 had previously been used in gene expression 
micro array experiments we used the alternative lines to attempt to control for clonal 
differences between the cell lines. We also also examined levels of histone modifications to 
see if EBNA 3C binding and repression cause enrichment of repressive marks (H3K27me3)  or 
loss of active marks (H3 acetylation and H4 acetylation). Our ChIP sequencing data revealed 
that there are two EBNA 3 binding sites at ITGB1, one promoter-proximal and one distal. A 
visualisation of our ChIP sequencing data in the University of California Santa Cruz (UCSC) 
genome browser is shown in Figure 4-3 A. This is annotated with scale (top panel), our ChIP 
sequencing track data (EBNA 3 panel), H3K27Ac (layered H3K27Ac panel) , the ITGB1 gene and 
TSS (for ease of graphical representation all exons are included regardless of isoform 
dependant inclusion) and positions of QPCR primers used at this locus. The layered H3K27Ac 
panel shows published ChIP sequencing data using antibodies against H3K27Ac from the EBV 
infected LCL GM12878; this mark is indicative of active enhancer elements. The y-axis of the 
EBNA 3 panel depicts reads per million background subtracted total reads (Fig 4-3 A). This is a 
measure of how many fragments of DNA from that site in the human genome were 
precipitated by the EBNA 3 antibody. Binding is only considered if the significance of the 
enrichment of fragments from that region passes a stringent threshold (p-value less than 1x10-
7). Peak height is therefore generally well correlated with significance; for comparison, the 
‘smallest’ peak called as significant in our data set is ~1.5 reads per million and the ‘highest’ 
observed peak is ~40 reads per million. 
ChIP QPCR using primers at both peaks and in the gene as well as a control site where no EBNA 
is bound (PPIA) confirmed that EBNA 3C binds to both EBNA 3 binding sites in both E3C3 and 
E3C7 (Fig 4-3 B). H3K27me3 significantly increased across the promoter and at sites ~1kb 
upstream and downstream from the TSS but not at the upstream EBNA 3C binding site in EBNA 
3C expressing cell lines compared to EBNA 3C negative ones (Fig 4-3 C). Increasing H3K27me3 
levels suggests that EBNA 3C may be coordinating epigenetic silencing through polycomb 
group proteins as previously demonstrated at the Bim locus (Paschos et al. 2009). It is known 
that H3K27me3 exists in broad areas of the human genome and is not confined to distinct 
peaks. Acetylation of histone H3 and H4 is generally decreased in the presence of EBNA 3C 
compared to control cell lines although this is more apparent for H3ac than H4ac (Fig 4-3 D, E).  
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Figure  4-3 EBNA 3C binds to ITGB1 and promotes epigenetic changes associated with gene repression. 
ChIP experiments conducted in the EBNA 3C positive cell lines E3C3, E3C7 and the EBNA 3C negative cell 
lines PZ1, PZ3. (A) EBNA 3 binding at the ITGB1 locus. Top panel; scale, EBNA 3 panel; our ChIP 
sequencing data displayed as reads per million background subtracted total reads and aligned with the 
human genome, H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE 
project, bottom panel; annotation of gene and direction of transcription. Numbers indicate the 5’ end of 
the forward primers used for ChIP-QPCR analysis relative to the TSS. Control primers spanned the TSS of 
PPIA. Percentage input signals, after subtraction of signals of controls with no antibody, are expressed 
relative to the highest signal obtained. Results are shown as ± standard deviations of two independent 
experiments. ChIP-QPCR data for EBNA 3C (B), H3K27me3 (C), H3ac (D) and H4ac (E). 
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This indicates a loss of active chromatin marks at ITGB1 which is also consistent with gene 
repression. 
4.3 EBNA 3C binds to and represses ITGA4 via a promoter-proximal site 
Along with ITGB1, ITGA4 gene products forms α4β1 integrin. This molecule is able to interact 
with VCAM-1 and promote adhesion and cell migration (Garmy-Susini et al. 2013). ITGA4 is 
bound by a promoter proximal EBNA 3 peak (Fig 4-4 A). Using ChIP QPCR EBNA 3C binding to 
this site was confirmed (Fig 4-4 B) and H3K27me3 levels were found to increase within the 
ITGA4 but not at the promoter or upstream regions in the presence of EBNA 3C (Fig 4-4 C). In 
PZ1 and PZ3 control cells the levels of H3ac were already low compared to the constitutively 
active control gene (PPIA); however levels of H3ac were detectably reduced at this gene (Fig 4-
4  D). Acetylation of H4 was reduced at primer sets for the peak and in the gene (Fig 4-4 E). 
Similarly to ITGB1 this suggests that EBNA 3C is able to bind to this locus and downregulate 
expression through epigenetic mechanisms. 
4.4 Binding of EBNA 3C to an intergenic peak at the ADAM locus causes epigenetic repression 
of ADAM28 and ADAMDEC1 
The ADAM28 gene was the most downregulated gene in BJAB EBNA 3C expressing cells 
compared to control cells (Table 4-1). ADAMDEC1 is related to ADAM28, is found in the same 
gene cluster and was also in the top 20 most downregulated genes. At the ADAM locus our 
ChIP sequencing data revealed a large peak of EBNA 3 binding between ADAM28 and 
ADAMDEC1 (Fig 4-5 A). As this was the most proximal EBNA 3 peak to both genes we used 
ChIP-QPCR to investigate whether EBNA 3C was capable of binding to this site. We used primer 
sets at the peak of binding as well as two flanking primer sets just outside the area of the 
genome significantly enriched by EBNA 3. The effect of EBNA 3C on levels of H3K27me3, H3ac 
and H4ac across this locus were also investigated by comparing ChIP QPCR data from control 
and EBNA 3C expressing cell lines. These data confirmed EBNA 3C was capable of binding to 
this site in E3C3 and E3C7 (Fig 4-5 B). Cells expressing EBNA 3C showed a dramatic increase in 
the polycomb associated mark H3K27me3 at the ADAMDEC1 promoter and within ADAM28 
compared to control cell lines. Interestingly this mark did not increase at the ADAM28 
promoter (primer sets -587. -87, +1523) and only subtly increased at the peak itself (primer 
sets 5’, mid, 3’) (Fig 4-5 C). H3ac was low over this locus in control cell lines compared to the 
control gene (PPIA); however this mark was decreased to background levels in the presence of 
EBNA 3C, indicative of repression (Fig 4-6 B). H4ac levels were higher than those of H3ac  
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Figure 4-4 EBNA 3C binds to ITGA4 and promotes epigenetic changes associated with gene repression. 
ChIP experiments conducted in the EBNA 3C positive cell lines E3C3, E3C7 and the EBNA 3C negative cell 
lines PZ1, PZ3. (A) EBNA 3 binding at the ITGA4 locus. Top panel; scale, EBNA 3 panel; our ChIP 
sequencing data displayed as reads per million background subtracted total reads and aligned with the 
human genome, H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE 
project, bottom panel; annotation of gene and direction of transcription. Numbers indicate the 5’ end of 
the forward primers used for ChIP-QPCR analysis relative to the TSS. Control primers spanned the TSS of 
PPIA. Percentage input signals, after subtraction of signals of controls with no antibody, are expressed 
relative to the highest signal obtained. Results are shown as ± standard deviations of two independent 
experiments. ChIP-QPCR data for EBNA 3C (B), H3K27me3 (C), H3ac (D) and H4ac (E). 
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Figure 4-5 Binding of EBNA 3C to an intragenic peak at the ADAM locus causes epigenetic repression of 
ADAM28 and ADAMDEC1. ChIP experiments conducted in the EBNA 3C positive cell lines E3C3, E3C7 and 
the EBNA 3C negative cell lines PZ1, PZ3. (A) EBNA 3 binding at the ADAM locus. Top panel; scale, EBNA 3 
panel; our ChIP sequencing data displayed as reads per million background subtracted total reads and 
aligned with the human genome, H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in 
the ENCODE project, bottom panel; annotation of gene and direction of transcription. Numbers indicate 
the 5’ end of the forward primers used for ChIP-QPCR analysis relative to the TSS. Control primers 
spanned the TSS of PPIA. Percentage input signals, after subtraction of signals of controls with no 
antibody, are expressed relative to the highest signal obtained. Results are shown as ± standard 
deviations of two independent experiments. ChIP-QPCR data for EBNA 3C (B), H3K27me3 (C). 
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Figure 4-6 Binding of EBNA 3C at the ADAM locus correlates with a decrease in acetylation at ADAM28 
and ADAMDEC1. ChIP experiments conducted in the EBNA 3C positive cell lines E3C3, E3C7 and the 
EBNA 3C negative cell lines PZ1, PZ3. (A) EBNA 3 binding at the ADAM locus. Top panel; scale, EBNA 3 
panel; our ChIP sequencing data displayed as reads per million background subtracted total reads and 
aligned with the human genome, H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in 
the ENCODE project, bottom panel; annotation of gene and direction of transcription. Numbers indicate 
the 5’ end of the forward primers used for ChIP-QPCR analysis relative to the TSS. Control primers 
spanned the TSS of PPIA. Percentage input signals, after subtraction of signals of controls with no 
antibody, are expressed relative to the highest signal obtained. Results are shown as ± standard 
deviations of two independent experiments. ChIP-QPCR data for H3ac (B), H4ac (C). 
106 
 
relative to the control gene but were only found to be significantly altered at the EBNA 3C 
binding site and at ADAMDEC1. At these sites the expression of EBNA 3C was correlated with a 
reduction in H4ac, further implicating epigenetic mechanisms in EBNA 3C mediated repression 
(Fig 4-6 C). 
4.5 Epigenetic repression of CXCL10 and CXCL11 in cells expressing EBNA 3C 
Chemokine signalling pathway genes were the most enriched cluster of repressed genes in the 
BJAB EBNA 3C -/+ gene expression microarray analysis with a total of 8 out of 47 repressed 
genes being involved in this pathway. Six of these genes are chemokine signalling molecules 
and are amongst the most consistently regulated genes across all EBNA 2 and 3 microarray 
expression data sets. Expression of CCL3L1/3 has been shown to be repressed by EBNA 3C in a 
BJAB background, repressed by EBNA 3A in an LCL background, activated by EBNA 3B and 
EBNA 3C in a BL31 background and activated by EBNA 2 in BL41, BJAB, LCL and Akata 
backgrounds (Chen et al. 2006; Maier et al. 2006; Spender et al. 2006; Zhao et al. 2006a; Zhao 
et al. 2006b; Lucchesi et al. 2008; Hertle et al. 2009; White et al. 2010; McClellan et al. 2012). 
Of the eight chemokine signalling genes repressed by EBNA 3C only CXCL11 is not regulated in 
any other array.  CXCL10 and CXCL11 are located in a gene cluster along with CXCL9 and 
coordinate lymphocyte migration (Groom and Luster 2011).  
Low levels of EBNA 3 binding to this locus was detected (Fig 4-7 A). We attempted to confirm 
EBNA 3C binding to these sites and investigate changes in histone modifications across this 
locus with and without the presence of EBNA 3C. Primer sets were designed to amplify DNA at 
each of the EBNA 3 binding sites (primer sets 1 and 3) and a region in between the two peaks 
where no EBNA 3 was shown to bind (primer set 2). We could not detect significant EBNA 3C 
binding at either site as QPCR signals obtained were similar to that of the EBNA 3C negative 
control cell lines and were significantly below the signal obtained at the ADAM binding site (Fig 
4-7 B). Following publication of our study the Kempkes lab reported binding of EBNA 3A to an 
intergenic region between CXCL9 and CXCL10.  The binding site was marked by high levels of 
H3K27ac in the EBV infected LCL GM12878 in ChIP sequencing data from the ENCODE project. 
Both CXCL9 and CXCL10 had been previously identified as targets of EBNA 3A regulation in LCLs 
by gene expression microarray analysis. To determine whether EBNA 3C targeted CXCL10 and 
CXCL11 via this site we used the published primer sets used to detect EBNA 3C binding; R1, R2 
and R3. ChIP-QPCR data from EBNA 3C expressing and control cell lines revealed that EBNA 3C 
does not associate with this site in a BJAB background (Fig 4-7 C). In contrast the Kempkes lab  
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Figure 4-7 EBNA 3C does not bind to regulatory sites at the CXCL locus ChIP experiments conducted 
in the EBNA 3C positive cell lines E3C3, E3C7 and the EBNA 3C negative cell lines PZ1, PZ3. (A) EBNA 
3 binding at the ADAM locus. Top panel; scale, EBNA 3 panel; our ChIP sequencing data displayed as 
reads per million background subtracted total reads and aligned with the human genome, H3K27ac 
panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE project, bottom panel; 
annotation of gene and direction of transcription. Location of primer sets designed to amplify peaks 
from our ChIP sequencing data (1 and 3) and an intervening primer set (2) are shown. Location of 
primer sets designed to amplify a reported region of EBNA 3A binding (R1, R2 and R3) are also 
indicated). Positive control of ChIP QPCR signal at ADAM binding site is shown. Percentage input 
signals, after subtraction of signals of controls with no antibody, are expressed relative to the 
highest signal obtained. Results are shown as ± standard deviations of two independent 
experiments. ChIP-QPCR data for EBNA 3C at CXCL11 upstream sites (B) and CXCL10 downstream 
sites (C). 
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Figure 4-8 Epigenetic repression of CXCL10 in cells expressing EBNA 3C ChIP experiments conducted 
in the EBNA 3C positive cell lines E3C3, E3C7 and the EBNA 3C negative cell lines PZ1, PZ3 at CXCL10. 
Numbers indicate the 5’ end of the forward primers used for ChIP-QPCR analysis relative to the TSS. 
Control primers spanned the TSS of PPIA. Percentage input signals, after subtraction of signals of 
controls with no antibody, are expressed relative to the highest signal obtained. Results are shown 
as ± standard deviations of two independent experiments. ChIP-QPCR data for H3K27me3 (A), H3ac 
(B), H4ac (C). 
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Figure 4-9 Epigenetic repression of CXCL11 in cells expressing EBNA 3C ChIP experiments conducted 
in the EBNA 3C positive cell lines E3C3, E3C7 and the EBNA 3C negative cell lines PZ1, PZ3 at CXCL11. 
Numbers indicate the 5’ end of the forward primers used for ChIP-QPCR analysis relative to the TSS. 
Control primers spanned the TSS of PPIA. Percentage input signals, after subtraction of signals of 
controls with no antibody, are expressed relative to the highest signal obtained. Results are shown 
as ± standard deviations of two independent experiments. ChIP-QPCR data for H3K27me3 (A), H3ac 
(B), H4ac (C). 
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observed a broad peak of EBNA 3A at this site with significant binding at all three primer sets 
(Harth-Hertle et al. 2013). 
In the EBNA 3C expressing cell lines H3K27me3 was observed to be significantly higher than 
that of the control cell lines across the whole of CXCL10 and 3’ end of CXCL11 indicative of 
gene repression by polycomb group proteins (Fig 4-8 A, Fig 4-9 A). CXCL10 was not associated 
with the active transcription marks H3ac and H4ac in either control cells or EBNA 3C expressing 
cells (Fig 4-8 B, Fig 4-9 B). In contrast H3ac and H4ac were evident at the promoter of CXCL11 
in control cells and reduced in cells expressing EBNA 3C (Fig 4-8 B, Fig 4-9 B). As we could not 
detect EBNA 3C binding at this locus these data suggest that EBNA 3C is indirectly repressing 
transcription of CXCL10 and CXCL11. However, changes in histone modifications suggests that 
the mechanism of indirect repression may be similar to that at directly bound genes such as 
ITGA4, ITGB1 and at the ADAM locus. 
4.6 Discussion 
Our data demonstrate that ITGA4, ITGB1, ADAM28 and ADAMDEC1 identified as highly 
repressed EBNA 3C target genes are bound at proximal and distal sites by EBNA 3C. This 
implicates binding of EBNA 3C to these elements in repression of these genes.  
Chemokines are an integral part of the immune response performing an important role in 
guiding the migration of immune response cells. Secreted chemokines and other alarmones 
can attract immune cells by increasing their adhesion to local endothelial cells via integrin 
signalling molecules such as integrin β2 and integrin αL (ITGAL)(collectively known as LFA1) 
interaction with ICAM1 (reviewed in (Newton and Dixit 2012)). It is therefore possible that the 
EBNA 2 and EBNA 3 proteins have a role in directly regulating these responses as the EBNA 2 
and 3 proteins themselves are highly immunogenic. Despite this the CD4+ and CD8+ T cell 
response very effectively controls EBV infection in vivo although they cannot clear the virus 
and an infected host will remain infected for the rest of their life (reviewed in (Landais et al. 
2005)). Chemokine and integrin signalling genes were known to be targets of EBNA 2 and 3 
proteins prior to this investigation through gene expression microarray analysis. However the 
mechanism of regulation was completely unknown.  
We previously identified chemokine and integrin signalling genes as some of the most 
significantly downregulated genes in EBV –ve EBNA 3C +ve B cell lymphoma BJAB compared to 
control cells. Using ChIP QPCR and guided by our ChIP sequencing data we were then able to 
confirm that EBNA 3C bound to sites proximal and distal to ITGB1, ITGA4, ADAM28 and 
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ADAMDEC1 in these cells. This is the first demonstration of cellular gene targeting by EBNA 3C 
that correlates with gene regulation. Furthermore we were able to show that the repression of 
these genes was likely mediated through a combination of H3K27me3 (a mark associated with 
the polycomb group protein EZH2) and modulating histone acetylation. Subsequent 
experiments by Sarika Khasnis in our laboratory further validated the repression of these 
genes. cDNA levels in EBNA 3C expressing cell lines (E3C3, E3C4 and E3C7) were compared to 
control cell lines (PZ1, PZ2 and PZ3) revealing cDNA levels of all of studied  genes here (as well 
as CCL3 and CCL4) was reduced or ablated in the presence of EBNA 3C (McClellan et al. 2012). 
CXCL10 and 11 play key roles in the attraction of leukocytes to sites of infection and 
inflammation. This property makes CXCL10 and 11 potent anti-tumour proteins as they can 
recruit cytotoxic T lymphocytes to malignant tissue (Sgadari et al. 1996; Hensbergen et al. 
2005). CXCL10 and 11 are both ligands for CXCR3 chemokine receptor along with CXCL9, which 
is in the same gene cluster. CXCR3 is found on CD8+ cytotoxic T cells, CD4+ type-1 helper T 
cells, natural killer (NK) cells, NKT cells and subsets of B cells and its ability to interact with this 
many ligands likely reflects the complex nature of its various roles in various cell types. Indeed, 
CXCL10, CXCL11 and CXCL9 have been shown to have redundant, synergistic and even 
antagonistic effects on CXCR3 in-vivo (reviewed in (Groom and Luster 2011)). Chemotaxis 
assays conducted by Sarika Khasnis using the BJAB series used in this study revealed that cells 
expressing EBNA 3C (E3C3, E3C4 and E3C7) caused reduced migration of CXCR3 expressing 
cells compared to control cells (PZ1, PZ2 and PZ3)(McClellan et al. 2012). This implicates EBNA 
3C mediated repression of CXCL10 and CXCL11 in immune evasion by EBV. The mechanism of 
regulation of CXCL10 and CXCL11 appears to be via indirect or long range mechanisms as no 
EBNA 3C peak could be verified at this locus. Two EBNA 3 peaks were detected upstream of 
CXCL11 by ChIP sequencing in Mutu III cells which could represent either an EBNA 3A or 3B 
binding sites. CXCL10 and CXCL11 cDNA levels have been shown to be reduced in an EBV 
negative EBNA 3A expressing cell line compared to controls (McClellan et al. 2012). However, 
only one of these peaks passed the significance threshold of 1x10-7 and the other was not 
highly significant. Data from the Kempkes lab reported an EBNA 3A binding site in an 
intergenic region between CXCL9 and CXCL10 which was proposed to mediate the observed 
repression of these genes by EBNA 3A. We did not detect a binding site for EBNA 3 proteins at 
this site, which is likely to be a result of cell-type specific EBNA 3 binding. Furthermore we did 
not detect EBNA 3C association with this site in a BJAB background. 
112 
 
Together, these data suggest that repression of CXCL10 and CXCL11 by EBNA 3C in E3C3, E3C4 
and E3C7 cell lines is an indirect effect of the presence of EBNA 3C in these cell lines. In this 
case it is possible that the peak of binding in the ChIP sequencing data represents a false 
positive and EBNA 3C is repressing this locus through other mechanisms. It is also possible that 
our ChIP-QPCR technique was incapable of detecting a site with such a low level of binding by 
ChIP sequencing data, and that at least some of the EBNA 3C mediated repression of CXCL10 
and CXCL11 is via interactions with binding sites observed via ChIP sequencing. These data 
further implicate that EBNA 3C is epigenetically repressing CXCL10 and CXCL11 via an unknown 
mechanism in order to evade to CD8+ and CD4+ T cell immune response. 
The integrin signalling pathway was also highlighted as an enriched pathway in our DAVID 
analysis of EBNA 3C downregulated genes. These were highlighted as part of the focal 
adhesion pathway but did not include ADAM28 despite the fact that this soluble protein is a 
ligand for α4β1 integrin. ADAMDEC1 was also not included, probably because very little is 
known about this protein and it has only recently been described as a soluble, active enzyme 
capable of proteolytic cleavage (Lund et al. 2013). This is a limitation of DAVID analysis as the 
pathway clustering only clusters and annotates well-described genes. Many human genes due 
to lack of study have a limited number of gene ontology terms ascribed to them meaning they 
will not appear in many clustering functions or pathways. The focal adhesion pathway is the 
subject of much research due to its role in cell migration and therefore tumour metastasis. The 
migration of immune cells through tissue is an essential role of combating infection and 
cancers. This is a highly regulated complex process and involves four major steps; rolling, 
activation, firm adhesion and transmigration. Only cells expressing the correct surface 
molecules can undergo this process, which in the case of T cells may involve activation via the 
T cell receptor or chemokines. Some of the key surface molecules involved in this process are 
LFA-1 (ITGAL-β2)  and α4β1 which bind ICAM-1 and VCAM-1 respectively. Rolling occurs when 
immune cells acquire a weak adhesion to a cell surface (e.g. endothelial surface) and requires 
expression of selectins, chemokine receptors and integrins. This greatly increases the chances 
of encountering other ligands that further activate the immune cell resulting in firm adhesion. 
LFA-1 is especially important in this process. Transmigration is less well understood as it 
requires de-adhesion and re-adhesion to new cells. In this situation α4β1 has been reported to 
be both a positive and negative regulator of the LFA-1 ICAM-1 adhesion (reviewed in (Denucci 
et al. 2009)). LFA-1 has been previously described to be regulated by EBV upon infection 
mimicking B-cell activation, an effect that has been attributed to the activity of the viral 
membrane protein LMP1 (Wang et al. 1987; Wang et al. 1990a). 
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To determine the relevance of this pathway to EBV immortalisation it is important to consider 
when EBNA 2 and the EBNA 3 family are expressed in vivo. In a healthy host this appears only 
to occur upon initial infection when the naive B cell takes on an activated phenotype and 
migrates to the germinal centre (GC). Once there EBV assumes a latency II phenotype and the 
EBNA 2 and EBNA 3 proteins are repressed. It is therefore possible that the regulation of this 
pathway aids EBV infected B cells to assume an activated phenotype and migrate to the 
germinal centre. Furthermore regulation of integrin receptor signalling genes may play a role 
in immune evasion as T cell recognition of infected cells requires adhesion via VCAM-1, either 
by evading contact or breaking contact once it has been established (reviewed in (Wu 2007)). 
The data presented here suggests that the regulation of focal adhesion and integrin genes by 
EBNA 3C is established through epigenetic mechanisms.  
Polycomb mediated gene repression has been shown to cause CpG methylation which results 
in long lasting gene repression, suggesting that the repressive effects of EBNA 3C may persist 
long after the transition of EBV from a latency III to a latency II phenotype. Such mechanisms 
of persistent epigenetic repression by EBNA 3C have already been reported at Bim (Paschos et 
al. 2009). If this is the case at these genes then EBNA 3C repression may persist into the GC 
and beyond. In the GC many of the survival signals required to avoid apoptosis are provided by 
contact with T cells and follicular dendritic cells which is mediated through VCAM-1 integrin 
interactions (Taylor et al. 1999; Yoon et al. 2014). It is important to note that whilst EBNA 3C 
binding to the loci described does correlate with repression, enrichment of H3K27me3 and a 
reduction of H3ac and H4ac, this does not prove that EBNA 3C is modifying histones by 
recruiting other gene silencing proteins. It is also not possible from these data to determine 
that the changes in H3K27me3, H3ac and H4ac precedes or proceeds EBNA 3C association with 
the human genome. However, given that EBNA 3C is a potent repressor of transcription when 
tethered to DNA and that it can associate with chromatin remodellers such as CTBP proteins; it 
is very likely that this is indeed the first documented evidence of EBNA 3C binding to the 
human genome and directly repressing nearby genes through the recruitment of cellular 
factors (Bain et al. 1996; Touitou et al. 2001). 
Whilst studying the effect of EBNA 3C alone is hugely informative it is clear that in vivo the 
story is far more complex. The genes targeted by EBNA 3C in this chapter have also been 
shown to be regulated by a variety of other EBNA proteins in other gene expression microarray 
data sets and cell lines. Whilst CXCL11 has only been shown to be downregulated by EBNA 3C 
in the BJAB background EBNA 3C expressing cells compared to control cells, CXCL10 has been 
114 
 
shown to be repressed by EBNA 3A in LCLs, upregulated by EBNA 3B in LCLs and BL cell lines, 
upregulated by EBNA 3C in LCLs and upregulated by EBNA 2. A similar mosaic of up and down 
regulation by the EBNA 3 family is observable in the other genes examined in this chapter 
(Table 4-3). ADAM28 and ADAMDEC1 are exceptions to this as the expression of both been 
shown to be repressed by EBNA 3C and EBNA 3A and activated by EBNA2, suggesting that 
cross talk between EBNA 2 and 3 proteins is context specific. It is also probably that the wide 
variety of cell backgrounds in which these data are obtained from play a role in gene 
regulation by EBNA 2 and 3 proteins. This likely represents the requirement of EBV to fine tune 
host gene expression with a remarkably limited set of latent genes. How the EBNA 2 and 3 
proteins perform these functions, if they act synergistically, antagonistically or redundantly 
and if all share similar mechanisms of regulation remains poorly understood. 
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5. Investigating EBNA 3A, 3B and 3C binding to key target genes and the 
role of shared EBNA 2 and 3 binding sites in gene regulation 
Many cellular genes are transcriptionally regulated by more than one of the EBNA 3 family  in 
cooperative and antagonistic ways (Paschos et al. 2009; White et al. 2010). Furthermore, it is 
well documented that EBNA 3 family proteins can both antagonise and cooperate with EBNA 2 
to regulate transcription and ChIP sequencing data indicates that EBNA 2 and 3 coincident 
binding sites are common in the human genome. The mechanism EBNA 2 and 3 protein 
transcriptional cross talk is largely unknown.  
EBNA 2 and EBNA 3 binding to RBPJĸ is mutually exclusive but it is not known if whether EBNA 
2 and EBNA 3C bind PU.1 simultaneously (Johannsen et al. 1995; Zhao and Sample 2000) 
(Grossman et al. 1994; Henkel et al. 1994; Le Roux et al. 1994; Waltzer et al. 1994; Robertson 
et al. 1995). It is also unknown if EBNA 3A, 3B and 3C can bind RBPJĸ or PU.1 simultaneously. 
Since our ChIP-sequencing analysis had used a pan specific antibody against EBNA 3A, 3B and 
3C we did not know whether these proteins associated with the same cellular DNA elements. 
We set out to investigate whether sites at specific target genes were bound by EBNA 3A, EBNA 
3B, EBNA 3C and the role of EBNA 2 and EBNA 3 shared sites 
5.1 Validation of antibodies specific to EBNA 3A, EBNA 3B and EBNA 3C and differential EBNA 
3 binding at ADAM and Bim 
We first set out to validate specific antibodies against EBNA 3A, EBNA 3B and EBNA 3C. 
Immunoprecipitations using ChIP conditions and buffers were carried out on non-crosslinked 
chromatin from the BL31 BAC cell series. We used antibodies against EBNA 3A (Exalpha, sheep 
polyclonal), EBNA 3B (Exalpha) sheep polyclonal and EBNA 3C (E3CD8 mouse monoclonal 
(Maunders et al. 1994)) and analysed precipitated proteins by western blotting. BL31 cells 
infected with BAC derived virus with a normal EBV genome is referred to as referred to as wild 
type (BL31 wtBAC) and expresses a full complement of latency III gene products. BL31 cells 
infected with a virus which lacks EBNA 3A, EBNA 3B or EBNA 3C are described as BL31 3AKO, 
BL31 3BKO and BL31 3CKO cell lines respectively. Cell lines also exist in which BL31 are infected 
with BAC derived virus that has EBNA 3C deleted and then restored and are described as BL31 
3CREV (revertant). 
A no antibody control was used in the immunoprecipitation as a negative control. Western 
blots from whole cell lysates revealed that EBNA 3A, EBNA 3B and EBNA 3C could not be 
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detected in the EBV negative BL31 line (Fig 5-1 A, D, G first lane). Analysis of whole cell lysates 
using antibodies against EBNA 3A, 3B and 3C confirm that EBNA 3A, EBNA 3B and EBNA 3C are 
knocked out in the appropriate cell lines but present in the BL31 wtBAC (Fig 5-1 A,D,G); 
furthermore EBNA 3B and 3C were present in BL31 3AKO (Fig 5-1 A), EBNA 3A and 3C were 
present in BL31 3BKO (Fig 5-1 D) and EBNA 3A and 3B were present in BL31 3CKO (Fig 5-1 G). 
Western blots probed with an anti-EBNA 3A antibody shows that EBNA 3A was observed in the 
BL31 wtBAC cell line but not in BL31 3AKO (Fig 5-1 B). Similar results were obtained from the 
same immunoprecipition samples probed with anti-EBNA 3B (Fig 5-1 E) or anti-EBNA 3C (Fig 5-
1 H) antibodies. If the EBNA 3A antibody used in the immunoprecipitation had cross reacted 
with either EBNA 3B or EBNA 3C then a band would be detected in these blots. This confirms 
that the EBNA 3A polyclonal antibody does not cross react with either EBNA 3B or EBNA 3C. 
Analysis using anti EBNA 3B and 3C antibodies shows that both the EBNA 3B polyclonal and 
EBNA 3C E3CD8 monoclonal antibodies are also specific to EBNA 3B and EBNA 3C respectively 
in immunoprecipitation experiments (Fig 5-1 E, F, H, I). These data demonstrates that all three 
antibodies do not cross react with other members of the EBNA 3 family and should specifically 
precipitate DNA bound by each EBNA 3. 
We sought to validate EBNA 3A, EBNA 3B or EBNA 3C specific DNA precipitation and elucidate 
potential differential binding of EBNA 3 proteins by examining a known EBNA 3 target sites 
from our ChIP sequencing data. For this we analysed the ADAM locus. It has been reported 
that regulation of genes by EBNA 3 proteins is cell type specific. For example in gene 
expression microarrays in EBNA 3B knock out LCL and BL31 cell lines different sets of genes 
have been reported to be regulated compared to wild type cell lines (White et al. 2010). This 
prompted us to conduct ChIP experiments in the BL line Mutu III and in PER253 LCLs, both of 
which express a full panel of latency III gene products. PER253 LCLs are derived from a healthy 
donor (code PER253) which were ex vivo infected with EBV resulting in LCL outgrowth and 
immortalisation. ChIP using the specific EBNA 3A, EBNA 3B and EBNA 3C antibodies was 
conducted and analysed using QPCR primer sets at the peak of binding and flanking regions as 
described previously. We also analysed ChIP DNA using primer sets for PPIA as a negative 
control and at CTBP2 as a positive control. We had subsequently validated that the CTBP2 
intragenic binding site was bound by all three EBNA 3 proteins and served as a good positive 
control for EBNA 3A, EBNA3B and EBNA 3C binding. ChIP QPCR data at the ADAM intragenic 
peak revealed that EBNA 3A (Fig 5-2 A) and EBNA 3C (Fig 5-2 C) were capable of significantly 
binding to this site in Mutu III cells but that EBNA 3B was not (Fig 5-2 B). 
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Figure 5-1 Validation of antibodies specificity for anti-EBNA 3A, anti-EBNA 3B and anti-EBNA 
3C. Western blot analysis of whole cell lysates from BL31, BL31 wtBAC, BL31 3AKO, BL31 3B KO 
and BL31 3CKO probed with anti 3A (A), 3B (D) and 3C (G) antibodies. Immunoprecipitations 
conducted under ChIP conditions using anti EBNA 3A (exalpha, sheep polyclonal), anti EBNA 3B 
(exalpha, sheep polyclonal), anti EBNA 3C (E3CD8, mouse monoclonal and no antibody 
negative control were subjected to western blot analysis. These were then probed for EBNA 3A 
(B,C), EBNA 3B (E,F) and EBNA 3C (H, I). Asterisks denote blots where signal obtained is similar 
to background binding found in the corresponding knock out cell line. 
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Fig 5-2 EBNA 3A and 3C bind to an intragenic peak at the ADAM locus in Mutu III cells and 
PER253 LCL. ChIP experiments conducted in Mutu III cells and PER153 LCLs. Primer sets for the 
peak of binding (mid) and adjacent regions (5’,3’) have been previously described. Control primers 
spanned the TSS of PPIA. Signal at the CTBP2 peak is displayed as a positive control. ChIP data is 
displayed as percentage input signals, after subtraction of signals of controls with no antibody. 
Results are shown as ± standard deviations of two independent experiments. ChIP-QPCR data for 
EBNA 3A (A), EBNA 3B (B) and EBNA 3C (C) in Mutu III cell lines. ChIP-QPCR data for EBNA 3A (D), 
EBNA 3B (E) and EBNA 3C (F) in PER253 LCL. 
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Association with EBNA 3A (Fig 5-2 D) and EBNA 3C (Fig 5-2 F) was also detectable in the LCL cell 
line whilst EBNA 3B signal was below that of the negative control PPIA (Fig 5-2 E). It is not 
possible to examine the percentage of input DNA precipitated between different antibodies as 
they will have different affinities for their antigen. Interestingly we noted that ADAM28 and 
ADAMDEC1 have both been reported to be repressed by EBNA 3A and EBNA 3C but not by 
EBNA 3B (Table 4-3). 
We also wished to analyse differential binding of EBNA 3 proteins at Bim, one of the best 
characterised EBNA 3A and EBNA 3C targets for transcriptional regulation. Both EBNA 3A and 
EBNA 3C have been shown to promote epigenetic silencing of Bim via unknown mechanisms. 
We analysed ChIP DNA precipitated by EBNA 3A, EBNA 3B and EBNA 3C by QPCR at primer sets 
in a small promoter proximal EBNA 3 peak at Bim (also known as BCL2L11). We also used 
primer sets either side of the peak as indicated and included positive and negative controls for 
EBNA 3 binding. This revealed that EBNA 3A and EBNA 3C also significantly associated with this 
binding site in both a Mutu III (Fig 5-3 B, D) and LCL (Fig 5-3 E, G) background. EBNA 3B was 
found to not bind to this site (Fig 5-3 C, F). To date there is no evidence of regulation of Bim by 
EBNA 3B suggesting that differential binding of EBNA 3 proteins to target genes is important to 
their function in co-regulating those genes.  
5.2 Identifying key target genes for analysis 
As previously discussed in Chapter 3, 25% of binding sites identified in our ChIP sequencing 
study were bound by both EBNA 2 and EBNA 3 proteins. We wished to investigate how the 
interplay between EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C at a specific gene modulated 
transcription. To select targets for further analysis we analysed the 300 most significant peaks 
of binding in the EBNA 3 data set. The UCSC genome browser was used to investigate each 
peak and record the nearest gene irrespective of distance or direction of the TSS, providing a 
list of 300 most significantly bound genes. We also recorded all other peaks which were most 
proximal to the 300 genes including the height of the largest peak for EBNA 2 and if EBNA 2 
and EBNA 3 peaks were found promoter proximally or at a distal site. To make the list more 
manageable we arbitrarily removed all genes that were not bound by an EBNA 3 peak with a 
height less than 10 leaving 63 genes (Table 5-1 and Table 5-2). This also removed the less 
significantly bound genes from further analysis.  
DAVID analysis revealed that the most enriched gene ontology (GO) terms in this list were 
regulation of transcription, phosphorylation and leukocyte activation (Table 5-3). The GO  
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Fig 5-3 EBNA 3A and EBNA 3C bind to a promoter proximal site at Bim in Mutu III and  PER253 LCL. ChIP 
experiments conducted in Mutu III cells and PER153 LCLs. (A) EBNA 3 binding at the Bim locus. Top panel; 
scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as reads per million background 
subtracted total reads and aligned with the human genome, H3K27ac panel; H3K27ac ChIP sequencing 
data from GM12878 cells in the ENCODE project, bottom panel; annotation of gene and direction of 
transcription. Location of primer sets for the peak of binding (2) and adjacent regions (1,3) are annotated. 
Control primers spanned the TSS of PPIA. Signal at the CTBP2 peak is displayed as a positive control. ChIP 
data is displayed as percentage input signals, after subtraction of signals of controls with no antibody. 
Results are shown as ± standard deviations of two independent experiments. ChIP-QPCR data for EBNA 3A 
(B), EBNA 3B (C) and EBNA 3C (D) in Mutu III cell lines. ChIP-QPCR data for EBNA 3A (E), EBNA 3B (F) and 
EBNA 3C (G) in PER253 LCL. 
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Table 5-1 List of genes bound by an EBNA 3 peak with a height of 10 or over. MACS peak data for 
EBNA 3 was sorted by p-value in Microsoft EXCEL and the 300 most significantly bound genes were 
manually investigated on the UCSC genome browser. Peak height was rounded to the nearest 
integer. Peak height of the most significant distal (>2kb from TSS) peak as well as any proximal 
peaks for both EBNA 3 and EBNA 2 were recorded. The height of any promoter proximal peak at a 
gene is displayed for EBNA 3 and EBNA 2 in the leftmost two columns. The height of the most 
significantly bound EBNA 3 distal peak and the number of other EBNA 3 peaks at this gene are 
recorded in the middle two columns. The height of the most significantly bound EBNA 2 distal peak 
and the number of other EBNA 2 peaks at this gene are recorded in the rightmost two columns. 
Cells are conditionally formatted such that that darker the shade of red or green the greater the 
peak height or number of other peaks at this gene for EBNA 3 and EBNA 2 respectively. Table is  
sorted alphabetically and split into two due to the number of genes (see Table 5-2) 
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Table 5-2 List of genes bound by an EBNA 3 peak with a height of 10 or over. MACS peak data for 
EBNA 3 was sorted by p-value in Microsoft EXCEL and the 300 most significantly bound genes were 
manually investigated on the UCSC genome browser. Peak height was rounded to the nearest 
integer. Peak height of the most significant distal (>2kb from TSS) peak as well as any proximal 
peaks for both EBNA 3 and EBNA 2 were recorded. The height of any promoter proximal peak at a 
gene is displayed for EBNA 3 and EBNA 2 in the leftmost two columns. The height of the most 
significantly bound EBNA 3 distal peak and the number of other EBNA 3 peaks at this gene are 
recorded in the middle two columns. The height of the most significantly bound EBNA 2 distal peak 
and the number of other EBNA 2 peaks at this gene are recorded in the rightmost two columns. 
Cells are conditionally formatted such that that darker the shade of red or green the greater the 
peak height or number of other peaks at this gene for EBNA 3 and EBNA 2 respectively. Table is  
sorted alphabetically and split into two due to the number of genes (see Table 5-1) 
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category for phosphorylation included many genes involved in cell cycle processes and another 
less significantly enriched GO term for the list was cell proliferation which 16/63 genes were 
annotated for (p-value 9.3x10-7, benjamini 3.6x10-5). To select genes for further analysis we 
discounted genes that were not bound by both EBNA 3 and EBNA 2 peaks with a heights of 10 
or more. From this list we selected genes that were annotated in one of the GO categories of 
regulation of transcription, phosphorylation/cell proliferation and leukocyte activation. We 
then examined the distribution of peaks at these genes, whether a gene was bound by 
promoter proximal, distal or intragenic peaks. We then chose the only set of three genes that 
allowed us to investigate each GO term category and each peak distribution; CTBP2, WEE1 and 
ITGAL. 
5.3 Coincident binding of EBNA 2, 3A, 3B and 3C at an intragenic peak at the CTBP2 gene 
C-terminal binding proteins CTBP1 and CTBP2 (collectively known as CTBP) play an important 
role in gene repression and are implicated in tumourigenesis due to their ability to repress a 
number of tumour suppressor genes (Chinnadurai 2009). Interestingly EBNA 3A and EBNA 3C-
mediated epigenetic repression of p16INK4A has been shown to be mediated by CTBP binding 
(Skalska et al. 2010). The repression of p16INK4A was found to be the main barrier to EBV 
induced proliferation as LCLs lacking p16INK4A could still proliferate with a conditional EBNA 3C 
switched off (Skalska et al. 2013).  EBV mediated regulation of CTBP2 transcription however 
has not been previously reported. ChIP sequencing identified a single, large intragenic peak of 
EBNA 2 and EBNA 3 binding between the second and third exons of the longer isoforms of 
CTBP2 (Fig 5-4 A). To validate EBNA 2 binding to this site and determine which of the EBNA 3 
proteins were bound, ChIP experiments were carried out using specific antibodies for EBNA 2, 
3A, 3B and 3C in the BL cell line Mutu III and the EBV immortalised LCL PER253. We used the 
promoter of the housekeeping gene peptidylprolyl isomerase A (PPIA) as a control site where 
no EBNA proteins were bound. Primers were designed to amplify DNA at the peak of binding of 
both EBNA 2 and EBNA 3 (primer set 2) and flanking primers (1 and 3) were designed ~1kb 
away from this the region of most significant binding. 
QPCR data obtained using these primers showed that all three EBNA 3 proteins associated with 
this site in Mutu III (Fig 5-4 C,D,E) and PER253 LCL (Fig 5-5 C,D,E). Binding of EBNA 2 to this site 
was validated in the Mutu III cell line (Fig 5-4 B) and we also detected binding in PER253 LCL 
(Fig 5-5 B). Binding signals were significantly above both the local control (flanking primers)  
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Figure 5-4 EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C all bind to an intragenic peak at CTBP2 in Mutu 
III cells. ChIP experiments conducted in Mutu III cells.(A) EBNA 2 (green) and EBNA 3 (red) binding at 
the CTBP2 locus. Top panel; scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as 
reads per million background subtracted total reads and aligned with the human genome, H3K27ac 
panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE project, bottom panel; 
annotation of gene and direction of transcription. Location of primer sets for the peak of binding (2) 
and adjacent regions (1,3) are annotated. Control primers spanned the TSS of PPIA. ChIP data is 
displayed as percentage input signals, after subtraction of signals of controls with no antibody. 
Results are shown as ± standard deviations of two independent experiments. ChIP-QPCR data for 
EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C (E). 
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Figure 5-5 EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C all bind to an intragenic peak at CTBP2 in 
PER253 LCL. ChIP experiments conducted in PER253 LCL.(A) EBNA 2 (green) and EBNA 3 (red) binding 
at the CTBP2 locus. Top panel; scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed 
as reads per million background subtracted total reads and aligned with the human genome, 
H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE project, bottom 
panel; annotation of gene and direction of transcription. Location of primer sets for the peak of 
binding (2) and adjacent regions (1,3) are annotated. Control primers spanned the TSS of PPIA. ChIP 
data is displayed as percentage input signals, after subtraction of signals of controls with no 
antibody. Results are shown as ± standard deviations of two independent experiments. ChIP-QPCR 
data for EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C (E). 
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and at PPIA in all QPCR experiments. Since CTBP2 has not previously been shown to be 
regulated by EBNA 2 or EBNA 3s we next investigated if binding correlated with changes in 
gene expression. Initial analysis was performed to determine which isoform is transcribed in B 
cells. In order to find a cell line in which CTBP2 was expressed we used (http://www.epstein-
barrvirus.org.uk/), a resource compiled by Dr Rob White (Imperial college) that stores gene 
expression microarray data for EBV proteins. Interestingly, we found evidence of regulation of 
CTBP2 by EBNA 3A. A previous analysis of EBNA 3A regulated genes using wild type and EBNA 
3AKO LCLs did not originally identify CTBP2 as a regulated gene (Hertle et al. 2009). The 
original study obtained data from a full EBNA 3A mutant (EBV-E3AmtB) and a truncated 
mutant (EBV-E3AmtA), which were combined for the final analysis. These two data sets were 
subsequently analysed separately by Dr Rob White which revealed that CTBP2 is de-repressed 
in the full EBNA 3A deletion mutant but not the truncated mutant (Fig 5-6 A). Cell lines used in 
this gene expression microarray were used to confirm repression of CTBP2 by EBNA 3A and to 
determine isoform usage. There are six proposed isoforms of CTBP2 as shown in Figure 5-4 A, 
from the top of the graphic to the bottom we termed these short (S) 1, S2 and long (L) 1, L2, L3 
and L4. Primers were designed to distinguish between each of these mRNA variants. These 
data indicate that the L2 isoform is the primary transcript in these LCLs (D3wt1) and confirmed 
that EBNA 3A was able to repress CTBP2 as LCLs generated using EBNA 3A deleted virus do not 
repress CTBP2 (D3mtB1) (Fig 5-6 B). 
We then confirmed de-repression of CTBP2 in other LCLs generated from EBNA 3A knock out 
virus infection of cells from two donors by examining transcript levels (Fig 5-7 A). A reduction 
of CTBP2 mRNA in the latency III Mutu III compared to the latency I Mutu I was also observed 
suggesting the combined effect of latency III proteins represses CTBP2 (Fig 5-7 A). To 
investigate the effects of EBNA 3B on CTBP2 transcription we used LCLs generated by infection 
of B cells from two different donors (PER142 and PER253) with wild type or EBNA 3B knock out 
virus (kindly provided by Dr Heather Long). In these cell lines we found that CTBP2 transcript 
levels were increased in 3BKO lines relative to wild type infected cells, indicating gene 
repression and providing the first evidence of transcriptional regulation of CTBP2 by EBNA 3B 
(Fig 5-7 B). CTBP2 was not expressed in uninfected BL31 cells so we could not examine the 
BL31 infected with BAC derived EBNA 3C knock out virus. CTBP2 is expressed in EREB 2.5 
estrogen-tagged EBNA 2 system but we could not detect any regulation by EBNA 2 with or 
without β-estradiol (Fig 5-7 C). However subsequent ChIP-QPCR analysis revealed that EBNA 2 
does not bind to the CTBP2 intragenic peak in these cells. Together these data reveal that the  
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Figure 5-6 CTBP2 isoform validation. (A) gene expression microarray data displayed as a dot plot 
from http://www.epstein-barrvirus.org.uk compiled by Dr Rob White. Plot shows raw expression 
data of CTBP2 from donor B cells (triangles, squares, diamonds) infected with wild type (wt, 
orange), EBNA 3A knock out virus (3AmtB, blue) and EBNA 3A truncation mutant (3AmtA, cyan). Y 
axis is log2 values with values less than 3 indicating no expression and values over 8 indicates 
robust expression. (B) Analysis of CTBP2 cDNA by PCR using primers specific to each of the CTBP2 
isoforms (S1, S2, L1, L2, L3, L4, L5, L6) in D3mtB1 and D3wt1 cell lines in which CTBP2 is expressed 
and repressed respectively.    
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Figure 5-7 CTBP2 is regulated by EBNA 3A and EBNA 3B in LCL backgrounds. (A) QPCR analysis of 
CTBP2 transcript levels using wild type (wt1, wt2, wt3) and EBNA 3A KO (mtB1, mtB2, mtB3) virus 
immortalised LCLs from two different donor (D2, D3) backgrounds. Data is normalised to GAPDH 
transcript levels and expressed as relative to D2wt1. (B) QPCR analysis of CTBP2 transcript levels in 
cDNA extracted from wild type LCLs immortalised by infection with B95.8 virus and EBNA 3B KO 
virus immortalised LCLs from two donors (PER142 and PER253). Data was normalised to GAPDH 
transcript levels and shown as relative to wild type levels of CTBP2 from each donor. (C) QPCR 
analysis of CTBP2 transcript levels using cDNA from EREB 2.5 which expresses a conditionally active 
EBNA 2 estrogen fusion mutant. Cells express EBNA 2 that is only transcriptionally active and 
nuclear localised in the presence of β-estradiol. Cells were stimulated with β-estradiol or DMSO (as 
a negative control) for 6 or 17 hours having been incubated in β-estradiol free media for 4 days. 
Transcript levels were normalised to GAPDH levels and expressed as relative to DMSO stimulated 
negative control. All cDNA data show the mean of two independent QPCR reaction each performed 
in duplicate. Error bars represent the range between two experiments. 
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intragenic peak at CTBP2 is bound by EBNA 2, EBNA 3A, EBNA 3B and EBNA 3C and at least 
EBNA 3A and EBNA 3B are capable of repressing CTBP2 transcription. 
5.4 Regulation of WEE1 by downstream distal EBNA 2 and EBNA 3C coincident binding sites 
One of the enriched GO terms of genes closest to the most significant EBNA 3 binding sites was 
phosphorylation. This included many genes involved in cell proliferation due the abundance of 
kinases and related proteins involved in this process. Cell proliferation itself was also enriched 
but not as significantly. One gene in both these categories was the G2 checkpoint kinase WEE1. 
WEE1 was first characterised in Schizosacchoromyces pombe (wee1) as a cell division cycle 
mutant (Russell and Nurse 1987). WEE1 is active in the G2/S phase and can  negatively 
regulate CDK1 by phosphorylation on Y15 to prevent entry into mitosis until DNA replication is 
complete (Featherstone and Russell 1991; McGowan and Russell 1995; Watanabe et al. 
1995)(reviewed in (Kellogg 2003)). EBV has previously been reported to deregulate the cell 
cycle at multiple points including the G2/M phase, including misregulation of CDK1 activity 
(Krauer et al. 2004b; Schlick et al. 2011). WEE1 therefore makes an attractive target for novel 
cell cycle regulation by EBNA 2 and 3 proteins. 
ChIP sequencing data reveal that WEE1 is the closest gene to two downstream, distal sets of 
EBNA 2 and EBNA 3 binding sites comprising a total of five distinct peaks (A,B,C,D,E) (Fig 5-8 A). 
These binding sites coincide with peaks of H3K27ac from ChIP sequencing data from the EBV 
immortalised LCL GM12878. Primers were designed to amplify each binding site (primer sets 
2,4,6,8,10) and intervening regions (primer sets 1,3,5,7,9). ChIP-QPCR using antibodies specific 
to EBNA 2, 3A, 3B and 3C revealed that, unlike CTBP2, differential binding of EBNA 3 proteins 
occurs at this locus. As CTBP2 was significantly bound by every EBNA examined we used this as 
a positive control. First, EBNA 2 binding to each of the five peaks was validated in Mutu III (Fig 
5-8 B). However, using antibodies against EBNA 3A we were unable to detect significant 
binding at EBNA 3 sites in Mutu III (Fig 5-8 C). Low-level of EBNA 3B binding to peaks A and B 
was detected but was negligible compared to the signal obtained at CTBP2 (Fig 5-8 D). In 
contrast significant EBNA 3C binding was detected at peak 5 (Fig 5-8 E). Similar result were 
observed in the PER253 LCL, EBNA 3B was shown not to bind to WEE1 (Fig 5-9 D) and EBNA 3A 
showed only low level association with at peak E (Fig 5-9 C). Like Mutu III data, EBNA 2 was 
shown to bind to every binding site annotated from ChIP-sequencing data (Fig 5-9 B) and EBNA 
3C bound primarily to peaks D and E at levels comparable to CTBP2. These data suggest that 
EBNA 3 binding is locus specific as EBNA 3A and EBNA 3B do not associate with WEE1 binding 
sites in multiple cell types. 
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Figure 5-8 EBNA 2 and EBNA 3C bind to distal sites at WEE1 in Mutu III. ChIP experiments 
conducted in Mutu III cell lines.(A) EBNA 2 (green) and EBNA 3 (red) binding at the WEE1 locus. Top 
panel; scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as reads per million 
background subtracted total reads and aligned with the human genome, H3K27ac panel; H3K27ac 
ChIP sequencing data from GM12878 cells in the ENCODE project, bottom panel; annotation of gene 
and direction of transcription. Each peak is annotated (A,B,C,D,E). Location of primer sets for the 
peaks of binding (2,4,6,8,10) and intervening regions (1,3,5,7,9) are annotated. Control primers 
spanned the TSS of PPIA. Signal at CTBP2 peak is shown as a positive control. ChIP data is displayed 
as percentage input signals, after subtraction of signals of controls with no antibody. Corresponding 
peaks are displayed below primer sets in red). Results are shown as ± standard deviations of two 
independent experiments. ChIP-QPCR data for EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C 
(E). 
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Figure 5-9 EBNA 2 and EBNA  3C bind to distal sites at WEE1 in PER253 LCL. ChIP experiments 
conducted in PER253 LCL.(A) EBNA 2 (green) and EBNA 3 (red) binding at the WEE1 locus. Top panel; 
scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as reads per million background 
subtracted total reads and aligned with the human genome, H3K27ac panel; H3K27ac ChIP 
sequencing data from GM12878 cells in the ENCODE project, bottom panel; annotation of gene and 
direction of transcription. Each peak is annotated (A,B,C,D,E). Location of primer sets for the peaks of 
binding (2,4,6,8,10) and intervening regions (1,3,5,7,9) are annotated. Control primers spanned the 
TSS of PPIA. Signal at CTBP2 peak is shown as a positive control. ChIP data is displayed as percentage 
input signals, after subtraction of signals of controls with no antibody. Corresponding peaks are 
displayed below primer sets in red). Results are shown as ± standard deviations of two independent 
experiments. ChIP-QPCR data for EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C (E). 
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To determine if EBNA 3C binding at this locus had an effect on gene transcription we analysed 
cDNA from a cell panel of BL31, BL31 wtBAC, BL31 3CKO and BL31 3CREV. These have been 
previously described in 5.1. In the EBV negative BL31 cell line WEE1 transcript could be 
detected and infection with wild type virus results in repression of WEE1 (Fig 5-10 A). WEE1 
was derepressed in the 3CKO cell lines with levels of WEE1 returning to that of BL31 consistent 
with 3C-mediated repression (Fig 5-10 A). Reinstating EBNA 3C in 3CREV cell lines results in the 
restoration of EBNA 3C mediated repression (Fig 5-10 A). These data suggest that EBNA 3C is 
responsible for the repression of WEE1 in a background where all latent genes are expressed. 
To analyse the effects of EBNA 2 on WEE1 mRNA expression we quantified WEE1 cDNA levels 
in the EREB 2.5 cell line expressing a conditionally active EBNA 2 estrogen fusion protein. 
Exposure to β-estradiol and consequent EBNA 2 activation for 6 and 17 hours resulted in 
increased levels of WEE1 mRNA (Fig 5-10 B). We also examined WEE1 mRNA levels in BL31, 
BL31 wtBAC and BL31 infected with BAC derived virus lacking EBNA 2 (BL31 E2KO) cell lines. As 
in the BL31 3C KO and revertant cell panel, the net effect of latency III gene products was 
repression of WEE1, however, cells infected with a virus lacking EBNA 2 showed further 
repression of WEE1 indicating that EBNA 2 acts as an activator of WEE1 gene expression (Fig 5-
10 C).  
Whilst these data do not prove that the binding sites downstream of WEE1 are directly 
regulating this gene, it demonstrates that EBNA 2 and EBNA 3C are capable of binding this 
locus and that this correlates with gene repression via EBNA 3C and increased expression in 
the presence of EBNA 2. Importantly we could not detect any regulatory effect of EBNA 3A or 
EBNA 3B, consistent with binding data at this locus. It is noteworthy that the effect of EBNA 3C 
on WEE1 expression appears to be dominant over the effects of EBNA 2 although a conditional 
dual knock out cell line would be necessary to confirm this. This expression data supports locus 
specific binding being functionally relevant to EBNA 2 and 3 mediated transcriptional 
regulation. 
5.5 ITGAL is differentially bound by EBNA 2 and 3 family proteins and binding is cell type 
specific 
Integrin alpha L (ITGAL or CD11a) forms the LFA-1 heterodimer (αLβ2) with integrin beta 2 
(ITGB2 or CD18). LFA-1 is widely expressed on the surface of myeloid and erythroid cells,  
including T and B lymphocytes. The inhibition of LFA-1 in T and B lymphocytes with a 
monoclonal antibody has been shown to block antigen-induced proliferation, T-cell mediated 
cytotoxicity, B cell aggregation and immunoglobulin production (reviewed in  
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Figure 5-10 WEE1 is regulated by EBNA 2 and EBNA 3C in a BL background and EBNA 2 in an LCL 
background. (A) QPCR analysis of WEE1 transcript levels in EBV negative BL31 and BL31 cells 
infected with either BAC derived wild type EBV (WtBac2 and WtBac3), EBNA 3C KO EBV (3CKO3 and 
3CKO6) or EBNA 3C revertant EBV (3Crev2 and 3Crev4). Data was normalised to GAPDH transcript 
levels and displayed as relative to BL31 WEE1/GAPDH mRNA. * indicates a p-value of less than 0.01 
by students t-test compared to the WtBac2 cell line. (B) QPCR analysis of WEE1 transcript levels 
using cDNA from EREB 2.5 LCLs expressing an EBNA 2 estrogen fusion mutant. Cells express EBNA 2 
that is only transcriptionally active and nuclear localised in the presence of β-estradiol. Cells were 
stimulated with β-estradiol or DMSO (as a negative control) for 6 or 17 hours having been incubated 
in β-estradiol free media for 4 days. Transcript levels were normalised to GAPDH levels and 
expressed as relative to DMSO stimulated negative control. (C) QPCR analysis of cDNA levels in EBV 
negative BL31, BL31 infected with wild type BAC derived virus and BL31 cells infected with a BAC 
derived virus lacking EBNA 2. All cDNA data show the mean of two independent QPCR reaction each 
performed in duplicate. Transcript levels were normalised to GAPDH levels and expressed as relative 
to BL31. Error bars represent the range between two experiments. 
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(Mazzone and Ricevuti 1995). LFA-1 was first described as a receptor that aided adhesion of 
cytotoxic T cells to their targets (Harlan 1985) but can also strengthen the adhesion of T 
lymphocytes to dendritic cells (Springer 1990). Rapid and transient stimulation by cytokines 
presented on the cell surface can activate LFA-1 and promote firm adhesion to ICAM-1 which 
can subsequently cause transmigration through epithelial cells (reviewed in (Denucci et al. 
2009). Importantly LFA-1 has also been shown to prevent B-cell apoptosis in the GC though 
adhesion to antigen presenting follicular dendritic cells (Lindhout et al. 1993).  
ChIP sequencing data revealed that ITGAL is bound by three distinct, coincident promoter 
proximal peaks (A, B and C) (Fig 5-11 A). This binding site was also coincident with H3K27ac 
ChIP sequencing data from GM12878 LCLs. Using primers designed to amplify each peak (2,4,6) 
and intervening regions (1,3,5) we conducted ChIP-QPCR at this locus using antibodies specific 
to EBNA 2, 3A, 3B and 3C in the BL cell line Mutu III and the PER253 LCL. These data were 
plotted alongside CTBP2 and PPIA as positive and negative controls respectively. We found 
that EBNA 2 bound primarily to peak C (primer set 6) in Mutu III, confirming ChIP sequencing 
data (Fig 5-11 B). Using antibodies against EBNA 3A revealed that the ITGAL promoter is not 
significantly bound by this factor as signals were comparable to that of the negative control 
(Fig 5-11 C). EBNA 3B and EBNA 3C on the other hand bound primarily to peak C and the signal 
obtained for EBNA 3B was 2 fold more than that of the positive control CTBP2 (Fig 5-11 D, E). 
In the PER253 LCL we found that EBNA 2 and EBNA 3B also associated with peak C (Fig 5-12 B, 
D) and, similarly to the Mutu III cell line, EBNA 3A did not bind at any of the investigated sites 
(Fig 5-12 C). Intriguingly, unlike Mutu III, EBNA 3C did not bind above background levels 
observed at PPIA in PER253 LCL at this locus (Fig 5-12 E). These data suggest that EBNA 3 
binding to particular cellular sites is cell type specific. 
ITGAL has previously been reported to be regulated by EBNA 3B and EBNA 3C in data from 
gene expression microarray experiments in the BL31 BAC system. ITGAL is expressed in BL31 
cells and is repressed upon infection by BAC derived wild type virus (Fig 5-13 A). Cells infected 
with virus lacking EBNA 3B or EBNA 3C show increased expression levels of ITGAL mRNA 
implicating them in transcriptional repression of ITGAL (Fig 5-13 A). This was not observed for 
BL31 cells infected with virus lacking EBNA 3A (Fig 5-13 A). Infection with virus lacking all three 
EBNA 3 proteins also results in ITGAL derepression but this does not pass significance 
thresholds set (Fig 5-13 A). We also examined ITGAL mRNA levels in LCLs generated from two 
donors (PER142 and PER253) infected with wild type or EBNA 3BKO virus, revealing that levels 
of ITGAL mRNA were increased in cells lacking EBNA 3B relative to wild type, implicating EBNA  
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Figure 5-11 EBNA 2, EBNA 3B and EBNA 3C bind to promoter proximal sites at ITGAL in Mutu III. 
ChIP experiments conducted in Mutu III cell lines. (A) EBNA 2 (green) and EBNA 3 (red) binding at the 
ITGAL locus. Top panel; scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as 
reads per million background subtracted total reads and aligned with the human genome, H3K27ac 
panel; H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE project, bottom panel; 
annotation of gene and direction of transcription. Each peak is annotated (A,B,C). Location of primer 
sets for the peaks of binding (2,4,6) and intervening regions (1,3,5) are annotated. Control primers 
spanned the TSS of PPIA. Signal at CTBP2 peak is shown as a positive control. ChIP data is displayed 
as percentage input signals, after subtraction of signals of controls with no antibody. Corresponding 
peaks are displayed below primer sets in red). Results are shown as ± standard deviations of two 
independent experiments. ChIP-QPCR data for EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C 
(E). 
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Figure 5-12 EBNA 2 and EBNA 3B bind to promoter proximal sites at ITGAL in PER253 LCL. ChIP 
experiments conducted in PER253 LCL. (A) EBNA 2 (green) and EBNA 3 (red) binding at the ITGAL 
locus. Top panel; scale, EBNA 2 and EBNA 3 panel; our ChIP sequencing data displayed as reads per 
million background subtracted total reads and aligned with the human genome, H3K27ac panel; 
H3K27ac ChIP sequencing data from GM12878 cells in the ENCODE project, bottom panel; 
annotation of gene and direction of transcription. Each peak is annotated (A,B,C). Location of primer 
sets for the peaks of binding (2,4,6) and intervening regions (1,3,5) are annotated. Control primers 
spanned the TSS of PPIA. Signal at CTBP2 peak is shown as a positive control. ChIP data is displayed 
as percentage input signals, after subtraction of signals of controls with no antibody. Corresponding 
peaks are displayed below primer sets in red). Results are shown as ± standard deviations of two 
independent experiments. ChIP-QPCR data for EBNA 2 (B), EBNA 3A (C), EBNA 3B (D) and EBNA 3C 
(E). 
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Figure 5-13 ITGAL is repressed by EBNA 3B and EBNA 3C in a BL background and repressed by 
EBNA 3B in a LCL background (A) gene expression microarray data displayed as a dot plot from 
http://www.epstein-barrvirus.org.uk compiled by Dr Rob White. Plot shows raw expression data of 
ITGAL from BL31 cells uninfected (green), infected with wild type BAC virus (wt-BAC, orange), EBNA 
3A knock out BAC virus (3AKO, blue), EBNA 3B knock out BAC virus (3BKO, pink), EBNA 3C knock out 
BAC virus (3CKO, grey), EBNA 3A/B/C knock out BAC virus (E3KO, red) or EBNA 3A and EBNA3C 
CTBP binding defective BAC virus (E3-CtBP, purple). Y axis is log2 values with values less than 3 
indicating no expression and values over 8 indicates robust expression. (B) QPCR analysis of  ITGAL 
transcript levels in cDNA extracted from wild type LCLs immortalised by infection with B95.8 virus 
and EBNA 3B knock out virus immortalised LCLs from two donors (PER142 and PER253). Data was 
normalised to GAPDH transcript levels and shown as relative to wild type levels of ITGAL from each 
donor. Data shows the mean of two independent QPCR reaction each performed in duplicate. Error 
bars indicates the range between two experiments. 
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3B in ITGAL transcriptional repression in LCLs.  Interestingly when we examined cDNA in other 
EBNA 3 positive and negative cell lines we could only detect regulation of ITGAL in LCLs by 
EBNA 3B (Fig 5-13 B). Together the ChIP and gene expression analysis reveal that in BL cell lines 
EBNA 3B and EBNA 3C both bind and repress this locus, whereas in the LCL studied only EBNA 
3B bound and repressed ITGAL. These data support the role of cell-type specific binding being 
functionally relevant to EBNA 2 and 3 mediated transcriptional regulation. 
5.6 EBNA 2 and 3 proteins compete for binding at coincident sites 
The data described here suggests that coincident binding of EBNA 2 and 3 proteins is 
functionally relevant to gene regulation. Furthermore, differential binding of EBNA 3 factors is 
predictive of regulation and is cell type and locus specific. A key remaining question to address 
is do the EBNA 2 and 3 proteins bind simultaneously to coincident sites and exert their 
influence on transcription as multi-EBNA complexes or do they bind separately. To address this 
question we used sequential ChIP experiments (reChIP) in a Mutu III cell line.  
Briefly, a ChIP experiment is performed but immunoprecipitated DNA-protein complexes are 
eluted from the primary antibody and then a second round of ChIP is performed with the same, 
or different antibodies. Using the same antibody acts as a positive control as complexes 
precipitates in the first ChIP will contain the protein for the second ChIP. For a negative control 
no antibody is added in the secondary ChIP. Using EBNA 2 as our antibody in the primary ChIP 
followed by the same antibody in the second round ChIP validated the reChIP experiment as 
DNA was enriched above the negative control of adding no antibody to the secondary ChIP (Fig 
5-14 A). Similar signals to the no antibody were obtained when using EBNA 3A, EBNA 3B or 
EBNA 3C specific antibodies in the secondary ChIP suggesting that EBNA 3 proteins do not co-
associate with EBNA 2 at the CTBP2 peak (Fig 5-14 A). To check that EBNA 3A, EBNA 3B and 
EBNA 3C antibodies were capable of precipitating DNA in the secondary ChIP, reChIP 
experiments were performed using EBNA 3A, EBNA 3B and EBNA 3C as the primary antibody. 
These data reveal that when the same EBNA  3 antibody is used in the primary and secondary 
ChIPs a signal over background is obtained showing that the EBNA 3A (Fig 5-14 B), EBNA 3B 
(Fig 5-14 C)and EBNA 3C (Fig 5-14 D) antibodies are able to precipitate DNA after two rounds 
of ChIP. We also used EBNA 2 specific antibodies in the secondary ChIP after a primary ChIP 
using and EBNA 3 antibody. For EBNA 3A, EBNA 3B and EBNA 3C primary ChIP EBNA 2 
secondary ChIP we detected signals comparable to that of the no antibody secondary ChIP 
control. This supports the finding from Figure 5-14 A that EBNA 3 and EBNA 2 proteins do not 
associate with the CTBP2 intragenic peak at the same time. 
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Figure 5-14 ReChIP analysis at the intragenic CTBP2 peak. ChIP experiments were performed with an 
antibody (primary), complexes were eluted and subjected to a second ChIP using a second antibody 
(secondary). DNA was analysed by QPCR using CTBP2 peak primers. (A) Re-ChIP analysis using anti 
EBNA 2 as a primary antibody and anti EBNA 2 (positive control)(2-2), EBNA 3A (2-3A), EBNA 3B (2-3B) 
and EBNA 3C 2-3C) as secondary antibodies. A no antibody secondary was also conducted (negative 
control)(2-NoAb). (B) Re-ChIP analysis using anti EBNA 3A as a primary antibody and anti EBNA 3A 
(positive control)(3A-3A) and EBNA 2 (3A-2) secondary antibodies. A no antibody secondary was also 
conducted (negative control)(3A-NoAb). (C) Re-ChIP analysis using anti EBNA 3B as a primary antibody 
and anti EBNA 3B (positive control)(3B-3B) and EBNA 2 (3B-2) secondary antibodies. A no antibody 
secondary was also conducted (negative control)(3B-NoAb). (D) Re-ChIP analysis using anti EBNA 3C as 
a primary antibody and anti EBNA 3C (positive control)(3C-3C) and EBNA 2 (3C-2) secondary 
antibodies. A no antibody secondary was also conducted (negative control)(3C-NoAb). Data is shown 
as a percentage of the primary ChIP input. Error bars represent ± standard deviations of two 
independent experiments. 
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We also analysed ReChIP DNA using primers specific for WEE1 peak E, a site bound only by 
EBNA 2 and EBNA 3C in Mutu III cell lines (see Fig 5-8). Using an EBNA 2 specific antibody in the 
primary ChIP we found that using an anti-EBNA 2 antibody in the secondary ChIP produced a 
signal above that of the negative control (Fig 5-15 A). We also found that anti-EBNA 3C 
antibody added to an EBNA 2 antibody primary ChIP and analysed by QPCR produced a signal 
comparible to the negative control, and EBNA 3A and EBNA 3B antibodies, which do not bind 
to this site (Fig 5-15 A). We then conducted QPCR on DNA precipitated from a ChIP using EBNA 
3C followed by a secondary ChIP using the same antibody and found that a signal above 
background was detectable, whereas using an EBNA 2 specific antibody produced a signal 
comparable to the negative control (Fig 5-15 B). QPCR analysis of reChIP DNA was performed 
using primers for ITGAL peak C. In Mutu III cells this site is bound by EBNA 2, EBNA 3B and 
EBNA 3C (see Fig 5-11). Data here shows that EBNA 3B and EBNA 3C antibodies do not enrich 
DNA at this site when added to a primary ChIP conducted with an anti-EBNA 2 antibody (Fig 5-
16 A) despite EBNA 3B (Fig 5-16 B) and EBNA 3C (Fig 5-16 C) antibodies being able to enrich 
DNA from this site after two rounds of ChIP. This data shows that EBNA 2 and EBNA 3 proteins 
do not associate with WEE1 peak E or ITGAL peak C at the same time.  
ReChIP experiments described here implicate competition between EBNA 2 and EBNA 3 factors 
for binding sites. At all the binding sites investigated EBNA 2 coincidentally bound with at least 
one EBNA 3 protein but in no QPCR experiments could we detect evidence that both were in a 
complex at the same site. ChIP data is a population average of millions of cells, therefore 
signals obtained by QPCR or sequencing showing coincident binding between EBNA 2 and 
EBNA 3 proteins likely represents the site being bound in subpopulations of cells by either 
EBNA 2, EBNA 3A, EBNA 3B or EBNA 3C. 
5.7 Discussion 
Prior to this investigation there were no known human DNA elements targeted by EBNA 2 and 
EBNA 3 proteins. Here we describe over 5300 coincident binding sites for EBNA 2 and 3 
proteins in the human genome which target over 3100 genes. We chose to investigate three 
genes targeted by coincident sites involved in important pathways for EBV pathogenicity and 
immortalisation. 
5.7.1 CTBP2 
We show here that the C-terminal binding protein CTBP2 is bound at an intragenic site by 
EBNA 2, 3A, 3B and 3C in the BL cell line MutuIII and the PER253 LCL (Fig 5-4 and Fig 5-5).  
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Figure 5-15 ReChIP analysis at the distal WEE1 peak E. ChIP experiments were performed with an 
antibody (primary), complexes were eluted and subjected to a second ChIP using a second antibody 
(seconday). DNA was analysed by QPCR using WEE1 peak E primers. (A) Re-ChIP analysis using anti 
EBNA 2 as a primary antibody and anti EBNA 2 (positive control)(2-2), EBNA 3A (2-3A), EBNA 3B (2-3B) 
and EBNA 3C 2-3C) as secondary antibodies. A no antibody secondary was also conducted (negative 
control)(2-NoAb). (B) Re-ChIP analysis using anti EBNA 3C as a primary antibody and anti EBNA 3C 
(positive control)(3C-3C) and EBNA 2 (3C-2) secondary antibodies. A no antibody secondary was also 
conducted (negative control)(3C-NoAb). Data is shown as a percentage of the primary ChIP input. Error 
bars represent ± standard deviations of two independent experiments. 
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Figure 5-16 ReChIP analysis at the promoter proximal ITGAL peak C. ChIP experiments were 
performed with an antibody (primary), complexes were eluted and subjected to a second ChIP using a 
second antibody (seconday). DNA was analysed by QPCR using ITGAL peak C primers. (A) Re-ChIP 
analysis using anti EBNA 2 as a primary antibody and anti EBNA 2 (positive control)(2-2), EBNA 3A (2-
3A), EBNA 3B (2-3B) and EBNA 3C 2-3C) as secondary antibodies. A no antibody secondary was also 
conducted (negative control)(2-NoAb). (B)Re-ChIP analysis using anti EBNA 3B as a primary antibody 
and anti EBNA 3B (positive control)(3B-3B) and EBNA 2 (3B-2) secondary antibodies. A no antibody 
secondary was also conducted (negative control)(3B-NoAb). (C) Re-ChIP analysis using anti EBNA 3C as 
a primary antibody and anti EBNA 3C (positive control)(3C-3C) and EBNA 2 (3C-2) secondary 
antibodies. A no antibody secondary was also conducted (negative control)(3C-NoAb). Data is shown 
as a percentage of the primary ChIP input. Error bars represent ± standard deviations of two 
independent experiments. 
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Furthermore this gene is regulated by EBNA 3A and 3B in LCLs (Fig 5-7). Currently CTBP2 has 
not been reported as regulated in any gene expression microarray investigating EBNA 2 or 3 
proteins. However re-analysis of data from LCLs generated from wild type virus or EBNA 3A 
deficient virus (Hertle et al. 2009) by Dr Rob White (Imperial College, London) revealed that in 
one EBNA 3A mutant virus studied regulation is detectable. CTBP2 was not included previously 
as a regulated gene lists because data from two different EBNA 3A mutant viruses was 
amalgamated. In one mutant virus EBNA 3A is deleted, and in the other mutant EBNA 3A is 
truncated and no protein is expressed (Hertle et al. 2009). CTBP2 mRNA levels are elevated in 
the full deletion mutant compared to wild type infected cells, but not in the truncation mutant 
(Fig 5-6 A). The mechanism of this remains unclear but it is possible that a low level and 
undetectable quantity of EBNA 3A protein is expressed in EBNA 3A truncation mutants and 
that this is capable of repressing CTBP2. 
In follow up experiments from this initial characterisation of binding sites, a colleague in our 
lab (Dr David Wood, university of Sussex) performed chromosome conformation capture (CCC) 
on this locus. CCC allows detection of a specific promoter-enhancer looping event. We know 
that many long range enhancer functions are mediated via this mechanism as discussed in the 
introduction. First, chromatin is cross linked with formaldehyde, creating a snapshot of the 
global 3D chromatin architecture by covalently binding proteins and DNA together. Then DNA 
is digested with a restriction enzyme chosen to isolate promoter and enhancer fragments of 
DNA. Complexes are then ligated and cross-links reversed. Proteins are digested with enzymes 
and DNA is purified. In this way a promoter enhancer DNA chimera will be created if the two 
sites were brought to close proximity via protein interactions. Primers can then be used that 
span restriction sites between the enhancer and promoter and the presence of enhancer 
promoter looping can be detected by QPCR.  
These experiments were carried out in a EBNA 3A KO LCL in which CTBP2 was expressed, and 
in a wild type infected LCL in which CTBP2 was repressed. In the wild type infected LCLs no 
promoter and intragenic enhancer looping was detected. However, in cells infected with a 
virus lacking EBNA 3A a loop between the enhancer and promoter was observed. This suggests 
that EBNA 3A is critical for the prevention of an activating loop from forming between the 
enhancer and promoter at CTBP2 (Fig 5-17). Unfortunately we could not investigate the effects 
of EBNA 3C on either regulation or looping at the CTBP2 locus as no such cell series we 
examined expressed CTBP2. We were able to detect both binding and repression of CTBP2 by 
EBNA 3B, however we do not know if repression is mediated by the prevention of activating  
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Figure 5-17 Model for regulation of CTBP2 via enhancer looping mediated by EBNA 2 and 3 
binding. (A) model for EBV modulation of CTBP2 promoter enhancer looping in wild type infected 
cells. (B) model for EBV modulation of CTBP2 promoter enhancer looping in infected cells lacking 
functional EBNA 2. (C) model for EBV modulation of CTBP2 promoter enhancer looping in infected 
cells lacking EBNA 3A. Intragenic enhancer is displayed as a red box. Promoter is displayed as an 
arrow with a cross through it if it is repressed. Unknown cellular binding partner of EBNA 2, 3A, 3B or 
3C is displayed as a grey oval. EBNA 2 is shown as a pink oval with 2 in and EBNA 3A, EBNA 3B and 
EBNA 3C as blue ovals with 3A, 3B or 3C in them respectively. Components of transcriptional 
machinery and looped DNA are annotated in situations where CTBP2 expression is de-repressed.   
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enhancer promoter looping. EBNA 3B is expressed in the EBNA 3A KO cell line in which the 
described CCC experiment was conducted in, therefore EBNA 3B does not prevent an 
activating loop by itself but may be required for EBNA 3A dependant repression of CTBP2. 
Another possibility is that activating loop formation may be partially inhibited by EBNA 3B in 
cells lacking EBNA 3A but as the assay performed was not quantitative we could observe no 
difference. We have been unable to address the role of EBNA 2 on the regulation of CTBP2 
because it is not expressed in cell series studied. However analysis of CTBP2 transcript levels in 
Mutu I compared to Mutu III reveals that the overall effect of latency III protein expression is 
repression of CTBP2 (Fig 5-7 A). This suggests that EBNA 3A (and potentially 3B and 3C) have a 
dominant role in the repression of this gene. 
C-terminal binding proteins were first characterised in 1993 as a binding partner of the C-
terminus of the adenovirus E1A protein (Boyd et al. 1993). E1A can activate and repress 
transcription and it appears that E1A mediated repression requires its association with cellular 
CTBP (Sollerbrant et al. 1996). The consensus binding motif for CTBP has been described and 
mutants in the E1A binding region for CTBP are defective for transformation and 
immortalisation (Schaeper et al. 1995). More recently the interaction of the C terminal region 
of E1A and CTBP has been shown to repress the transforming properties of E1A and play a role 
in enhancing viral replication during productive infection (Cohen et al. 2013; Subramanian et al. 
2013).  
The CTBP family consists of two highly related but unique proteins CTBP1 and CTBP2. CTBP1 
and CTBP2 share a 72% amino acid identity and are encoded by genes on chromosome 4 and 
21 respectively. This distinction was only revealed in 1998 (Katsanis and Fisher 1998) and to 
this day CTBP1 and 2 are often collectively termed as CTBP, making the differentiation of the  
function of these two proteins a more difficult task. It is noteworthy that CTBP1 has not been 
identified as a regulated target of EBNA 2 and 3 proteins, nor was it identified as a gene closest 
to a peak. However, a single significant coincident intragenic peak is found at this gene (Fig 5-
18). CTBP1 may not have been identified as a gene closest to a EBNA 2 or EBNA 3 binding site 
as each peak is assigned to a single gene, in this case this may have been determined to be 
HV535469 or HV535487. These are completely unannotated human cDNAs with no known 
function or known protein expression. It would be informative to investigate CTBP1 and this 
intragenic binding site.  
Both CTBP1 and 2 appear to bind to the same consensus motif described in the C terminus of 
E1A and recent work has shown that CTBP1 and CTBP2 perform redundant and unique  
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Figure 5-18 EBNA 2 and EBNA 3 proteins bind to an intragenic site at CTBP1 in Mutu III. EBNA 2 
(green) and EBNA 3 (red) binding at the CTBP1 locus. Top panel; scale, EBNA 2 and EBNA 3 panel; our 
ChIP sequencing data displayed as reads per million background subtracted total reads and aligned 
with the human genome, H3K27ac panel; H3K27ac ChIP sequencing data from GM12878 cells in the 
ENCODE project, bottom panel; annotation of genes and direction of transcription.  
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functions; for example, during productive adenovirus infection the E1A-CTBP2 complex 
restricts viral replication more than E1A-CTBP1 (Subramanian et al. 2013). Crucially whilst 
CTBP1 is both nuclear and cytosolic, CTBP2 appears to be nuclear only due to the presence of a 
nuclear localisation domain in its N terminus (Zhao et al. 2006c). Furthermore mice deficient in 
CTBP1 are viable whereas CTBP2 null mice are not (Hildebrand and Soriano 2002). Proteomics 
analysis in Hela cells of the binding partners of CTBP1 and CTBP2 revealed both common and 
unique binding partners of both proteins. Unique binding partners of CTBP2 include the 
transcription factor E2F7 and components of the NuRD complex which have been shown to 
play a critical role in cell cycle regulation and histone modifications (Zhao et al. 2014). 
Importantly, here we report that EBV preferentially targets CTBP2 for transcriptional 
repression. These findings are important to the study of EBV as transcriptional regulation by 
the key EBNAs has not distinguished between CTBP1 and CTBP2. For example, EBNA 3A and 3C 
have been shown to repress some of its targets, including p16INK4A, (Skalska et al. 2010) in a 
CTBP dependant manner, but it is unknown whether CTBP1 or CTBP2 or both are involved. As 
we show here that EBNA 3A is a potent repressor of CTBP2 transcription this may infer that 
EBV preferentially requires CTBP1 as a cellular binding partner. It is also possible that 
repression of CTBP2 by EBNA 3A is part of an auto-regulatory loop whereby EBNA 3A controls 
its own repressive activity by regulating CTBP2 transcription.  
The role of CTBP proteins in the cell appears to be very diverse. It has been proposed that 
CTBP proteins exert their transcriptional influence by acting as a scaffold to recruit chromatin 
modifying enzymes such as HDACs, polycomb group proteins and histone methylatransferases 
(Shi et al. 2003; Kuppuswamy et al. 2008). siRNA knock down of CTBP1 and CTBP2 results in a 
decrease in mitotic events, reduction of proliferation and increase in apoptosis in breast 
cancer cells caused by abnormalities in chromosome alignment (Bergman et al. 2009). 
Genome-wide analysis of CTBP binding sites in the human genome reveals that CTBP proteins 
primarily bind to distal elements (1823/6607 sites are promoter proximal) and that genes 
targeted are enriched for GO terms including: cellular response to DNA damage, cell cycle, cell 
proliferation, cell death, cell adhesion and chromatin modifications (Di et al. 2013). Notably, 
consensus binding motifs for cellular TFs centred under CTBP peaks show an enrichment for 
ETS (PU.1) transcription factors amongst others (Di et al. 2013). CTBP2 specifically has also 
been reported to influence cancer cell migration by induction of the T-cell lymphoma invasion 
and metastasis I (Tiam1) protein. Upregulation of Tiam1 was discovered through reporter 
assays in which KLF8 was shown to recruit CTBP2 to three elements up to 1.8kb from the 
Tiam1 promoter (Paliwal et al. 2012). This highlights the fact the CTBP2 can act as a co-
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repressor and activator of transcription. CTBP proteins are also bound by p14ARF which targets 
them for proteasomal degradation, modulating their repressive role in the cell death pathway. 
CTBP2 was shown to bind to the Bik promoter and repress its transcription. Transcriptional 
repression found to be alleviated in the presence of p14ARF (Kovi et al. 2010). Intriguingly 
depletion of CTBP2 has also been shown to decrease the level of MYC and some of its 
downstream targets identifying further unique activities of CTBP2 that may be relevant to EBV 
induced transformation (Zhang et al. 2014). 
Our analysis has therefore highlighted a potential role for the regulation of CTBP2 in EBV 
immortalised cells, and additional experiments are now required to investigate this further. It 
is important to determine if EBNA 3A and EBNA 3C bind to CTBP2 or CTBP1 and explore the 
effect of CTBP2 on growth. Importantly, like Bim, we have found that CTBP2 is not expressed in 
many of the cell lines available to us. The repression of Bim is well characterised and involves 
initial recruitment of PRC components and H3K27me3 by EBNA 3A and EBNA 3C. This is 
followed by PRC2 protein recruitment and CpG methylation and persistent repression. It will 
therefore be informative to investigate H3K27me3 and CpG methylation at CTBP2 upon 
expression of EBNA 3A and EBNA 3C. 
5.7.2 WEE1 
Whilst EBV nuclear antigens have not been previously shown to regulate WEE1, it is 
upregulated following initial infection. It has been  reported that 4-7 days post infection EBV 
infected cells undergo a period of hyperproliferation which is marked by a heightened DNA 
damage response (DDR) and cell proliferation gene expression in the host cell (Nikitin et al. 
2010). One of the upregulated cell proliferation genes at this time after infection is WEE1, the 
expression of which is then reduced during the process of outgrowth to an LCL. Furthermore 
the DDR kinases ATM and Chk2, which are induced in the hyperproliferation period have been 
shown to supress EBV-mediated transformation and initial B-cell proliferation (Nikitin et al. 
2010). EBNA 3C is required to attenuate the DDR during this period as cells infected with EBNA 
3CKO virus rapidly accumulated DDR genes and marks, crippling them for long term outgrowth. 
Analysis of raw data from gene expression microarray data from the BL31 BAC cell series 
(White et al. 2010) reveals that EBNA 3C may regulate WEE1 although this did not pass 
significance thresholds set in their analysis (Fig 5-19). The large spread of expression levels of 
WEE1 in wild type BAC and 3C revertant cell lines is likely responsible for this. This suggests 
that even in established EBV immortalised cells WEE1 is still partially repressed by EBNA 3C. 
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Figure 5-19 WEE1 is regulated by EBNA 3C in BL background. Gene expression microarray data 
displayed as a dot plot from http://www.epstein-barrvirus.org.uk compiled by Dr Rob White. 
Plot shows raw expression data of WEE1 from BL31 cells uninfected (green), infected with wild 
type BAC virus (wt-BAC, orange), EBNA 3A knock out BAC virus (3AKO, blue), EBNA 3B knock out 
BAC virus (3BKO, pink), EBNA 3C knock out BAC virus (3CKO, grey), EBNA 3A/B/C knock out BAC 
virus (E3KO, red) or EBNA 3A and EBNA3C CTBP binding defective BAC virus (E3-CtBP, purple). Y 
axis is log2 values with values less than 3 indicating no expression and values over 8 indicates 
robust expression. 
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We detected five distinct peaks of binding for EBNA 2 and 3 proteins by ChIP sequencing and 
showed that these sites were bound by EBNA 2 and EBNA 3C by ChIP QPCR. We further 
discovered that WEE1 is upregulated by EBNA 2 and downregulated by EBNA 3C. Subsequent 
chromosome confirmation capture experiments performed by Dr David Wood showed that 
this regulation is mediated through the modulation of enhancer-promoter looping (McClellan 
et al. 2013). In EBV negative BL31 cell lines where WEE1 is expressed (Fig 5-10 A), no looping 
between the promoter and enhancers was observed. Cells infected with wild type EBV BAC 
expressing all latent genes, enhancer-promoter looping was detectable from each enhancer to 
the promoter. In these cells expression of WEE1 is repressed (Fig 5-10 A). Infection with an EBV 
BAC with EBNA 3C deleted did not promote enhancer-promoter looping, in these cells WEE1 is 
expressed despite the presence of all other latent proteins (Fig 5-10 A). BL31 cells infected 
with a EBV BAC that has had EBNA 3C removed and subsequently restored also showed 
looping from both enhancers to the WEE1 promoter. These cells exhibit re-repression of WEE1 
(Fig 5-10 A). We therefore propose a model where in wild type infected cells EBNA 3C is able to 
bind predominantly to peak 5, promoting looping between both enhancers and the promoter 
and gene repression (Fig 5-20 A). Wild type cells lacking functional EBNA 2 showed increased 
repression indicating that EBNA 2 may be able to compete with EBNA 3C and partially inhibit 
the formation of a repressive loop (Fig 5-20 B). In cells with no functional EBNA 3C, WEE1 is 
derepressed and no looping between the promoter and enhancers is detected indicating that 
EBNA 3C is primarily responsible for loop formation (Fig 5-20 C).  
WEE1 was first discovered through characterisation of Saccharomyces cerevisiae mutants that 
produced cells half the length of a wild type and were partly impaired for cell viability and 
growth rate (Thuriaux et al. 1978). It was further found that of the mutants bearing the wee 
phenotype, 51 mapped to WEE1 and one mapped to cdc2 (CDK1) implicating interplay 
between these proteins. From this data WEE1 was proposed to be involved in the rate limiting 
control determining when mitosis occurs and to be a negative regulator of the cell cycle (Nurse 
and Thuriaux 1980). Elevated levels of WEE1 transcription during the hyperproliferative stage 
of infection may be a response to DNA damage induced by aberrant proliferation to delay 
entry into mitosis. EBNA 3C repression of WEE1 may be counteracting WEE1 induced cell cycle 
arrest following WEE1 activation by the DNA damage response. However, this does not explain 
the role of EBNA 2 transcriptional activation of WEE1. Furthermore, EBNA 2 protein is 
detectable 12 hours post infection and is at a level similar to that of LCLs by 32 hours (Alfieri et 
al. 1991). EBNA 3C is then transcribed after EBNA 2 mediated promoter switching from Wp to  
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Figure 5-20 Model for regulation of WEE1 via enhancer looping mediated by EBNA 2 and 3C 
binding. (A) model for EBV modulation of WEE1 promoter enhancer looping in wild type infected 
cells. (B) model for EBV modulation of WEE1 promoter enhancer looping in infected cells lacking 
functional EBNA 2. (C) model for EBV modulation of WEE1 promoter enhancer looping in infected 
cells lacking EBNA 3C. Distal enhancers are displayed as a red box. Promoter is displayed as an arrow 
with a cross through it if it is repressed. Unknown cellular binding partner of EBNA 2 or 3C is 
displayed as a grey oval. EBNA 2 is shown as a pink oval with 2 in and EBNA 3C as a blue oval with 3C 
in. Components of transcriptional machinery and looped DNA are annotated in situations where 
WEE1 expression is de-repressed. Unknown repressive complex proteins and promoter enhancer 
looping are displayed in situations where WEE1 transcription is repressed. 
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Cp at around 48 hours (Woisetschlaeger et al. 1991) so precedes the events described by 
Nikitin et al (Nikitin et al. 2010). Given this information WEE1 is likely to be regulated through a 
change in pattern of cellular transcription factor expression or chromatin landscape. It would 
be informative to examine epigenetic modifications at the WEE1 gene and enhancers during 
the time course of the initial stages of infection.  
Together this data and published work suggests that EBNA 3C directly represses WEE1 via a 
repressive promoter enhancer loop shortly after initial infection. A period of hyperproliferation 
after initial infection induces a DNA damage response and over expression of WEE1 which is 
subsequently attenuated by EBNA 3C. It may be that part of this attenuation is due to WEE1 
transcriptional repression by EBNA 3C. It is not clear exactly when during the period of 
hyperproliferation EBNA 3C binds to and represses WEE1 and should be investigated further. 
5.7.3 ITGAL 
ITGAL plays a vital role in directing T and B lymphocytes to sites of infection or damage and 
mediates pathways such as apoptosis through cell-cell contacts. Secreted chemokines can 
attract immune cells by increasing their adhesion to local endothelial cells via integrin 
signalling molecules including ITGAL and integrin β2 (collectively known as LFA-1) interaction 
with ICAM1 (reviewed in (Newton and Dixit 2012)). LFA-1 is essential to lymphocyte migration 
through endothelial cells and is involved in rolling, weak adhesion, firm adhesion and 
transmigration. Furthermore LFA-1 has been previously described to be upregulated by LMP1, 
mimicking B-cell activation (Wang et al. 1987; Wang et al. 1990a). 
At ITGAL we found three distinct promoter proximal binding sites for EBNA 2 and 3 proteins by 
ChIP seq data. EBNA 2 and EBNA 3B were confirmed to bind to peak C in both Mutu III and 
PER253 LCLs. Interestingly, EBNA 3C was found to only significantly bind in the BL cell line 
Mutu III and not in PER253 LCLs. The mechanism of this is unknown but it is possible that a 
particular TF required by EBNA 3C to bind this site is absent in the PER253 LCL, or that the 
binding of another factor specifically occludes EBNA 3C binding in this cell line. These data  
were confirmed by analysis of cDNA data in which we could only detect regulation of ITGAL by 
EBNA 3B in LCLs whereas both EBNA 3B and EBNA 3C were shown to regulate it in a BL line (Fig 
5-13). This is consistent with a model where gene regulation is determined by specific binding 
of EBNA 2 and EBNA 3 proteins. 
Unlike CTBP2 and WEE1, ITGAL was only bound by promoter proximal sites so there was no 
need to perform CCC experiments. However, subsequent luciferase reporter assays performed 
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in our lab by Opeoluwa Ojeniyi, in which the ITGAL promoter and binding sites were cloned 
upstream of the luciferase gene, revealed EBNA 2 mediated activation of ITGAL (McClellan et 
al. 2013). EBNA 2 dependent activation was inhibited in the presence of any of the EBNA 3 
family of proteins. In contrast, ChIP assays performed in chromatin context revealed only EBNA 
3B and EBNA 3C were able to bind and repress this locus. Luciferase assays were conducted 
out of chromatin context, and this data may suggest that EBNA 3A binding and repression of 
ITGAL may require certain histone modifications. Similarly to CTBP2 and WEE1, the repressive 
effect of EBNA 3 proteins appears to be dominant at ITGAL shared EBNA 2 and EBNA 3 binding 
sites.  
Given the prominent role of LFA-1 in leukocyte migration, EBNA 2 and EBNA 3 regulation of 
ITGAL could facilitate infected B-cell entry into the GC. LMP1 and EBNA 2 mediated activation 
of ITGAL transcription could be responsible for producing an activated B-cell phenotype which 
begins the process of differentiation and migration to the GC. As EBNA 2 expression precedes 
that of EBNA 3 proteins in vivo (Woisetschlaeger et al. 1991), it is possible that repression of 
ITGAL is required at a later time point, perhaps evading the immune response by inhibiting 
interactions with CD8+ and CD4+ T cells. EBNA 3B and EBNA 3C mediated repression may also 
involve recruitment of PcG proteins and persistent repression of ITGAL. This may then aid 
survival in the GC after EBV loses latency III gene expression.  
Here we provide important mechanistic information into how EBV deregulates the host 
transcriptome. We show that EBNA 2 and EBNA 3 proteins bind to enhancer elements and 
others in the lab have shown that this can direct regulation of target genes by stimulating 
enhancer-promoter looping. We also demonstrate that binding of EBNA 2 and 3 proteins is cell 
type specific, suggesting that the balance of cellular TFs and cofactors within a cell modulates 
which sites are targeted. Binding is also context specific, and EBNA 3 proteins do not all bind to 
the same sites within a cell, which indicates that each EBNA 3 has either differential binding 
partners, or can respond to different histone modifications at a site. ReChIP experiments have 
revealed that despite EBNA 2 and EBNA 3 proteins targeting many shared sites they do not 
appear to bind to them at the same time, suggesting that part of the transcriptional regulation 
by these factors may be through competitive binding. Finally, we have used our ChIP 
sequencing data to uncover some of the mechanisms employed by EBV to regulate Bim, ADAM, 
CTBP2, WEE1 and ITGAL, all of which have relevance to EBV induced transformation and 
immortalisation. 
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6. Discussion 
The EBV EBNA 2 and EBNA 3 family are potent regulators of transcription; and EBV mediated 
infection and immortalisation is dependent on the activity of EBNA 2, EBNA 3A and EBNA 3C 
(Cohen et al. 1989; Tomkinson and Kieff 1992; Tomkinson et al. 1993; Young and Murray 2003). 
Upon infection of a resting B cell EBNA2 and the EBNA 3 family alter the cellular transcriptome 
facilitating B-cell activation like changes causing entry of the infected cell into the GC; 
eventually resulting in lifelong persistent infection. In this study we characterise EBNA 2 and 
EBNA 3 binding sites in the human genome and investigate their functional implications on 
transcription. 
6.1 EBNA 2 and EBNA 3 binding sites in the human genome 
ChIP sequencing was carried out in the Mutu III cell line using antibodies against EBNA 2 and a 
pan specific antibody which precipitates EBNA 3A, 3B and 3C revealed over 21000 EBNA 2 and 
over 7000 EBNA 3 binding sites in the human genome. These sites are predominantly distal to 
gene TSSs and 25% of all binding sites are shared between EBNA 2 and EBNA 3 proteins. 
Recently ChIP-sequencing experiments have shown that enhancer elements are more common 
than originally thought. Enhancers can modulate transcription regardless of the orientation of 
the element and can act over distances of several hundred to several thousand base pairs 
(Banerji et al. 1983). It is now believed that enhancers alone may account for 10% of the 
human genome (Bulger and Groudine 2011). Modulation of enhancer function plays a role in 
cancer development as a number of single nucleotide polymorphisms at cancer risk loci map to 
known enhancer elements (Pomerantz et al. 2009; Ahmadiyeh et al. 2010). Enhancers 
commonly consist of a cluster of TF binding sites and interplay between TFs at enhancers is 
functionally relevant (Thanos and Maniatis 1995). It appears protein bound enhancers are 
functionally similar to promoter proximal elements and can physically contact the promoter in 
question via DNA looping. In fact promoter enhancer looping may be the common mechanism 
by which enhancers exert their transcriptional influence (Vilar and Saiz 2005). The enhancer 
sites that EBNA 2 and 3 proteins target also co-localise with ChIP sequencing data from the 
ENCODE project for epigentetic marks associated with enhancers and B-cell transcription 
factors. These include RBPJĸ and PU.1, which are known DNA targeting cellular TFs for the 
EBNA 2 and EBNA 3 family (Grossman et al., 1994)(Johannsen et al. 1995; Sjoblom et al. 1995; 
Sjoblom et al. 1998; Zhao and Sample 2000). Other B-Cell transcription factors enriched at 
binding sites included EBF1 which has also been implicated in targeting EBNA 2 to cellular sites 
(Zhao et al. 2011). 
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Many other B-cell transcription factors co-localised with our ChIP-sequencing data sets 
including PAX5, IRF4 and BATF. However, we have no direct evidence that these TFs were 
aiding the recruitment of EBNA 2 and 3 proteins to binding sites. As EBV induces an activated 
B-cell phenotype upon infection it is highly likely that many of the enhancers it occupies are 
involved in B-cell differentiation and development. Such enhancers will also be targeted by B-
cell transcription factors is the absence of EBV infection. Indeed, the question of what exactly 
EBNA proteins are doing differently to normal B-cell transcription factors is a fundamental one. 
The best characterised TF binding partner of EBNA 2 and 3 proteins is RBPJĸ. RBPJĸ is bound by 
intracellular NOTCH which is cleaved at the membrane following activation (Radtke et al. 2010). 
NOTCH/RBPJĸ signalling in B-cells is critical to B-cell development. Strong NOTCH1 signalling 
drives cells towards a T-cell fate (Dallas et al. 2005) whereas NOTCH2 signalling preferentially 
selects specific B-cell fates (Saito et al. 2003; Gibb et al. 2010). Furthermore, NOTCH signalling 
in GC B cells protects B-cells from apoptosis, increasing the chances of the cells survival and 
subsequent maturation into a circulating memory B-cell (Yoon et al. 2009). Importantly, EBNA 
2 can mimic the effects of intracellular NOTCH and perform similar functions at particular 
genes (Sakai et al. 1998). So are EBNA 2 and 3 proteins simply copying the function, or 
‘pretending’ to be numerous B-cell transcription factors involved in driving B-cells towards the 
memory compartment? This appears unlikely as EBV is nearly 100% associated with endemic 
BL suggesting that EBV proteins have a unique regulatory effect compared to any human 
proteins (Young and Rickinson, 2004). 
EBNA 2 and 3 may also play a role in targeting of cellular TFs to aberrant sites. PU.1 can bind its 
cognate site in condensed chromatin and recruit histone modifying factors to create a poised 
chromatin state, facilitating binding of other factors such as EBF1, E2A and HATs leading to 
gene transcription (Zaret and Carroll 2011). However at other loci PU.1 is unable to bind its 
cognate sequence and a requirement for additional factors, histone marks or non-coding RNA 
molecules, has been shown (Choukrallah and Matthias 2014). EBNA 2 and 3 activity could 
therefore modulate which sites can be bound by cellular TFs. This may in fact prove a great 
problem for the study of human DNA elements as the majority of ChIP sequencing 
experiments conducted in the ENCODE project, including the data set to which our ChIP 
sequencing data is aligned to, was conducted in EBV immortalised LCLs expressing a full 
latency III pattern of gene expression. If EBV is capable of targeting cellular TFs to aberrant 
sites many known enhancer sites described in ENCODE could in fact be EBV specific. 
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These mechanisms may play a part in EBNA 2 and 3 interactions with cellular TFs and 
enhancers but the most likely mechanism of transcriptional regulation is by altering bound TF 
function, and aberrant recruitment of regulatory cofactors to TF binding sites by EBNA 2 and 
EBNA 3. EBNA 2 is known to bind to the repression domain of RBPJĸ without interfering with 
the RBPJĸ DNA binding domain thereby activating repressed RBPJĸ targets (Hsieh and Hayward 
1995). Our ChIP sequencing data also revealed an association of EBNA 2 and EBNA 3 bound 
sites with epigenetic marks associated with active and poised enhancers. Given that the 
repressive function of EBNA 3A and 3C is best characterised by the activity of PcG group 
proteins it was surprising that H3K27me3 and EZH2 were not shown to be enriched at EBNA 3 
binding sites. This may be due to the fact that PcG protein activity results in broad areas of 
H3K27me3 in the genome rather than defined peaks. However, whether EBNA 2 and 3 
proteins cause or are recruited by poised and active marks remains unknown. EBNA 3C can 
interact with the histone acetylatransferase p300, mediating gene activation by histone 
acetylation (Subramanian et al. 2002) and EBNA 2 can recruit HATs including p300, CBP and 
KAT2B (Wang et al. 2000). This suggests that EBNA 2 and 3 proteins are capable of altering the 
chromatin at which they are bound to create poised and activating enhancer marks. It is 
therefore likely that EBNA2 and 3 proteins are recruited to and create active and poised 
enhancers. 
To determine the significance of EBNA 2 and 3 genomic associations we compared our ChIP 
sequencing data with published gene expression microarray data on EBNA 2 and EBNA 3 
proteins. A gene was determined as bound by EBNA 2 or EBNA 3 proteins if it was the most 
proximal gene to a peak. Our analysis revealed that 8386 genes were bound by EBNA 2 and 
3937 were bound by EBNA 3 and that in some cases there was remarkable overlap between 
bound and regulated genes. This was especially true in EBNA 2 gene expression microarray 
data sets, each of which had over half of reported regulated genes bound by EBNA 2. In one 
data set 22/23 (95.7%) genes regulated were bound and in another 56/64 (87.5%). EBNA 3 
bound and regulated genes also showed a large degree of overlap. In an EBNA 3C regulated 
data set 195/430 (45.3%) genes regulated were bound by EBNA 3 proteins. This is especially 
remarkable given that there are less than half the number of EBNA 3 bound genes than EBNA 2 
bound genes. The determination of a gene being bound because it is most proximal to a peak 
is imperfect as it is documented that enhancers can act over significant genomic distances, 
interact with multiple promoters and even interact with genes on other chromosomes 
(Spilianakis et al. 2005; Lomvardas et al. 2006). Furthermore enhancers ‘skip’ genes, contacting 
and regulating a gene specifically over another that is closer. Also a gene that is bound in our 
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ChIP sequencing data and regulated in gene expression microarray data sets does not prove 
that it is the activity of EBNA 2 and 3 proteins at that site coordinating its regulation. Despite 
this EBNA 2 and 3 binding seems to correlate well with gene regulation.  
Therefore we can conclude that EBNA 2 and 3 proteins associate extensively with cellular DNA 
elements, especially enhancers, in order to regulate host gene transcription. 
6.2 Histone modifications and EBNA 3C DNA binding 
Analysis of gene expression microarray data set performed in our lab revealed that EBNA 3C 
specifically represses chemokine signalling and integrin receptor signalling pathways (Table 4-
2). We further determined that many of the most repressed genes in these pathways were 
bound by EBNA 3 proteins from our ChIP sequencing data. It has previously been reported that 
genes repressed by EBNA 3C show changes in histone modification associated with repression. 
For example histones at p16INK4A  and Bim show increased H3K27me3 in the presence of EBNA 
3A and EBNA 3C (Paschos et al. 2009; Skalska et al. 2010). This mark is deposited by the PcG 
protein EZH2 and is proposed to result in recruitment of other chromatin modifying enzymes 
including PRC1 which can lead to CpG methylation and persistent gene repression (Simon and 
Kingston 2009). Recruitment of PcG proteins by EBNA 3A and 3C is dependent on their 
interactions with co-repressors such as CTBP proteins (Touitou et al. 2001; Skalska et al. 2010). 
Furthermore EBNA 3 target genes have been shown to undergo changes in histone acetylation 
associated with repression including NOTCH2 and TOX (White et al. 2010). 
The gene expression microarray experiment performed in our lab compared mRNA from EBV 
negative B-cell lymphoma (BJAB) E3C4 stably expressing EBNA 3C with that of the BJAB PZ2 
which is transfected with an empty plasmid. We therefore conducted ChIP experiments using 
antibodies for histone modifications at repressed genes in the related cell lines E3C3, E3C7, 
PZ1 and PZ3. We also used antibodies against all EBNA 3 proteins as E3C3 and E3C7 only 
express EBNA 3C and we could be certain that this would be the only EBNA 3 protein we would 
precipitate. In agreement with current knowledge on EBNA 3C mediated repression we 
detected changes in histone modifications associated with repression at ITGB1, ITGA4, 
ADAM28, ADAMDEC1, CXCL10 and CXCL11 (Fig 4-2 – Fig 4-5). We also detected EBNA 3C 
binding at the ADAM locus, ITGB1 and ITGA4 (Fig 4.2 – Fig 4-5). At the time of publication this 
was the first evidence of EBNA 3C interaction with the human genome.  
We could not confirm EBNA 3C binding to two low level EBNA 3 binding sites at the CXCL locus 
(Fig 4-7), furthermore, we could not validate these sites in Mutu III cells using the same 
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antibody that was used for EBNA 3 proteins in the ChIP sequencing experiment. It may 
therefore be that these sites are an artefact of ChIP sequencing analysis. This would suggest 
that regulation of CXCL10 and CXCL11 by EBNA 3C is via a long range interactions or an indirect 
effect of the presence of EBNA 3C. Conversely it could be that the ChIP sequencing experiment 
is more sensitive than our conventional ChIP method and this site is indeed responsible for the 
direct repression of CXCL10 and CXCL11. 
Increases in levels of H3K27me3 and decreases in H3ac and H4ac were almost ubiquitous 
across repressed loci. An interesting observation was that in EBNA 3C expressing cells levels of 
H3K27me3 were increased more downstream of the TSS rather than at the promoter (see Fig 
4.4 C, Fig 4-5 C and Fig 4-8 A for examples). Furthermore, at the two distal peaks studied there 
was a limited increase in H3K27me3 in the presence of EBNA 3C compared to control cells (Fig 
4-3 C and Fig 4-5 C). This supports our finding that EBNA 3 peaks are not enriched for 
H3K27me3 (Fig 3-10). These observations are however difficult to explain. If EBNA 3C is 
associating with a TF to bind a distinct site, then recruiting co-regulators like CTBP2 which then 
recruits PcG proteins it would be expected that high levels of H3K27me3 at EBNA 3C binding 
sites would be observed. It may be that PcG proteins are indirectly recruited to EBNA 3C sites 
and then loop to intragenic sites to deposit H3K27me3. It may also be that the effect of EBNA 
3C is to create poised chromatin at silencers facilitating repressive complex recruitment. The 
delineation between enhancers and silencers is not a strong one and whether a DNA element 
acts as an enhancer or silencer is likely dependent on what is bound to it at the time 
(Murayama et al. 2004). Acetylation of histones H3 and H4 was found to be most abundant at 
promoters and at the ADAM locus distal site EBNA 3C binding site (Fig 4-3 – Fig 4-6). H3ac and 
H4ac was almost always reduced in cells expressing EBNA 3C at sites that were acetylated in 
PZ1 and PZ3. This suggests that EBNA 3C promotes chromatin condensing excluding binding of 
activating proteins to promoters and enhancers. 
It is important to note that we have not proved that EBNA 3C binding directly recruits proteins 
that repress these loci. It is possible that EBNA 3C binding to investigated sites is coincidental 
and the presence of repressive histone modifications and gene repression in EBNA 3C 
expressing cells is a downstream effect of a different target of EBNA 3C regulation. However, 
as discussed previously, binding does appear to strongly correlate with regulation from 
analysis of published microarray data (Table 3-2). Furthermore we know that EBNA 3C can 
associate with histone deacetylases and repressive cofactors that can in turn recruit PcG 
proteins (reviewed in (Allday 2013)). CCC experiments also showed that at the ADAM locus, 
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EBNA 3C alone was able to direct enhancer promoter loops to both ADAM28 and ADAMDEC1. 
This data, along with confirmed EBNA 3C binding (Fig 4-5 B), transcriptional repression and 
associated changes in histone modifications (Fig 4-5 C and Fig 4-6) allows a near complete 
mechanism for repression of ADAM28 and ADAMDEC1 by distal EBNA 3C binding sites. Future 
experiments at this locus should attempt to determine which cellular TF targets EBNA 3C to 
the enhancer and what proteins recruited by EBNA 3C are essential for epigenetic repression.   
The relevance of this data in vivo is more difficult to determine. Chemotaxis assays performed 
in our lab by Sarika Khasnis showed that EBNA 3C expressing BJAB cells caused reduced 
attraction of CXCR3 (the receptor for CXCL10 and CXCL11) expressing cells compared to control 
cells (McClellan et al. 2012). Integrin receptor signalling may also play a role in immune 
evasion as lymphocyte infiltration into infected areas is facilitated by interactions between 
α4β1 integrin, VCAM-1 and ADAM28 (Bridges et al. 2002; Bridges et al. 2005). Furthermore, 
integrin signalling is important for cell adhesion and migration so its regulation may allow EBV 
infected B-cells entry into the GC. Once in the GC integrin receptor signalling is crucial in 
providing adequate survival signals for B-cells via T-helper cells (Taylor et al. 1999; Yoon et al. 
2014). It is important to note that by the time an EBV infected B-cell gets to the GC it no longer 
expresses EBNA 3C. However, at Bim epigenetic marks and gene repression persist after 
conditional EBNA 3C is removed, and recently epitope-tagged EBNA 3C has been shown to 
bind to the Bim promoter (Paschos et al. 2009; Paschos et al. 2012). We further know that 
EBNA 3C can physically associate with CTBP proteins and that the CTBP protein binding domain 
of EBNA 3C is required for repression of Bim (Touitou et al. 2001). Future experiments at these 
loci should focus on the timing of the EBNA 3C mediated repression via H3K27me3 and look 
for evidence for subsequent CpG methylation. Furthermore, analysis of this gene subset in 
other cell lines expressing a full panel of latent gene expression will be necessary to describe 
the function of EBNA 2, which has been shown to activate most genes investigated in this 
chapter (Table 4-3). In conclusion, this data suggests that association of EBNA 3C with DNA 
elements results in the recruitment of cofactors which alter the chromatin landscape and 
repress transcription. 
6.3 The influence of shared sites and DNA looping 
Previous studies at the viral LMP1 promoter have shown co-activation by EBNA 2 and EBNA 3C 
which is entirely dependent on PU.1 binding sites at the gene promoter (Zhao and Sample 
2000). Initial analysis of ChIP sequencing data revealed that 25% of all binding sites for EBNA 2 
and EBNA 3 proteins were shared sites (Fig 3-8 C). This was perhaps not surprising as EBNA 2 
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and 3 proteins are known to share cellular TF binding partners. This data provided us with the 
first opportunity to study how EBNA 2 and 3 binding to shared genomic sites modulates 
transcription. To do this we required specific EBNA 3A, EBNA 3B and EBNA 3C antibodies. We 
confirmed antibody specificity by immunoprecipitation experiments using ChIP conditions and 
buffers in the BL31 cell series which showed that antibodies used did not co-precipitate other 
EBNA 3 proteins (Fig 5-1). We first validated these antibodies in ChIP experiments at EBNA 3 
only binding sites at the ADAM intragenic peak and the Bim promoter. Only EBNA 3A and 
EBNA 3C were shown to bind to these sites (Fig 5-2 and Fig 5-3). Importantly, ADAM28, 
ADAMDEC1 and Bim have only been reported to be regulated by EBNA 3A and EBNA 3C and 
not EBNA 3B (Hertle et al. 2009; White et al. 2010; McClellan et al. 2012). 
We then investigated shared binding sites at CTBP2, WEE1 and ITGAL and found that EBNA 2 
bound to every binding site discovered by ChIP sequencing in both Mutu III and PER253 LCL 
(Fig 5-4, 5-5, 5-8, 5-9, 5-11 and 5-12). EBNA 3 binding was more varied and showed locus 
specific and cell type dependent binding which correlated with gene repression. Only EBNA 3C 
was shown to bind significantly and regulate WEE1 (Fig 5-8 and Fig 5-9). At ITGAL EBNA 3B and 
EBNA 3C were shown to bind in Mutu III cell lines, correlating with gene repression (Fig 5-11 
and Fig 5-13). In PER 253 LCL lines only EBNA 3B showed significant binding at ITGAL, which 
was only found to be regulated in LCL lines by EBNA 3B (Fig 5-12 and Fig 5-13). This striking 
correlation between binding and regulation provides a mechanism for differential gene 
regulation by EBNA 3 proteins. 
Extensive overlap in genes regulated by EBNA 3 proteins has been reported (White et al. 2010). 
Interestingly, in this study genes only regulated by a single EBNA 3 protein or any combination 
of pairs of EBNA 3 proteins were also described. EBNA 3C appears to be especially important in 
EBNA 3 mediated regulation as only 9/1201 genes were reported to be regulated by EBNA 3A 
and EBNA 3B but not EBNA 3C. Furthermore, EBNA 3C was shown to regulate the most genes 
without another EBNA 3 protein regulating the same gene (see (White et al. 2010) Fig 1.). Here 
we provide a simple mechanism to explain this finding, that genes regulated by EBNA 3B are 
targeted by an EBNA 3B binding site. Genes regulated by EBNA 3A and EBNA 3C are targeted 
by an EBNA 3A and EBNA 3C binding site and so on. 
Unfortunately, we have very little evidence about how differential binding of EBNA 2 and 3 
proteins occurs. The obvious answer is that they associate with different cellular TFs. However, 
to date most research has been conducted on known TF binding partners, particularly RBPJĸ. 
This study and others indicate a number of other B-cell transcription factor consensus motifs 
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and binding by published ChIP sequencing being enriched at EBNA 2 and 3 binding sites. This 
however is not sufficient to prove these cellular TFs are targeting EBNA 2 and 3 proteins to 
DNA. One candidate TF for differential targeting of EBNA 2 and 3 proteins is EBF1 which has 
been implicated in targeting EBNA 2 to genomic sites (Zhao et al. 2011) but to date shows no 
evidence of EBNA 3 proteins association. Furthermore the most significant TF consensus motif 
for the top 300 most significant EBNA 2 binding sites in our ChIP sequencing data set was EBF1 
(Fig 3-15). This suggests that differential EBNA 2 and 3 binding and correlated regulation may 
depend on which TF they are able to associate with, the prediction being that at each has at 
least one TF that only it can associate with. EBF1 should be investigated further as a potential 
EBNA 2 only targeting TF. It is also possible that the binding of EBNA 2, EBNA 3A, EBNA 3B and 
EBNA 3C to the same cellular TF alters which sites that particular TF binds to. Both mechanisms 
for differential gene targeting are likely true. The different EBNA 2 and 3 proteins almost 
certainly have different affinities for different cellular TFs and are also likely to be able to 
individually specify the same TF to particular DNA elements. ChIP sequencing studies using 
specific EBNA 3A, EBNA 3B and EBNA 3C antibodies would allow detection of EBNA 3A, EBNA 
3B and EBNA 3C only sites. These could then be compared to existing ChIP sequencing data on 
cellular TFs and enriched TF consensus motifs at EBNA 3A, EBNA 3B or EBNA 3C only sites 
could be compared to identify candidate TFs. 
 One fundamental question we wished to address was do the EBNA 2 and 3 proteins bind to 
the same site at the same time as part of a multi-EBNA2/3 complex. Using ReChIP exeriments 
and QPCR at CTBP2, WEE1 and ITGAL we show here that EBNA 2 does not appear to bind to 
shared sites at these genes at the same time as EBNA 3 proteins (Fig 5-14 – Fig 5-16). This 
suggests that mutually exclusive binding of EBNA 2 and EBNA 3 proteins has functional 
relevance. After publication of this data an EBNA 3A binding site was identified in an intergenic 
region between CXCL9 and CXCL10 (Harth-Hertle et al. 2013). This site was also bound by EBNA 
2 and RBPJĸ in ChIP sequencing data published from another group (Zhao et al. 2011). By using 
a HA-tagged Dox inducible EBNA 3A they showed that EBNA 2 occupancy of this enhancer was 
reduced 24 hours after Dox induction with EBNA 3A, with a corresponding increase in HA-
tagged EBNA 3A binding to this site. This data further suggests that EBNA 2 and EBNA 3 
proteins cannot bind a single site at the same time. This may be a site specific phenomena and 
evidence that this is true at every shared site will be difficult to obtain.  
We could not perform reChIP experiments to observe if EBNA 3A, EBNA 3B and EBNA 3C were 
able to bind the same site at the same time. This is partly because the EBNA 3 antibodies 
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generally precipitate less DNA than the EBNA 2 antibody, either due to reduced affinity for the 
epitopes, less EBNA 3 protein or less EBNA 3 genomic associations. This is problematic in 
reChIP experiments as DNA is lost at each precipitation, wash and elution step in a 
conventional ChIP, and a reChIP has double the amount of these steps to a conventional ChIP. 
To get an estimate of how much DNA is lost it is possible to compare percentage ChIP input 
signals in Fig 5-4 with Fig 5-14, Fig 5-8 with Fig 5-15 and Fig 5-11 with Fig 5-16. This is in no way 
quantitative as these data are from two different ChIP experiments. This reveals that signal at 
binding sites is fairly consistently reduced by 10 fold or more by performing a secondary ChIP. 
Recent data has reported that EBNA 3A is co-precipitated by antibodies against a TAP-tagged 
EBNA 3C in IP experiments (Paschos et al. 2012). Also, EBNA 3A and 3C have been reported to 
physically interact in a yeast two hybrid system and colocalise in immunofluorescence studies 
(Krauer et al. 2004a; Calderwood et al. 2007). However, this does not show that EBNA 3A and 
EBNA 3C target DNA at the same time. Future experiments should focus on improving the 
ReChIP technique. The creation of an oligo library which is fused to two different EBNA 
proteins would help as this would act as a perfect positive control. Optimisation of this 
experiment or using a scaled up ChIP method may also help to validate EBNA 3 differential 
binding via reChIP. 
Follow up CCC experiments performed in our lab by Dr. David Wood (University of Sussex) 
revealed that promoter enhancer looping was mediated by EBNA 3A and EBNA 3C at CTBP2 
and WEE1 respectively. In wild type infected LCLs in which CTBP2 is repressed, no loop 
between the intragenic enhancer and promoter was detected (Fig 5-7 A and (McClellan et al. 
2013)). In cells infected with EBNA 3AKO virus in which CTBP2 is derepressed, a loop between 
the promoter and enhancer was detected. This directly implicates EBNA 3A in the repression of 
CTBP2 by EBNA 3A by the prevention of activating loop formation. CCC experiments carried 
out in EREB 2.5 expressing a conditionally active EBNA 2 did not detect promoter enhancer 
looping with or without EBNA 2 but this is perhaps not surprising as EBNA 2 does not bind to 
this site in EREB 2.5 cells (McClellan et al. 2013). We therefore do not know anything about 
EBNA 2 function at CTBP2 as we could not detect CTBP2 expression in any cell panel with 
conditional or knock out EBNA 2 (Fig 5-7 C). We also do not know the role of EBNA 3B or EBNA 
3C in this interaction although we present evidence here that EBNA 3B can repress CTBP2 
transcription (Fig 5-7 B). A few possibilities exist as to the role of differential binding at CTBP2. 
Given that EBNA 3B can repress CTBP2 it is possible that EBNA 3B is able to partially prevent 
activating loop formation but as the CCC experiments performed were not quantitative we 
could not detect this. It is also possible that EBNA 3B represses CTBP2 via mechanisms 
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completely unrelated to EBNA 3A mediated looping, or that EBNA 3B repression requires EBNA 
3A mediated looping and vice versa. Furthermore, as repression of CTBP2 by EBNA 3B was 
detected in a different cell line it is possible that which EBNA 3 performs repression via 
promoter enhancer looping is cell type specific. To improve our understanding of differential 
binding and promoter enhancer looping it will be necessary to analyse CCC experiments using 
quantitative techniques such as QPCR. In the case of CTBP2 it would also be informative to 
explore cell lines with conditional EBNA 3C and EBNA 2 which express CTBP2, but to our 
knowledge, no such cell lines exist.   
Promoter-enhancer looping at WEE1 was shown to be entirely dependent on the presence of 
EBNA 3C. Here, EBNA 3C mediated promoter enhancer looping was associated with gene 
repression (McClellan et al. 2013). This is, to our knowledge, the first demonstration of 
repressive promoter enhancer DNA looping. Data presented here shows that EBNA 2 has an 
activating role at this locus although the mechanism of this is unknown. It may be that EBNA 2 
partially prevents EBNA 3C mediated promoter enhancer looping by directly competing for 
binding sites (Fig 5-10 B, C).  
At ITGAL we observed a cell type specific difference in binding correlated with a cell type 
specific difference in regulation (Fig 5-11 E and Fig 5-12 E). Cell type specific differences in 
regulation have been reported in gene expression microarray data for EBNA 3B (White et al. 
2010) and EBNA 2 (Maier et al. 2006). This data offers a simple explanation for these findings; 
in one cell line it binds, in the other it does not bind. This is made more complex by the high 
proportion of shared sites between EBNA 2 and EBNA 3 such that one protein not binding may 
increase binding of other factors, as demonstrated at CXCL9 and CXCL10 (Harth-Hertle et al. 
2013). The fundamental question that needs to be addressed now is why is binding different 
between cell lines. An obvious answer is epigenetic silencing of a site in one cell line and not 
another, and histone modifications undoubtedly play a role, but at ITGAL EBNA 3B was shown 
to bind to the promoter in both cell types, whereas EBNA 3C could not. This suggests that the 
chromatin environment was specifically permissive to EBNA 3B at this site. If it is true that each 
EBNA has its own set of TF binding partners then relative abundances of TFs between cell lines 
could also account for these data. It is likely that cell type specific binding will only start to be 
understood once ChIP sequencing experiments have been carried out on multiple, well 
characterised, EBV infected cell lines. One obvious candidate is GM12878 and other EBV 
infected cells from which the ENCODE project is constructed. It is possible to hypothesise that 
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cell type specific binding will be a mixture of: expression levels of individual EBNAs, expression 
levels of their TF binding partners and histone modifications at target sites. 
There are many in vivo implications of this work. Apart from showing the mechanisms of EBNA 
2 and EBNA 3 mediated transcriptional regulation we have identified novel targets of 
regulation from this ChIP sequencing data. CTBP2 has never been reported to be regulated by 
EBNA 2 or EBNA 3 proteins, indeed previous work in the EBV field has failed to distinguish 
between CTBP1 and CTBP2. Our findings strongly suggests that we should as EBNA 3A seems 
to preferentially repress CTBP2 by preventing activating loop formation. Furthermore this work 
allows us to understand how genes are regulated. WEE1 expression was reported to be 
induced in the hyperproliferation phase shortly after infection and is then repressed. The data 
presented here shows this may be at least partly due to EBNA 3C mediated repressive loop 
formation. ITGAL is expressed upon EBV infection resulting in increased surface LFA-1 and an 
activated B-cell phenotype, our data suggests that at some point in EBV life cycle this is 
required to be repressed, primarily by EBNA 3B via binding to promoter proximal sites. 
ADAM28 and ADAMDEC1 show similar patterns of regulation in array data and both are 
consistently repressed by EBNA 3A and EBNA 3C. Here we find that EBNA 3A and EBNA 3C bind 
to an intragenic site and EBNA 3C is able to coordinate repressive loops to the promoter of 
each gene and stimulate epigenetic silencing of the whole locus. 
The data presented here is of crucial importance to understanding how EBV regulates the host 
transcriptome. We show that EBNA 2 and 3 proteins associate extensively with the human 
genome, primarily targeting enhancer elements. We provide evidence for gene-specific and 
cell background specific binding of EBNA 3 proteins being functionally relevant to the 
transcriptional regulation of target genes, and that genes targeted have extensive in vivo 
importance to EBV induced transformation and biology. The transcriptional control processes 
described here provide novel mechanisms of host-cell reprogramming by EBV and further the 
understanding of transcription in general. The ChIP sequencing data is now publically available 
and we hope it will be a useful resource for others in the field. 
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Appendix C  
                     primers   
                          Real time PCR primers for QPCR   
primer set primer sequence 5' to 3' notes 
viral genome 
LMP1 
(-)310 
Fw (MW 311) GGCCAAGTGCAACAGGAA   
Rv (MW 310) GCAGATTACACTGCCGCTTC   
(+)34 
Fw (MW 140) AGAGGAGGAGAAGGAGAGCAA   
Rv (MW 139) CCTGAGGATGGAACACGAC   
(+)574 
Fw (MW 148) TGAGCAGGATGAGGTCTAGGA   
Rv (MW 147) GGAGATTCTCTGGCGACTTG   
(+)1564 
Fw (MW 150) GTGTTGTGCAGAGGTCTGATG   
Rv (MW 149) CCTTCACACACCACACAGGT   
(+)2238 
Fw (MW 144) GGACACGCTCCTTCTTGG   
Rv (MW 143) ACTGGCTGGATTCTACGCTACT   
salmon genome 
insulin 
salmon 
insulin 
Fw (MW424) TGAGACAGACACCACCAAAGA   
Rv (MW425) CGAACCCAGCCTTCACAA   
Human genome 
ADAM28 
(-)587  
Fw (MW506) TCCTCATTGCCAGTTATGACA   
Rv (MW507) CTCACACAAGTGTACTCTCAGGAAG   
(-)87  
Fw (MW508) AGGACCACAGCTTCGAGGT   
Rv (MW509) CCTCCTCTCCAGTGAGACAGA   
(+)1523 
Fw (MW615) GTGATCTTGGCTCACTGCAA   
Rv (MW616) AATTAGCCGAGCGTGGTG   
(+)13274 
Fw (MW613) CAACCAGAGAACTGAGGCACT   
Rv (MW614) AGCAATGTGGCATGTGTGAT   
(+)19387 
Fw (MW510) ACAGGAGCATGCACTCTTCA   
Rv (MW511) GGCAATGTTCTGCTGCAA   
ADAMDEC1 
(-)1281 
Fw (MW514) AGAGTTCACCATTCCAGGATTC   
Rv (MW515) TCCAGAGATAGGCATCCTTCTTA   
(-)79 
Fw (MW516) GTAGATATGCACGCGACCAC   
Rv (MW517) TTGAGGACTCACATCTGGACA   
(+)228 
Fw (MW518) GTGGGATCTCCCAGCTACC   
Rv (MW519) AATGCTGGTGTGATGGTACG   
ADAM peak 
5' 
Fw (MW544) ACCATAAAGCCATGGGTCAG   
Rv (MW545) GGAGTACAGTTTGGAGCTCATATTT   
mid 
Fw (MW540) CTTCATGGCTACAGACTCTTGG peak primer 
Rv (MW541) CCTATGTCTCGCTTCCTGCT peak primer 
200 
 
3' 
Fw (MW542) TCCGGTGACTAAAGTATATGTAGGG   
Rv (MW543) CTCCATGCTGGATTGATTACAA   
Bim (BCL2L11) 
1 
Fw (MW870) CAGAGGGAGGAGAGCTCAAA   
Rv (MW871) GAGTTTCTAAGCCGCTCTGG   
2 
 Fw (MW876) CTGGTGAAGGGTCGTAGGTC peak primer 
 Rv (MW877) CCCGATACTACGAGCAGGTC peak primer 
3 
Fw (MW878) AGGACAAGTGGCGAGGACT   
Rv (MW879) GCCAGTCACCTGGAGACAA   
CTBP2 
1 
Fw (MW834) TGGCTATGTCACAGCGATTC   
Rv (MW835) ACCGTGCCTGATGGAGTT   
2 
Fw (MW836) TTGCATATTTGGGATTTCAGTTT peak primer 
 Rv (MW837) TTCTGTGTGAAACAGTTGTGGTT peak primer 
3 
 Fw (MW838) CCAGGACAACGTCTGAGTGA   
 Rv (MW839) CCATCGCCATGTTAACAGAA   
CXCL10 
(-)893 
Fw (MW476) ACAGTGTCTTGGAGCTGAACC   
Rv (MW477) GCACGCATAGAGACAGACCTT   
(-)177 
Fw (MW474) TCAAAGCAGGCCAGTCCTAT   
Rv (MW475) AACAGCAAGTTGTGCCTGATT   
(+)130 
Fw (MW488) AAGGAACATCAAAGGATACTTAATTTG   
Rv (MW489) TCCCTCTTATTTATAAGCATGCAGT   
(+)541 
Fw (MW490) TGATGTGATCCATTCCTCCTC   
Rv (MW491) AGAGAAGGTTAGCACAGTGTTCATT   
(+)1426  
Fw (MW472) ATGAATGCATAGCAGCAGGA   
Rv (MW473) CTGACTCTGGCTTCAGATTGG   
(+)1975 
Fw (MW599) GAATGCTCTTTACTTCATGGACTTC   
Rv (MW600) TCTACCTTCCTGTATGTGTTTGGA   
CXCL11 
(-)893 
Fw (MW482) CGTGGCATGGAGTTACTGAA   
Rv (MW4830 AGCTCCTCCTGCCTTCTCTT   
(-)295 
Fw (MW480) CAGTCTTCCTGAATGAATGACAA   
Rv (MW481) CCAGATGGTAACCAGCCTTC   
(+)46 
Fw (MW492) AAGCTGAAGTAGCAGCAGCA   
Rv (MW493) GCACACAATATCACAGCCAAG   
(+)594 
Fw (MW494) CCAGTAACAGTTGTGTTAAGTGCTATT   
Rv (MW495) TAGCTGGTGGTGAACGTGAG   
(+)1660 
Fw (MW478) TTGATGCTTACAACTATTCTGTTGTG   
Rv (MW479) CAATGTCTCCACCGTAACCA   
(+)2147 
Fw (MW595) GCAATATCTTGGACACATCTGAA   
Rv (MW596) AAAGTGATTGCTAGGTATACATTTGCT   
CXCL11 upstream peak (our ChIP sequencing data) 
1 
Fw (MW611) GTGGTGGTAACTGGATGAGTGA peak primer 
Rv (MW612) ACACTATGTACATTACGTGCCACA peak primer 
201 
 
2 
Fw (MW609) ACCAACGCTCATTTCCTGTT   
Rv (MW610) ACCTTTATTTCCTTCACTCCTCTTC   
3 
Fw (MW607) TGGTTGGCTGTAAAGGAAGAATG peak primer (not MACS) 
Rv (MW608) AATCAGCAGTGATTGATTCCTAGA peak primer (not MACS) 
CXCL10 downstream EBNA 3A binding site (Harth-Hertle et al 2013) 
R1 
Fw (MW1237) CAGGGACGGTAAGAGCCTTC described as peak see ref 
Rv (MW1238) AAATTCAAACAGGCCTGGAG described as peak see ref 
R2 
Fw (MW1239) TTAGCAAGGGTGGACGGTAG described as peak see ref 
Rv (MW1240) TCACAAGGCACTTCATCGTC described as peak see ref 
R3 
Fw (MW1241) GTGTTTGCTCAAGGCCCTAC described as peak see ref 
Rv (MW1242) TGCTTGCAGGGAAGGATATAAG described as peak see ref 
ITGA4 
(-)445 
Fw (MW548) GCTGTCTCTCTGGTTGCTGA   
Rv (MW549) AACGCAACACACCTGAACTG   
(+)77 
Fw (MW550) GGGCTGCAGAGGAAGTGT   
Rv (MW551) TGACAAAGACGTTATGGCTATTC   
(+)657 
Fw (MW552) CTGCGCCTCATCTCTTGG   
Rv (MW553) AACACTAAACGGCCACTACCC   
(+)1145 
Fw (MW554) GTGCGTTATGGTGCAAGGT   
Rv (MW555) CGCCACAGATGTGCAGTC   
ITGAL 
1 
Fw MW820 CAGGCTGGAGTACAGTGGTG   
Rv MW821 GAGGCTGAGGCAGGAGAAT   
2 
 Fw MW822 TGTAAAGGGTATCTCACTGTGGTT peak primer A 
Rv MW823 ATAAATGGCCAACATGCACA peak primer A 
3 
 Fw MW824 AGGCTGGTCTCGAACTCTTG   
Rv MW825 CGGTGGCTCACACCTCTAA   
4 
Fw MW826 TGCACCTGTGGTTTCAGCTA peak primer B 
Rv MW827 CGATCACAGCTCAATGCAAC peak primer B 
5 
Fw MW828 ACCCAGCCTCCAATTCTTTAG   
Rv MW829 TTTCTCTGGACCTTGAAAGATGT   
6 
Fw MW830 TGCTTACACTTCCTCCCTGAA peak primer C 
 Rv MW831 TTTCTCACAGAGGCAACAGG peak primer C 
ITGB1 
(-)13540 
Fw (MW627) TGCACCTTGGCAGATTGA   
Rv (MW628) GGTTGAGAGCTGGTTGCTG   
(-)885 
Fw (MW558) CAGGATAGCAGCTTGCCAGT   
Rv (MW559) GCATGTCGATTCGATGATTG   
(-)220 
Fw (MW560) CTTCGCAGAGGAGGAAACTG   
Rv (MW561) GACCGGGACAAAGGAACC   
(+)1019 
Fw (MW562) CGCGTGTCATTTCTTAGGC   
Rv (MW563) TGATCATACCAATGAGTGCAAA   
PPIA 
PPIA 
Fw (MW200) GGGCCGAACGTGGTATAA Spans PPIA TATA box 
Rv (MW201) CCATGGCTAATAGTACACGGTTT Spans PPIA TATA box 
202 
 
WEE1 
1 
Fw (MW798) CAAGCCATCTTCACACCTCA   
Rv (MW799) TTGAGACCAGCCTAGACAACAA   
2 
Fw (MW800) TGCTAAGTGGATGAGGCAGA   
Rv (MW801) TGCACAGCTGCATTCCTC   
3 
Fw (MW802) TTGCTGCAACACCAGCTC   
Rv (MW803) CACCAGGAACACTGGAGACA   
4 
Fw (MW804) TCCAGACAGCACCAGGAAG   
Rv (MW805) CTGTGGGAAAGTCCTCCAGT   
5 
Fw (MW806) TACAGGCGTGAGCCACTG   
Rv (MW807) GTCTGCACCAAGTGACAAGC   
6 
Fw (MW808) GGGACTCCTGGTGTTAGTCCT   
Rv (MW809) CATAGAAGGAGGCCTGTCAAA   
7 
Fw (MW810) ACCACTGCAGGAAGCGTTAT   
Rv (MW811) GATTCGTGCACATCTGTTGAA   
8 
Fw (MW812) ACCCGGTCCTAACTGGAGA   
Rv (MW813) GAGCCTCGCTCCAGAGACT   
9 
Fw (MW814) GGACATTGTATTTATTCAGGTCCA   
Rv (MW815) GCTCCCTGAATCCTATCCACT   
10 
Fw (MW816) CCCTGGGTTAGTCATGCAA   
Rv (MW817) GACTCCCATGTGTGGTTGG   
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Appendix D 
primers 
cDNA amplifying primers 
primer set primer sequence 5' to 3' notes 
Human genome 
CTBP2 
Fw (MW840) GAGTGATCGTGCGGATAGG CTBP2 exon 5  
Rv (MW841) GAGTCCGCTGTCTCTTCCAC CTBP2 exon 6  
S1 
Fw (MW853) TACAGGTCGTGGGCTGGTAT CTBP2 S1 exon 1/2 
Rv (MW854) CTTCAGGATGGGCATCTCC CTBP2 S1 exon 2 
S2 
Fw (MW855) ACCATGCTTGCACCAGAAC CTBP2 S2 exon 1 
Rv (MW856) TTCAGGATGGGCATCTCC CTBP2 S2 exon 2 
L1 
Fw (MW857) ATGGCCTACGTCGTCATACC CTBP2 L1 exon 1 
Rv (MW858) GGAATACACCTTCATTGGTTCAA CTBP2 L1 exon 2 
L2 
Fw (MW859) CGGGACGAGGGTTTCATC CTBP2 L2 exon 1/2 
Rv (MW860) CTATAGTTCACACGATGGGCTGT CTBP2 L2 exon 2 
L3 
Fw (MW861) CGGGACGAGATGGAGAAA CTBP2 L3 exon1/2 
Rv (MW862) GTACTCTGCAGCCAGGAGGA CTBP2 L3 exon 2 
L4 
Fw (MW863) CCAAGTTGGAATTAGCATCCTC CTBP2 L4 exon 1 
Rv (MW864) TAGTTCACACGATGGGCTGT CTBP2 L4 exon 2 
ITGAL 
Fw (MW832) CCAAGTCAAGCACATGTACCA ITGAL exon 25 
Rv (MW833) ACGCTCCACTGGTGTGTG ITGAL exon 26 
WEE1 
Fw (MW818) TGAAGAGGGCGATAGTCGTT WEE1 exon 8  
Rv (MW819) CACCAGCAGCACATACCACT WEE1 exon 9 
 
 
 
 
 
 
 
 
 
 
 
